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ABSTRACT 
 
The incidence of metabolic syndrome, which is a risk factor for cardiovascular disease 
(CVD) and type 2 diabetes mellitus (T2DM) is increasing rapidly. Changes in dietary 
fat composition from saturated fat (SFA) to monounsaturated fat (MUFA) from olive 
oil, which is highly consumed in a Mediterranean diet, might improve risk factors for 
CVD and T2DM. However, the underlying molecular mechanisms for these beneficial 
health effects are not completely known. Moreover, more knowledge is needed about 
health status and biomarkers that allow early detection of onset of diseases such as 
metabolic syndrome, CVD and T2DM.  
 
The aim of this thesis was twofold; first, to investigate the acute and longer-term 
effects of intake of different types of dietary fat. Second, to examine whether a more 
comprehensive phenotyping of health status can be achieved by application of 
nutrigenomics tools and challenges tests.  
 
A controlled dietary intervention study was performed in healthy abdominally 
overweight subjects to investigate the effects of 8-weeks consumption of diets high in 
SFA or MUFA on insulin sensitivity, serum lipids and adipose tissue whole genome 
gene expression. Moreover, the effects of replacement of SFA by MUFA, as part of a 
western-type diet and as part of a Mediterranean diet, on peripheral blood mononuclear 
cell (PBMC) whole genome gene expression and plasma protein levels were 
investigated.  
Plasma protein profiles of the subjects before the intervention were used to define 
proteins and protein clusters that were associated with BMI and insulin concentrations. 
Similar analyses were performed in a second overweight population to verify the 
findings. 
In two other studies, the response capacity of subjects with different metabolic risk 
phenotypes to a high-fat challenge varying in fat type and to an extreme caloric 
restriction challenge were determined. 
 
Results from our first study showed that consumption of a SFA-rich diet increased 
expression of inflammation-related genes in adipose tissue whereas consumption of a 
MUFA-rich diet led to a more anti-inflammatory gene expression profile, without 
changes in insulin sensitivity or increases in body weight. Moreover, high MUFA 
intake from olive oil, both in a western-type diet and in a Mediterranean-type diet, 
lowered expression of genes involved in oxidative phosphorylation in PBMCs and 
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lowered serum LDL and plasma ApoB, Connective Tissue Growth Factor and 
myoglobin concentrations.  
In plasma of the healthy participants clusters of proteins associated with BMI or insulin 
could be identified. These clusters included previously reported biomarkers for disease 
and potential new biomarkers.  
The high-fat challenge study showed that the plasma metabolic response and the 
PBMC gene expression response to high-fat challenges were affected by the presence 
of obesity and/or diabetes. Comparison of responses to high SFA, MUFA and n-3 
PUFA loads showed that a high MUFA load induced the most pronounced response.  
The caloric restriction study revealed that PBMC gene expression profiles were 
different between metabolic syndrome subjects and healthy subjects, mainly for genes 
involved in pathways related to mitochondrial energy metabolism. Moreover, we 
observed that the caloric restriction challenge magnified differences in PBMC gene 
expression profiles between the subject groups. 
 
In conclusion, this thesis showed that 8-weeks consumption of a SFA-rich diet resulted 
in a pro-inflammatory gene expression profile in adipose tissue whereas consumption 
of a MUFA-rich diet caused a more anti-inflammatory profile, in addition to reductions 
in LDL cholesterol, some plasma proteins and expression of oxidative phosphorylation 
genes in PBMCs. Since the effects of the diets on inflammation were still local and not 
accompanied by systemic changes in inflammatory status or insulin sensitivity we 
hypothesize that adipose tissue could be an early response organ for dietary fat-induced 
changes. The changes in pro-inflammatory gene expression might be one of the first 
hallmarks in the development of adipose tissue inflammation and insulin resistance 
which on the longer term may lead to inflammation-related diseases such as metabolic 
syndrome. 
Our studies showed the potential of whole genome expression profiling, plasma 
profiling and the use of challenges tests to detect subtle diet effects and small 
differences in health status. Using these tools in future studies will result in more 
knowledge about health status and about mechanisms behind dietary effects. 
Eventually this might lead to earlier detection of small deviations from a healthy 
phenotype and to evidence-based dietary advice to improve health and to prevent 
disease. 
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Metabolic syndrome 
The incidence of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) is 
increasing rapidly and accounts for a substantial proportion of health care costs. 
Moreover, these chronic diseases represent a major cause of death in western society. 
The presence of the metabolic syndrome is a risk for these diseases [1, 2]. The term 
metabolic syndrome, or insulin resistance syndrome, was already mentioned in the 
1980s as a concept to describe a group of metabolic risk factors that often cluster 
together [3]. The exact definition of the syndrome has been subject to changes since 
then and is still slightly different for each health authority. The National Cholesterol 
Education Program’s Adult Treatment Panel III defined the metabolic syndrome as a 
cluster of at least three or more of the following metabolic risk factors; central obesity 
(waist circumference ≥102 cm for men and ≥88 cm for women), elevated fasting 
glucose (≥ 5.6 mmol/L), elevated triglycerides (≥ 1.7 mmol/L), reduced HDL 
cholesterol (≤1.03 mmol/L for men and ≤ 1.29 mmol/L for women) and hypertension 
(≥ 130/85 mmHg) [4, 5]. In order to improve these risk factors changes in lifestyle are 
recommended as an early intervention approach and dietary interventions should have 
a major role in this.  
 
Dietary fat and the prevention of diabetes 
Several epidemiological and observational studies showed that a high amount of fat in 
the diet could be important for the risk to develop diabetes and CVD. However, besides 
the amount of fat in the diet, the type of fat in the diet might also influence metabolic 
processes in the development of disease [6]. Adherence to a traditional Mediterranean 
type of diet, which is relatively high in fat (± 35 en%), is associated with lower CVD 
mortality [7, 8] and is inversely associated with features of the metabolic syndrome [9, 
10]. Several health promoting effects of the Mediterranean diet have been ascribed to 
its high olive oil content, although other characteristics of the diet (e.g. abundant use of 
fruits, vegetables, cereals, legumes, nuts, seeds, moderate intake of fish and red wine 
and low intake of dairy products,  and meat) [8, 11, 12] might also contribute to the 
health effects.  
A Mediterranean diet contains a high percentage (16-30%) of monounsaturated fat 
(MUFA) from olive oil whereas a western-type diet contains a relatively high 
percentage of saturated fat (SFA) from butter, cheese and meat. Dietary intervention 
studies have shown that replacement of SFA by MUFA in the diet can reduce total 
cholesterol, LDL cholesterol and triglyceride concentrations [13, 14]. However, 
whether replacement of SFA with MUFA could also improve insulin sensitivity is still 
controversial [15]. Some intervention studies [16, 17] showed that insulin sensitivity 
increased after replacing SFA with MUFA but results from two recent multicenter 
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studies [18, 19] did not provide evidence that the replacement of SFA with MUFA 
could ameliorate insulin sensitivity.  
The exact mechanisms underlying the possible association between fatty acid intake 
and insulin sensitivity are not completely clear but different mechanisms have been 
proposed. A traditional idea how fatty acids could affect insulin resistance is via 
alterations in cell membrane composition which can change membrane fluidity. This 
might affect insulin action through changes in ion permeability, cell signalling or 
altered insulin receptor binding and affinity. A higher desaturation and fluidity of the 
phospholipids in the muscle cell membrane was found to be associated with higher 
insulin sensitivity [16, 20].  
Overconsumption of dietary fatty acids, especially SFA, can also result in 
accumulation of fatty acid intermediates (e.g. diacylglycerol and ceramide) in skeletal 
muscle, liver and adipose tissue, which can lead to activation of several serine kinases 
such as protein kinase Cθ (PKCθ), c-Jun N-terminal kinase (JNK1), IκB kinase β 
(IKKβ) and in this way negatively regulate insulin action [21, 22].  
From the molecular point of view, dietary fatty acids are considered as dietary signals 
that can affect metabolism by activating transcription factors and thereby influencing 
gene expression [23]. Dietary fatty acids can have distinct effects on gene expression 
depending on their molecular structure. Small changes in structure (e.g. from saturated 
to unsaturated) can influence gene expression and the processes that are activated. 
Consumption of more unsaturated fatty acids instead of SFA might change the activity 
of specific fatty acid-regulated transcription factors, such as peroxisome proliferator-
activated receptors (PPARs), Sterol Regulatory Element-Binding Proteins (SREBP), 
liver X receptor and NF kappa B, thereby affecting lipid, carbohydrate, and protein 
metabolism, as well as immune processes and cell growth [24, 25]. SFA on the other 
hand, may activate toll-like receptors (TLRs) of the innate immune response, which 
lead to activation of the NFκB and JNK pathway and could contribute to insulin 
resistance [26, 27].   
Dietary fatty acids are mainly stored in white adipose tissue but in situations of chronic 
positive energy intake and decreased capacity and expandability of the subcutaneous 
adipose tissue depot fatty acids can also accumulate in other tissues such as skeletal 
muscle, liver, heart, and pancreatic β cells. Accumulation of fat in these tissues might 
impair tissue functioning and can result in tissue insulin resistance [21, 28]. The total 
amount of intracellular lipids is influenced by the balance between the rate of fatty acid 
oxidation and triglyceride synthesis. Dietary fatty acids may affect this intracellular 
lipid balance since different fatty acids were found to have different oxidation rates 
[29, 30].  
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Insulin sensitivity and adipose tissue inflammation  
During the last decades, evidence has been accumulating suggesting a link between 
insulin resistance and chronic low-grade inflammation in adipose tissue. Adipose tissue 
has not only a function in energy storage but also acts as an endocrine organ by 
producing and secreting hormones and adipokines needed for glucose homeostasis, 
energy metabolism, food intake and body weight regulation, hemostasis, and immune 
function [28, 31]. A good balance of secretion of pro- and anti-inflammatory 
adipokines is essential for optimal body functioning but this balance can get disturbed 
when adipose tissue mass is increasing, as in subjects with obesity or metabolic 
syndrome. Increased adipose tissue mass can lead to changes in adipose tissue 
morphology, characterized by adipocyte hypertrophy, hypoxia, adipocyte death and 
infiltration of inflammatory cells such as macrophages and T-cells [32-35]. This results 
in increased production and secretion of a wide range of pro-inflammatory molecules, 
mainly from the non-adipocyte fraction of adipose tissue, and in decreased secretion of 
important metabolic regulatory molecules such as adiponectin [36, 37]. Secretion of 
these pro-inflammatory molecules into the bloodstream can affect the metabolic 
function of other organs and may impair insulin signalling in peripheral tissues, thereby 
causing whole body insulin resistance (figure 1) [38, 39].  
The immune system and the metabolic system are highly integrated, driven by the 
evolutionary need to withstand starvation and to elicit an affective immune response to 
infectious challenges [33]. Due to the close integration of the immune and metabolic 
system disturbances in the metabolic system can have impact on the immune system 
and vice versa. Nowadays, obesity is considered as a state of chronic low-grade 
inflammation and metabolic diseases such as T2DM and CVD also have a large 
inflammatory component [40].  
Several dietary factors were found to affect inflammation [41-43]. SFA was suggested 
to have pro-inflammatory effects, mainly based on observational and in vitro studies 
[22, 44-47]. A Mediterranean dietary pattern was found to reduce circulating 
inflammatory proteins and was considered as anti-inflammatory [48, 49].  
Extensive research has been done investigating the effect of obesity or weight loss 
interventions on inflammatory processes in adipose tissue [50-53]. However, the 
impact of consumption of different dietary fatty acids, without weight loss, on 
processes in the adipose tissue is less well explored and needs further attention.  
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Figure 1 Increases in adipose tissue mass leading to insulin resistance and cardiovascular disease 
 
Although diet may affect several processes related to inflammation and insulin 
sensitivity traditionally only a few physiological endpoints, such as plasma insulin, 
glucose and some inflammatory cytokines, were measured in dietary intervention 
studies. This made it difficult to unravel the underlying mechanisms behind the health 
effects of specific diets or dietary components and therefore a more comprehensive 
approach is necessary. 
 
Nutrigenomics 
Nutrigenomics research will allow to get more knowledge on these underlying 
mechanisms since it investigates the genome-wide influences of nutrition on the 
transcriptome, proteome and metabolome of cells, tissues or organisms [23, 54]. The 
transcriptome reflects the genes that are being expressed and transcriptomics examines 
the expression level of messenger RNA in a cell population or tissue at any given time 
and under various conditions. Transcriptomics uses high-throughput tools such as 
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whole genome DNA microarrays which enables an almost unbiased comprehensive 
analysis of changes in the expression of all genes in case-control or control-
intervention samples. The use of transcriptomics gives insights in the genome-wide 
effects of specific diets or dietary components and in this way will increase 
understanding about the effect of nutrition on metabolic processes [54].  
 
Peripheral Blood Mononuclear Cells 
The application of transcriptomics in nutrition research is very promising but there are 
some restrictions for the use in human studies. For transcriptomics tissue samples are 
needed, but the availability of tissues from human subjects participating in dietary 
intervention studies is usually limited due to practical and ethical reasons. Muscle and 
adipose tissue biopsies are still relatively easy to collect and therefore the most 
sampled biopsies in human intervention studies. Theoretically it is possible to collect 
biopsies from other tissues such as intestine, prostate or liver but these have to be 
obtained through more invasive procedures which are usually not performed in healthy 
subjects in dietary intervention trials. Since tissue availability is a primary limitation 
several studies have investigated the use of human peripheral blood cells for human 
nutrigenomics research.   
Peripheral blood mononuclear cells (PBMCs), a mixture of T-cells, B-cells and 
monocytes, are easily obtainable by venipuncture and are an interesting source of 
biological material. In the first place because PBMCs have been shown to be 
metabolically active  but also because it is assumed that PBMCs might reflect 
physiological and pathological processes in different body tissues since they circulate 
throughout the whole body [55]. Moreover, PBMCs also play a role in inflammatory 
pathways that lead to atherosclerosis. Gene expression profiles of PBMCs were shown 
to reflect diseases states [56-58] and changes in diet composition [24, 59] and thus 
might serve as a suitable tool for nutrigenomics research. 
 
Biomarkers of health 
Nutrition research nowadays mainly focuses on prevention of metabolic disease and 
improvement of the health of individuals through diet. In order to achieve the highest 
benefit of nutrition subjects at risk to develop disease have to be identified as early as 
possible. To identify these subjects there is a need for very early biomarkers of disease 
to measure early signs of deviations from healthy metabolism. While currently only 
several single markers for disease are identified, new genomic techniques might help to 
define more extensive marker profiles of health and early disease state, both at 
transcriptome and proteome level. A marker profile, compared to single markers, might 
provide additional information on different and not always overlapping phases of 
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disease development. Especially in multifactorial, complex diseases such as T2DM and 
CVD this multi-marker approach is expected to be very suitable for early risk 
assessment [60]. 
 
Nutritional challenge 
Health status is often determined on the basis of metabolic measures, such as glucose, 
insulin, cholesterol, or triglycerides in the fasting state. Fasting metabolic measures are 
rather stable and not largely influenced by preceding meal intake. Therefore it is easier 
to set reference values for health status to which individual values can be compared. 
However, individuals spent the largest part of the day in the non-fasting condition and 
during a day their metabolic system has to cope with successive food intake. Every 
meal elicits a metabolic and inflammatory stress response and the body needs to 
respond to maintain homeostasis. The ability of subjects to respond to nutritional 
challenges can reflect the robustness and flexibility of their biological system and 
might give a better indication of health and disease risk than fasting measures [61, 62].   
Well-known examples of nutritional challenge tests are the oral fat loading test which 
can be used to detect impairments in lipid handling and the oral glucose tolerance test 
(OGTT) that is widely used to identify subjects with diabetes. The OGTT is used for 
diagnostic purposes because it gives an indication of the glucose clearance capacity of 
the body and it will enable the identification of impaired glucose tolerant subjects 
which cannot be recognized based on fasting glucose measurements [63].  
 
Body fat distribution 
Metabolic health can be impaired by increased adipose tissue mass as in the case in 
obesity. Recent studies have shown that it is not necessarily the amount of extra 
adipose tissue, but more importantly, the place where excess fat is stored that 
determines the metabolic health of a subject. The general idea is that as long as the 
subcutaneous adipose tissue depot has the capacity to store fat properly, adverse health 
effects of extra adipose tissue are limited [28]. However, when energy intake exceeds 
the storage capacity of subcutaneous adipose tissue, fat is deposited as visceral fat in 
the abdominal area and accumulates in ectopic depots such as liver [64]. Visceral 
adipose tissue appears to play an important role in the development of metabolic 
syndrome, diabetes and CVD [65, 66], but the underlying mechanisms are not 
completely clear. It might be because visceral fat is metabolically more active 
compared with subcutaneous fat. Moreover, because of its location the visceral adipose 
tissue can release its metabolic products such as free fatty acids into the portal vein, 
which provides direct delivery to the liver and might thereby promote liver insulin 
resistance.  
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Waist circumference has often been used as a surrogate measure of abdominal fat, but 
this measure cannot distinguish the amount of subcutaneous and visceral abdominal 
fat. For the measurement of the different abdominal fat depots magnetic resonance 
imaging (MRI) has been shown to be a valid method [67].  
 
OUTLINE THESIS 
 
In this thesis the acute and longer-term effects of intake of different types of dietary fat 
were investigated in subjects with different metabolic health profiles. To examine 
responses in adipose tissue, PBMCs and plasma nutrigenomics tools were used. 
First, an 8-weeks completely controlled dietary intervention study was performed to 
investigate the effects of consuming a high saturated (SFA) or high monounsaturated 
(MUFA) fat diet on insulin sensitivity and adipose tissue gene expression in 
abdominally overweight subjects (chapter 2).  
In the same dietary intervention study the effects of MUFA as part of a western-type 
diet and the effects of MUFA as part of a full Mediterranean (MED) diet on PBMC 
gene expression and plasma protein levels were investigated (chapter 3).  
The abdominally overweight subjects that participated in the intervention study were 
healthy but at risk to develop metabolic syndrome and related diseases because of their 
age and abdominal overweight. In these subjects protein profiling was used to improve 
the phenotypic characterization of these subjects and to identify new candidate profiles 
for early biomarkers of obesity-related diseases such as CVD and T2DM (chapter 4). 
In a second study the metabolic, immune and PBMC response to high-fat challenges in 
subjects with different metabolic risk phenotypes (i.e. lean healthy, obese healthy and 
obese diabetic) were characterized and the responses to different types of fat (i.e. SFA, 
MUFA and n-3 PUFA) were compared. The effect of abdominal body fat distribution 
on the response to a high-fat challenge was also examined (chapter 5). 
In the last study the effects of an extreme caloric restriction challenge on PBMC gene 
expression profiles in healthy subjects and subjects with metabolic syndrome were 
measured (chapter 6).  
In chapter 7 the results described in the previous chapters are discussed and evaluated.
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obesity-linked proinflammatory gene 
expression profile in adipose tissue of subjects 
at risk of metabolic syndrome 
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ABSTRACT  
 
Background: Changes in dietary fat composition could reduce the risk for developing 
metabolic syndrome. The adipose tissue is an interesting tissue in this respect because 
of its role in lipid metabolism and inflammation. 
Objective: Our objective was to investigate the effect of a saturated fatty acid (SFA)- 
and a monounsaturated fatty acid (MUFA)-rich diet on insulin sensitivity, serum lipids, 
and gene expression profiles of adipose tissue of subjects at risk for metabolic 
syndrome.  
Design: A parallel controlled-feeding trial was conducted in 20 abdominally 
overweight subjects. Subjects received an SFA diet or an MUFA diet for 8 wk. Plasma 
and subcutaneous adipose tissue samples were obtained, and insulin sensitivity was 
measured by using a hyperinsulinemic-euglycemic clamp. Adipose tissue samples 
underwent whole genome microarray histologic analysis. Plasma and adipose tissue 
fatty acid composition and concentrations of serum cholesterol and plasma cytokine 
were determined.  
Results: Consumption of the SFA diet resulted in increased expression of genes 
involved in inflammation processes in adipose tissue, without changes in morphology 
or insulin sensitivity. The MUFA diet led to a more anti-inflammatory gene expression 
profile, which was accompanied by a decrease in serum LDL-cholesterol 
concentrations and an increase in plasma and adipose tissue oleic acid content. 
Conclusion: Consumption of an SFA diet resulted in a proinflammatory ‘obese-linked’ 
gene expression profile, whereas consumption of a MUFA diet caused a more anti-
inflammatory profile. This suggests that replacement of dietary SFA by MUFA could 
prevent adipose tissue inflammation and may reduce the risk for inflammation-related 
diseases such as metabolic syndrome.  
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INTRODUCTION 
 
The presence of the metabolic syndrome represents a risk factor for cardiovascular 
diseases and type 2 diabetes mellitus and is characterized by central obesity, insulin 
resistance, dyslipidemia and hypertension [1, 2]. The pathogenesis of the syndrome is 
not completely understood but involves a complex interaction between genetic and 
lifestyle factors [68, 69]. Diet is one of the lifestyle factors that has been changed in the 
past decades, and this might have contributed to the enormous increase in the 
prevalence of obesity. With this increasing prevalence of obesity, there is growing 
interest in adipose tissue biology.  
In addition to its function as energy-storage organ, adipose tissue has important 
endocrine functions that are characterized by the release of adipocytokines and 
adipochemokines. Changes in adipose tissue mass are often accompanied by changes 
in production of these adipokines [70, 71]. Several studies have shown that obesity is 
accompanied by an increase in chronic low-grade inflammation in adipose tissue. This 
inflammation is characterized by macrophage infiltration and expression of 
inflammatory genes [72, 73]. Subsequent weight loss in obese subjects could reduce 
the gene expression of proinflammatory molecules, thereby improving the 
inflammatory status [50, 74]. The question is whether a change in diet without weight 
loss can result in similar changes in adipose tissue inflammatory status.  
One of the dietary components that is known to be positively associated with 
concentrations of inflammation markers in plasma is saturated fatty acids (SFA) [75-
77]. The replacement of an SFA-rich diet with a monounsaturated fatty acid (MUFA)-
rich diet can cause a decrease in plasma inflammatory molecules [49, 78] and could 
thereby result in an improvement in insulin sensitivity and LDL-cholesterol 
concentrations [79, 80]. 
One of the ways through which fatty acids may exert their effects on inflammation is 
through activation of peroxisome proliferator-activated receptors (PPARs). PPARs 
have regulatory roles in lipid and glucose homeostasis and activation of PPAR can 
decrease inflammation [81]. Activation of PPAR by fatty acids increases with chain 
length and degree of unsaturation of the fatty acid [82]. It is plausible that a shift in 
type of dietary fat from SFA toward MUFA might decrease the expression of 
inflammatory genes in adipose tissue via PPAR.  
To study the effects of changes in type of dietary fat on insulin sensitivity and adipose 
tissue functioning, we conducted a controlled-feeding trial in which we investigated the 
effect of an SFA-rich diet and an MUFA-rich diet on insulin sensitivity and whole-
genome transcriptional changes in adipose tissue from healthy subjects at risk of 
metabolic syndrome. 
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SUBJECTS AND METHODS 
 
Subjects 
Our study population was a subgroup of the participants who were included in a 
previously reported controlled-feeding trial [83]. Twenty persons from this trial were 
selected on the basis of their willingness to participate in additional measurements. 
Inclusion criteria were: age between 45 and 60 years and body mass index (BMI; in 
kg/m2) ≥ 25 or waist circumference ≥ 80 cm for women and ≥ 94 cm for men. Subjects 
were excluded if they were hypercholesterolemic subjects (total cholesterol ≥ 
8mmol/L) or if they had non-treated diabetics according to World Health Organization 
criteria [84]. Subjects provided informed consent, and the Medical Ethical Committee 
of Wageningen University (Netherlands) approved the study. 
 
Study design 
All subjects consumed an SFA-rich run-in diet for two wk. After run-in, the subjects 
were allocated to one of the intervention diets, which they consumed for 8 wk. Ten 
subjects received an SFA diet, which was similar to the run-in diet, and 10 subjects 
received an MUFA-rich diet. The diets were comparable with regard to carbohydrates, 
protein, total fat and dietary fiber. The SFA diet contained 19% SFAs and 11% 
MUFAs and the MUFA diet contained 11% SFAs and 20% MUFAs, mainly in the 
form of refined olive oil. During the study, 90% of energy need was supplied by the 
diet on the basis of the energy requirements of the subjects. For the remaining 10%, 
subjects had a limited choice from low-fat products.  
Subjects were advised to maintain their usual physical activity pattern. Body weight 
was monitored, and the level of energy intake was adjusted in order to prevent weight 
changes.  
 
Body weight and body composition 
Body weight, waist circumference and body composition were measured before and 
after intervention. Body composition was determined by air displacement 
plethysmography (BodPod; Life Measurement, Concord, CA)[85].  
 
Assessment of insulin sensitivity 
Insulin sensitivity was assessed by using the euglycemic-hyperinsulinemic clamp 
procedure as described by DeFronzo et al. [86]. The clamp measurements were 
performed before and during the run-in period and in the final 2 wk of the intervention. 
Glucose was clamped at a concentration of 5 mmol/L by titrating a variable infusion 
rate of glucose (20%) against a fixed infusion rate of insulin (Actrapid, Novo Nordisk 
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Farma BV, Alphen a/d Rijn, Netherlands, 40 mU.m-2.min-1). Glucose infusion rate was 
computed on the basis of glucose concentrations measured at 5-min intervals 
throughout the clamp. Once a steady state of 5 mmol/L glucose was reached for ≥ 30 
min, whole-body insulin sensitivity (M-value) was determined and expressed in µmol 
glucose.kg fat free mass-1.min-1.  
 
Adipose tissue 
Subcutaneous adipose tissue samples were obtained by needle biopsy from the 
periumbilical area under local anesthesia. The samples were collected after an 
overnight fast, before the clamp measurement. The samples were rinsed to eliminate 
blood and two-thirds of the sample was immediately frozen in liquid nitrogen and 
stored at -80°C. The remainder was fixed in formalin, dehydrated and embedded in 
paraffin for histology. 
 
Plasma fatty acid profile, cholesterol and plasma cytokines 
Venous blood was collected after an overnight fast at the end of the run-in period and 
at the end of the intervention period. Plasma free fatty acids (FFAs) were measured by 
gas-liquid chromatography as previously described [87]. Plasma FFA fractions were 
expressed as a percentage of total FFA.  
Concentrations of total and HDL-cholesterol were determined by a Dimension Clinical 
Chemistry System (Dade Behring Inc, USA). LDL-cholesterol was calculated by using 
the formula of Friedewald et al. [88].  
Concentrations of adiponectin, complement 3 (C3) and Regulated upon Activation 
Normal T-cell Expressed and Secreted / Chemokine CC-motif Ligand 5 
(RANTES/CCL5) were determined in plasma using the Luminex xMAP technology 
platform (Rules Based Medicine, Austin, Texas, USA). 
 
Adipose tissue fatty acid composition.  
Fatty acid composition of adipose tissue was measured according to the method of 
Deslypere et al [89]. Methylesters were prepared, separated by capillary gas 
chromatography, and detected with a flame ionization detector (Agilent 5890 Series II 
and 6890N). 
 
Histologic analysis 
Sections 3-µm thick were obtained from each adipose tissue sample. Hydrogen 
peroxide (3%) was added, followed by normal horse serum. The sections were 
incubated overnight (4°C) with anti-MAC-2 primary antibody (1:2000, Cedarlane 
Laboratories, Canada) and afterward for 30 min with a biotinylated horseradish 
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peroxidase-conjugated secondary antibody (horse anti-mouse IgG, Vector Laboratories, 
Burlingame, Canada). Histochemical reactions were performed by using Vector's 
Vectastain ABC Kit (Burlingame, CA) and Sigma Fast 3,3'-diaminobenzidine as 
substrate (Sigma, St. Louis, MO) [90]. Sections were counterstained with 
haematoxylin. For each subject we examined 3 adipose tissue sections before and 3 
sections after intervention. Sections were of comparable size, and we counted the 
MAC-2-positive cells that were present in the sections. 
 
RNA extraction 
Total RNA was isolated from adipose tissue by using Trizol reagent (Invitrogen, 
Breda, NL) and purified by using the Qiagen RNeasy Micro kit (Qiagen, Venlo, NL). 
RNA  integrity was checked on an Agilent 2100 bioanalyzer (Agilent Technologies, 
Amsterdam, NL).  
 
Microarray processing 
Total RNA (500 ng/sample) was labeled by using a one-cycle cDNA labeling kit 
(MessageAmpTM II-Biotin Enhanced Kit, Ambion) and hybridized to human whole 
genome GeneChip arrays encoding 17.699 genes, designed by the European 
Nutrigenomics Organisation and manufactured by Affymetrix (Santa Clara, CA). 
Sample labeling, hybridization to chips, and image scanning was performed according 
to the manufacturers’ instructions. 
 
Microarray data analysis 
Quality control was performed and fulfilled the criteria for array hybridization 
suggested by the Tumor Analysis Best Practices Working Group [91]. Microarrays 
were analyzed by using the reorganized oligonucleotide probes as described by Dai et 
al. [92]. All individual probes for a gene were combined, which allowed the possibility 
of detecting overall transcription activity, on the basis of the latest genome and 
transcriptome information, instead of on the basis of the Affymetrix probe set 
annotation. Expression values were calculated with the Robust Multichip Average 
(RMA) method and normalization  was done by using quantile normalization [93, 94].  
Only probe sets with normalized signals >20 on >5 arrays were defined as expressed 
and selected for analysis. Individual genes were defined as changed when comparison 
of the average normalized signal intensities showed a P-value <0.05 in a two-tailed 
paired t-test with Bayesian correction (Limma) [95].  
Data were analyzed with the use of Ingenuity Pathway Analysis version 6.0 (Ingenuity
 
Systems, Redwood City, CA), GenMAPP 2 (www.genmapp.org), Metacore version 4.7 
(GeneGo Inc, Kanata, Canada) and Gene Set Enrichment Analysis 
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(http://www.broad.mit.edu/gsea/). Because the results were similar, only results from 
Ingenuity Pathway Analysis are displayed. Our analysis identified canonical pathways 
that were most significant to the data set. The analysis was performed for up- and 
down-regulated gene sets separately. Array data has been submitted to the Gene 
Expression Omnibus (accession no. GSE14954). 
 
cDNA synthesis and quantitative real-time PCR 
Quantitative real-time polymerase chain reaction (q-PCR) was used to confirm 
microarray data. First, 500 ng of total RNA was reverse transcribed with a Promega 
cDNA synthesis kit (Promega Benelux BV, Leiden, NL). cDNA was PCR-amplified 
with Platinum Taq DNA polymerase (Invitrogen, Breda, NL) on a Biorad I-Cycler 
PCR machine. Primer sequences were chosen based on the sequences available in 
PRIMERBANK (http://pga.mgh.harvard.edu/primerbank/index.html). The mRNA 
expression of all genes was normalized to β-actin expression. 
 
Statistical analysis 
The statistical package SPSS (version 15.0; SPSS, Chicago, IL) was used for analysis 
of the data. Changes within diet groups were determined by paired t-tests. Differential 
changes between the diet groups were examined by unpaired t-tests.  
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RESULTS 
 
Subjects 
Baseline characteristics of the subjects are shown in table 1. No significant differences 
were observed, except for age, which was higher in the MUFA diet group (by 6.9 ± 2.6 
y). All subjects completed the trial. Weight slightly decreased with the SFA diet (-1.3 ± 
1.7 kg) and with the MUFA diet (-0.9 ± 1.3), but weight changes were not significantly 
different between the diet groups. Values are reported as means ±SDs. 
 
Table 1  Baseline characteristics of the subjects 
 
 SFA-rich diet  
(n=10) 
MUFA-rich diet  
(n=10) 
Age (y)   52.0 ± 6.3 58.9 ± 5.3* 
Sex (M/F)  5 / 5 5 / 5 
Body weight (kg)  79.8 ± 12.3 77.4 ± 14.2 
BMI (kg/m2)   26.1 ± 2.9 28.3 ± 6.6 
Waist circumference (cm) Men 102.0 ± 6.6 98.8 ± 6.5 
 Women 89.0 ± 4.2 96.8 ± 23.3 
Body fat percentage (%) Men 28.0 ± 3.1 31.3 ± 5.9 
 Women 36.6 ± 8.2 41.8 ± 12.1 
HDL cholesterol (mmol/L)  1.25 ± 0.28 1.28 ± 0.26 
Triglycerides (mmol/L)  1.06 ± 0.42 1.10 ± 0.34 
Insulin sensitivity (µmol.kg FFM-1.min-1)  52.47 ±  18.87 51.74 ± 12.48 
All values are shown as means ± SDs 
*significantly different from the SFA-rich diet group, P<0.05 (t-test) 
Abbreviations: saturated fatty acid (SFA), monounsaturated fatty acid (MUFA) 
 
Insulin sensitivity 
Clamps were used to determine the effect of the diets on insulin sensitivity. Although 
average changes in insulin sensitivity within the diet groups were positive with both 
diets, no significant changes were observed within and between the diet groups (table 
2). 
 
Lipids  
Mean (±SD) changes in plasma fatty acid composition are shown in table 2. Plasma 
total SFA (-4.04 ± 1.39%) was lower, whereas plasma total MUFA (6.23 ± 1.50%) and 
plasma oleic acid (6.15 ± 1.34%) were higher with the MUFA diet than with the SFA 
diet. No significant changes in total FFA concentrations were observed with the diets. 
The MUFA diet reduced serum total cholesterol (-0.60 ± 0.19 mmol/L) and LDL-
cholesterol (-0.49 ± 0.13 mmol/L) compared with the SFA diet but did not affect serum 
HDL cholesterol (table 2).  
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Table 2 Changes in assessed variables due to the intervention 
 Baseline1 Within group comparison2 Between group 
comparison 
(MUFA-SFA) 
 SFA diet 
(n = 10) 
MUFA diet 
(n = 10) 
SFA diet 
(n = 10) 
MUFA diet 
(n = 10) 
Difference1 P 
value 
Insulin sensitivity  
(µmol.kg FFM-1.min-1) 
52.47±18.87 51.74±12.48 5.40±10.14 7.79±16.32 2.38±6.08 0.70 
Total cholesterol (mmol/L) 5.57±1.10 5.67±0.62 -0.04±0.23 -0.64±0.54* -0.60±0.19 0.01 
LDL-cholesterol (mmol/L) 3.94±0.94 3.99±0.63 -0.03±0.25 -0.52±0.34* -0.49±0.13 <0.01 
HDL-cholesterol (mmol/L) 1.25±0.28 1.28±0.26 -0.02±0.08 -0.10±0.17 -0.08±0.06 0.20 
Plasma total FFA (g/L) 0.14±0.04 0.15±0.03 -0.01±0.04 -0.00±0.03 0.01±0.02 0.42 
Plasma total SFA(%) 35.04±1.66 34.95±2.65 0.26±2.59 -3.79±3.54* -4.04±1.39 0.01 
Plasma total MUFA(%) 40.52±2.83 38.59±3.44 -2.15±4.10 4.07±2.37* 6.23±1.50 <0.01 
Plasma oleic acid(%) 34.35±2.22 32.30±2.80 -1.97±3.70 4.18±2.09* 6.15±1.34 <0.01 
Plasma total PUFA(%) 22.53±2.56 24.43±3.61 1.38±5.66 -0.08±3.90 -1.46±2.18 0.51 
Adipose tissue total SFA(%) 30.00±2.52 29.92±2.17 0.09±0.73 -0.06±0.65 -0.15±0.31 0.63 
Adipose tissue total 
MUFA(%) 
51.32±2.90 51.45±2.23 -0.13±0.71 0.32±0.85 0.45±0.35 0.21 
Adipose tissue oleic acid(%) 34.35±2.22 32.30±2.81 -0.20±0.65 0.50±0.57* 0.70±0.27 0.02 
Adipose tissue total 
PUFA(%) 
22.53±2.56 24.43±3.61 0.01±0.53 -0.08±0.30 -0.09±0.19 0.64 
Adiponectin (µg/mL) 3.07±0.65 3.96±1.68 -0.20±0.35 -0.13±0.51 -0.07±0.19 0.72 
Complement 3 (mg/mL) 0.90±0.12 0.96±0.11 -0.01±0.08 0.05±0.13 -0.07±0.05 0.20 
RANTES/CCL5 (ng/mL) 5.49±4.66 8.51±5.43 -4.16±5.08 -7.08±5.65 2.95±2.41 0.24 
1Values are means ± SDs, 2Values are mean changes ± SDs, *changed within the diet group (p<0.05), within group 
comparison were made by paired t test; between-group comparisons were made by standard t test. Abbreviations: 
Saturated Fatty Acids (SFA), Monounsaturated Fatty Acids (MUFA), Polyunsaturated fatty acids (PUFA), free fatty acid 
(FFA), Free fatty acid (FFM), Regulated on activation normal T cell expressed and secreted/chemokine (C-C motif) 
ligand 5 (RANTES/CCL5) 
 
Adipose tissue fatty acid composition 
Fatty acid profiling in adipose tissue was used to determine incorporation of dietary 
fatty acid composition in adipose tissue (table 2). Similar to plasma fatty acid 
composition, the oleic acid fraction of the adipose tissue fatty acids was significantly 
higher (0.70 ± 0.27%) upon the MUFA diet than with the SFA diet. 
 
Microarray analysis 
Microarray analysis was performed on adipose tissue before and after intervention. 
From the 16314 genes on the array, 13280 genes were expressed in adipose tissue 
(figure 1). Intervention with the SFA diet resulted in changed expression of 1523 genes 
whereas intervention with the MUFA diet resulted in changed expression of 592 genes. 
Of these genes, 76 were differentially expressed on both diets. Similar numbers of 
genes were up- and down-regulated. To gain further insight into the role of these genes, 
pathway analysis was performed. A total of 38 canonical pathways were altered by the 
SFA diet whereas 12 pathways were regulated by the MUFA diet (figure 1). The top 
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ten most significantly up and downregulated pathways for each diet are listed in figure 
2. For the MUFA diet, only 5 pathways were significantly up-regulated. Consumption 
of the SFA diet resulted in the most strongly regulated pathways, which were mainly 
up-regulated and primarily included processes related to immune function and 
inflammation. The down-regulated pathways included amino acid metabolism and fatty 
acid metabolism. The genes that were down-regulated within the pathway of fatty acid 
metabolism are mainly involved in fatty acid oxidation and triglyceride synthesis. 
Consumption of the MUFA diet resulted in an up-regulation of phospholipid 
metabolism and degradation and eicosanoid signaling and in a down-regulation of the 
complement system and pyruvate metabolism. Sterol regulatory element-binding 
protein-1 (SREBP-1) and SREBP-1-dependent genes involved in lipogenesis were 
down-regulated as well. 
 
 
 
Figure 1 Selection of genes in microarray analysis. Abbreviations: Robust Multichip Average (RMA), Saturated 
Fatty Acids (SFA), Monounsaturated Fatty Acids (MUFA) 
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Figure 2 Top 10 significantly up- and down-regulated canonical pathways of each diet according to Ingenuity 
Pathway Analysis. Black bars indicate the saturated (SFA)-rich diet, and grey bars indicate the monounsaturated 
(MUFA)-rich diet. Numbers next to the bars indicate the number of significantly changed genes involved in each 
pathway. The significance of each pathway is indicated by –log(P value) >1.3 which corresponds to P<0.05. The 
dashed vertical line crosses the x-axis at –log(P value) = 1.3 
 
The individual expression changes of genes involved in the most markedly altered 
immune pathways are depicted in a heatmap in supplemental data figure 1 
(http://www.ajcn.org/content/90/6/1656/suppl/DC1). Overall, consumption of an SFA 
diet for 8 wk resulted in an increased expression of genes involved in immune 
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processes whereas the same genes were not changed or down-regulated after 
consumption of the MUFA diet.  
Several genes that are known to be involved in inflammation and that were not present 
in the pathways in figure 2 were also up-regulated with an SFA diet and are shown in 
figure 3. These included markers for recruitment of leukocytes, genes involved in 
prostaglandin synthesis and monocyte/macrophage markers. Consumption of the 
MUFA diet, however, resulted in a down-regulation of several adipose tissue 
macrophage genes.  
In concordance with the increase in expression in markers of inflammation, expression 
of the antiinflammatory adipokine adiponectin (ADIPOQ) and transcription factor 
PPARγ was decreased on the SFA diet. Clear differences in individual responses to the 
diets  are also shown in figure 3.  
 
Figure 3 Gene expression changes of other well-known immune related genes, which were significantly changed 
with one of the diets (paired t-test with Bayesian correction). Each row represents a single gene, each column 
represents a single person in a diet group. The expression scale is log2-based and ranges from ≤-0.5 (green) to ≥ 
0.5 (red). 
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Immunohistochemistry 
To investigate whether the diet-induced gene expression changes also resulted in 
protein or morphological changes in adipose tissue, immunohistochemical analysis for 
MAC-2 was performed. The adipose tissue seemed apparently healthy, and only a few 
MAC-2-positive cells that formed characteristic crownlike structures was seen for  only 
one person who received the SFA diet (supplemental data figure 2 
http://www.ajcn.org/content/90/6/1656/suppl/DC1). 
 
Confirmation of gene expression data 
To confirm gene expression changes revealed by microarray analysis, q-PCR was used. 
Genes for q-PCR were selected based on their role in different inflammatory processes. 
Expression of ADIPOQ, RANTES/CCL5, CD14, CD163 and ras-related C3 botulinum 
toxin substrate 2 (RAC2) also significantly changed with q-PCR (figure 4). The change 
in expression of complement subcomponent C1q (C1QB), cathepsin S (CTSS) ,integrin 
beta 2 (ITGB2) and PPARγ showed the same direction and extent of change as the 
microarray data but was not significant.  
 
 
 
Figure 4 Validation of genes with quantitative real-time polymerase chain reaction (q-PCR). Black bars represent 
the mean (±SD) log2-transformed expression changes with the saturated fatty acid (SFA)-rich diet after 
intervention and grey bars represent the log2-transformed expression changes with the monounsaturated fatty acid 
(MUFA)-rich diet. For q-PCR data, significance was determined by using a paired t-test. *significantly different, 
P<0.05.  
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Adiponectin, Complement 3 and RANTES/CCL5 in plasma 
To elucidate whether changes observed in adipose tissue for gene expression level 
were also reflected by changes in plasma, concentrations of adiponectin, C3 and 
RANTES/CCL5 were measured. In concordance with the gene expression in adipose 
tissue, plasma adiponectin concentrations decreased in 8 out of 10 subjects with the 
SFA diet (-0.20 ± 0.35 µg/mL) and did not change with the MUFA diet (-0.13 ± 0.51 
µg/mL). Plasma C3 concentrations were not changed (-0.01 ± 0.08 and 0.05 ± 0.13  
mg/mL for the SFA and MUFA diets, respectively) and plasma RANTES/CCL5 
concentrations were significantly decreased with both diets (-4.16 ± 5.08 and -7.08 ± 
5.65 ng/mL for the SFA and MUFA diets, respectively). 
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DISCUSSION  
 
Several studies have shown increased inflammation in adipose tissue of obese subjects 
and revealed its possible role in the development of insulin resistance [96-98]. Our 
study suggests that the type of dietary fat is an important component in the cause of 
adipose tissue inflammation. We showed in a controlled-feeding trial that consumption 
of an SFA diet results in increased expression of genes involved in inflammatory 
processes, whereas consumption of an MUFA diet results in a decreased expression of 
inflammatory genes in adipose tissue of abdominally overweight subjects. 
Consumption of the diets did not change insulin sensitivity, but total and LDL 
cholesterol concentrations were decreased with the MUFA diet. 
Some of the inflammation processes that were strongly up-regulated on the SFA diet 
were T and B cell receptor signaling and leukocyte extravasation signaling. This could 
be indicative of increased attraction of immune cells toward the adipose tissue with 
subsequent infiltration of the tissue and increased local inflammation. It is well known 
that macrophages can infiltrate adipose tissue in obese subjects, and the presence of T-
cells in adipose tissue of obese and diabetic mice and humans has recently been 
confirmed [99-101]. In addition to the up-regulation of lymphocyte-related processes, 
up-regulation of macrophage markers was observed with the SFA diet. Consumption of 
the MUFA diet resulted in antiinflammatory effects because the expression of genes 
involved in complement system and expression of macrophage marker genes were 
decreased. For both diets immunohistochemical staining of macrophages showed no 
changes in macrophage infiltration in the adipose tissue samples. In addition to 
inducing expression of genes involved in inflammation, the SFA diet reduced 
expression of genes involved in fatty acid β-oxidation and triglyceride synthesis. This 
could point to decreased lipid handling capacity of the adipocytes, possibly as a cause 
or a consequence of increased inflammation.  
So far, inflammation in adipose tissue is reported to be present predominantly in 
obesity. Microarray expression profiling of adipose tissue from obese and non-obese 
Pima Indians showed an over-expression of genes involved in immune processes in 
obese subjects [52, 73]. Many of these overexpressed genes, such as CTSS, IL-8 and 
ITGB2, were also up-regulated in our study in response to the SFA diet. In addition, 
adiponectin expression in adipose tissue and adiponectin plasma concentration, which 
are usually decreased in obesity, were lowered on the SFA diet [102]. Furthermore, 
weight loss in obese subjects resulted in decreased expression of genes involved in T 
and B cell receptor signaling [100], whereas we observed that consumption of the SFA 
diet induced these processes [74, 100].  
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In consideration of the similarities between the gene expression profiles in obesity and 
gene expression changes due to the SFA diet, we hypothesize that consumption of the 
SFA diet leads to an obese-linked gene expression profile in the adipose tissue without 
obtaining an obese phenotype. Our study subjects were non-diabetic, were only 
moderately overweight, and did not gain weight during the study, indicating that the 
observed up-regulation of inflammatory processes in their adipose tissue was not due 
to weight gain but can only be explained by consumption of the SFA diet. A high SFA 
intake is associated with elevated concentrations of plasma inflammation markers [75-
77] but has never been shown to induce inflammation-related gene expression in 
adipose tissue. 
We observed a large interindividual variation in response to the diets. Possible reasons 
for this could be the genetic and epigenetic variation between the subjects. [103]. In 
addition, adipose tissue samples were obtained before completing the run-in period, 
and dietary patterns before the study might have influenced the individual response. On 
the basis of the outcome of our study, we speculate that subjects were consuming less 
SFA before start of the study than was provided by our intervention.  
On the basis of former studies [17, 79, 80], we hypothesized that consumption of an 
MUFA diet would improve insulin sensitivity and cholesterol concentrations 
accompanied by gene expression changes in processes contributing to improvements in 
health. The MUFA diet did not affect insulin sensitivity but reduced total and LDL 
cholesterol. In addition, a change to a more unsaturated fatty acid profile in both 
plasma and adipose tissue was observed, accompanied by the down-regulation of 
proinflammatory genes in adipose tissue. It is hard to distinguish within this study 
whether the beneficial effects observed with the MUFA diet are due to increased 
MUFA content or decreased SFA content; it could be a combination of both. 
Despite increases in inflammatory gene expression, which is associated with decreased 
insulin sensitivity [104], we did not observe changes in insulin sensitivity. A possible 
reason might be that the intervention period was too short to induce significant 
changes. Yet, this also shows the high potential for use of gene expression profiles as a 
sensitive and early marker for nutrition-induced changes. 
The changes in adiponectin plasma concentration are in line with the gene expression 
changes in adipose tissue, whereas the changes in plasma RANTES/CCL5 and C3 are 
not. In contrast to adiponectin, RANTES/CCL5 and C3 are not secreted only by 
adipose tissue but also by other tissues that are apparently not affected in this early 
inflammatory stage. Furthermore, an increase in inflammatory gene expression in 
adipose tissue does not necessarily result in adverse effects on whole body level. A 
controlled immune response indicates that the body is able to react properly to certain 
triggers, thereby protecting itself from infections and diseases. We hypothesize that the 
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observed gene expression changes  while on the SFA diet are early local responses 
restricted to the adipose tissue. Prolonged consumption of an SFA diet might result in 
more systemic effects leading to adverse health effects on whole-body level. 
The question remains how consumption of an SFA diet could lead to an ‘obese’ 
proinflammatory gene expression profile in adipose tissue of healthy, abdominally 
overweight subjects. In obesity, inflammation is usually accompanied by increased 
plasma fatty acids and increased adipose tissue mass. Both can result in increased 
inflammation, either due to hypoxia in the expanding adipose tissue, or due to lipid 
overload in various organs [98, 104]. However, we did not observe changes in total 
plasma FFA concentrations or changes in total adipose tissue mass for either of the 
diets; nor did we observe changes in expression of genes involved in hypoxia. A 
possible mechanism for the changed expression of inflammatory genes may be that the 
consumed fatty acids have different affinities to bind and activate immune processes 
regulating receptors such as the Toll like receptors (TLR) and nuclear receptors such as 
PPARs. It is known that SFA can modulate TLR activation and the expression of target 
genes of these receptors, which are involved in the inflammatory response [105, 106]. 
In our study, we observed that the SFA diet induced expression of different TLRs, the 
adaptor protein myeloid differentiation primary response gene 88 (MYD88) and its 
target genes, e.g. IL-8, RANTES/CCL5, chemokine ligand 4 (CCL4), CD86, 
prostaglandin-endoperoxide synthase 2 (PTGS2) and chemokine ligand 10 (IP-10). 
This could point toward a role of the TLR pathway in SFA-mediated gene expression. 
Another finding is the down-regulation of the transcription factor PPARγ and several 
target genes- ie lipoprotein lipase (LPL), 1-acylglycerol-3-phosphate O-acyltransferase 
2 (AGPAT2) and adiponectin. SFA are poor ligands for PPARγ [107], and because 
PPARγ activation results in the down-regulation of inflammation, a decreased 
activation of PPARγ by SFA might lead to increased inflammation. This could suggest 
a possible role of PPARγ in the SFA-mediated expression of genes involved in 
inflammation. 
In conclusion, our study shows that consumption of an SFA diet, compared with a 
MUFA-rich diet, leads to a proinflammatory obese-linked gene expression profile in 
adipose tissue of persons at risk for metabolic syndrome. Adipose tissue gene 
expression appears to be affected by diet before adipose tissue morphology or insulin 
sensitivity are changed and might be one of the first hallmarks in the development of 
metabolic syndrome.  
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ABSTRACT 
 
Background: The Mediterranean diet is considered as health promoting, the effect 
often being ascribed to its high content of monounsaturated fatty acids (MUFA) and 
polyphenols. These bioactive compounds can affect gene expression and might in this 
way regulate pathways and proteins related to cardiovascular disease prevention. 
Objective: This study aimed to identify the effects of replacement of saturated fat 
(SFA) by MUFA in a western-type diet and the effects of a full Mediterranean (MED) 
diet on whole genome peripheral blood mononuclear cell (PBMC) gene expression and 
plasma protein profiles.  
Design: Abdominally overweight subjects were allocated to a 8 wk completely 
controlled SFA-rich diet, a SFA-by-MUFA-replaced diet (MUFA diet) or a MED diet. 
Concentrations of 124 plasma proteins and PBMCs whole genome transcriptional 
profiles were assessed. 
Results: Consumption of the MUFA and MED diet, compared with the SFA diet, 
decreased expression of oxidative phosphorylation (OXPHOS) genes, serum lipids and 
plasma Connective Tissue Growth Factor, myoglobin and Apo B concentrations. The 
MED diet additionally lowered plasma α-2-macroglobulin concentration compared 
with the SFA diet. Within the MED diet group concentrations of several pro-
inflammatory proteins were lowered. 
Conclusion: We conclude that MUFA as replacement of SFA in a western-type diet 
had similar effects on lowering expression of OXPHOS genes as in a MED diet. We 
hypothesize that replacement of SFA by MUFA increased metabolic health as reflected 
by lowered serum lipids and certain plasma proteins, thereby reducing metabolic stress 
and OXPHOS activity in PBMCs. The MED diet may have additional anti-atherogenic 
effects by lowering concentrations of pro-inflammatory plasma proteins. 
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INTRODUCTION 
 
The importance of a healthy and balanced diet in the prevention of chronic diseases 
such as diabetes, cardiovascular disease (CVD) and cancer has been extensively 
studied and several dietary components with positive or negative health effects have 
been identified. Most studies have focused on the relation of single dietary components 
with disease, whereas a diet is a mixture of many dietary components that can interact 
with each other [108]. Nutritional scientists and institutions stimulate the translation 
from nutrient-based recommendations to food based recommendations [109] [110]. 
The Mediterranean diet has received considerable attention in this respect. It is 
characterized by a high intake of olive oil, fruits, vegetables, legumes, nuts, unrefined 
cereals, moderate intake of wine, and low to moderate intake of dairy products, meat, 
poultry, and fish [8, 111]. In spite of the relatively high fat content in the form of olive 
oil, consumption of the diet has been associated with a lower risk for CVD and 
metabolic syndrome [10, 112]. Furthermore, it has been associated with lower risk for 
certain types of cancer and with positive effects on cognitive function and longevity [7, 
111-114]. Consumption of a Mediterranean diet has shown to affect CVD risk by 
lowering serum LDL cholesterol, increasing serum HDL cholesterol, improving blood 
pressure, hemostasis and endothelial function, but it is also suggested to influence 
inflammation and oxidative stress [17, 49, 115-118]. Virgin olive oil was identified as 
one of the main health promoting components of the Mediterranean diet, due to its high 
content of monounsaturated fat (MUFA) and polyphenols [118, 119].  
The underlying mechanism of the positive effects of olive oil and the Mediterranean 
diet are still not fully understood. Components of the Mediterranean diet may execute 
their positive effects by decreasing circulating inflammatory and vascular markers in 
plasma and by decreasing expression of activation markers on PBMCs [49, 120-122]. 
In part this can be done by activation of cellular adaptive response pathways as 
numerous components of the diet are ligands of transcription factors that control gene 
expression of large sets of target genes [123]. We recently showed that longer term 
intake of distinct types of fatty acids had differentiating effects on gene expression 
profiles in PBMCs [59] and others showed that virgin olive oil consumption can alter 
PBMC gene expression [124, 125]. As PBMCs are of pivotal importance in the 
development of atherosclerosis characterization of the effects of consumption of the 
Mediterranean diet and of the MUFA component of the diet on whole genome gene 
expression changes in PBMCs may reveal leads towards possible molecular 
mechanisms.  
We investigated the effects of replacement of SFA by MUFA from refined olive oil in 
a western type diet and the effects of a full MED diet high in MUFA from extra virgin 
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olive oil on whole genome PBMC gene expression. We also measured the effects of 
these diets on 124 plasma proteins implicated in chronic diseases, inflammation, 
endothelial function and metabolism. Our study will enable the differentiation between 
the effects of a single food component such as MUFA from olive oil and the effects of 
a mixture of foods such as in the MED diet on both PBMC gene expression and plasma 
proteins. 
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SUBJECTS AND METHODS 
 
Subjects 
In this study 60 healthy men and women were initially included. Inclusion criteria were 
age between 45 and 60 years and body mass index ≥ 25 kg/m2 or waist circumference ≥ 
80 cm for women and ≥ 94 cm for men. Subjects were excluded if they were 
hypercholesterolemic (total cholesterol ≥ 8 mmol/L), used anti-hypertensive or 
cholesterol-lowering medication or if they had non-treated diabetes according to World 
Health Organization criteria [84]. Subjects provided informed consent, and the Medical 
Ethical Committee of Wageningen University (the Netherlands) approved the study. 
 
Study design 
All subjects consumed a western type diet high in SFA (19 en %) for a two weeks run-
in period to standardize dietary conditions. After run-in, the subjects were allocated to 
one of the intervention diets, which they consumed for 8 weeks. Subjects received 
either the western type SFA diet, which was similar to the run-in diet, a western type 
diet in which SFA was largely replaced by MUFA, mainly from refined olive oil 
(MUFA diet), or a Mediterranean type diet (MED diet) high in MUFA from extra 
virgin olive oil and other Mediterranean components (i.e. fatty fish, unrefined grain 
products, nuts, legumes and red wine). During the study, 90% of the energy need of the 
subjects was supplied by the test diet, for the remaining 10% subjects had limited 
choice of low-fat products which they all recorded. The composition of the diets is 
shown in table 1. Values are based on chemical analysis of complete duplicate diets 
plus the calculated contribution of the recorded low-fat products. The duplicate diets 
were collected daily for one energy level in each intervention group and pooled over all 
days. Subjects were advised to maintain their usual physical activity pattern. Body 
weight was monitored, and energy intake was adjusted to prevent weight changes. 
A more detailed description of the study design and the diets has been published 
previously [117]. 
 
Blood collection and PBMC isolation  
Fasting venous blood samples were collected at baseline, which is at the end of the run-
in period, and after 8 weeks diet intervention. Immediately after blood collection, 
PBMCs were isolated by using the BD Vacutainer Cell Preparation Tubes according to 
the manufacturer’s instructions. 
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Table 1 Mean daily intake of energy and nutrients of subjects on the SFA, MUFA, or MED diets according to 
duplicate portions plus recorded foods.  
 SFA diet MUFA diet MED diet 
Energy (MJ/d) 10.7 10.4 10.3 
Total fat (energy-%) 36.8 39.9 40.2 
SFA (energy-%) 19.2 10.9 10.7 
MUFA (energy-%) 10.7 20.3 21.4 
PUFA (energy-%) 5.4 7.0 6.5 
n-3 PUFA (energy-%) 0.4 0.6 0.8 
n-6 PUFA (energy-%) 5.0 6.4 5.6 
Protein (energy-%) 13.5 11.4 14.5 
Carbohydrates (energy-%) 47.3 46.4 41.1 
Dietary fibre (g/MJ) 2.4 2.4 3.6 
Cholesterol (mg/MJ) 25.7 24.2 25.6 
Alcohol (energy-%)* 2.3 2.2 4.2 
 
*Red wine was provided in the MED diet group. Alcohol consumption (maximum 2 glasses/day) was allowed in 
the other diet groups as well, with the exception of red wine. 
Abbreviations: Saturated Fatty Acids (SFA), Monounsaturated Fatty Acids (MUFA), Mediterranean (MED) and 
Polyunsaturated Fatty Acids (PUFA). 
 
RNA isolation and microarray analysis 
RNA was isolated of all PBMC samples by using the Qiagen RNeasy Micro kit 
(Qiagen, Venlo, Netherlands). The RNA yield was quantified with a Nanodrop ND 
1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE), and RNA 
integrity was checked on an Agilent 2100 bioanalyzer with RNA 6000 Nano chips 
(Agilent Technologies, South Queensferry, United Kingdom). Samples were only 
accepted for microarray analyzes if the RNA integrity number (RIN) was > 8.  
Total RNA (500 ng/sample) was labeled by using an one-cycle cDNA labeling kit 
(MessageAmpTM II-Biotin Enhanced Kit; Ambion Inc, Nieuwekerk a/d IJssel, 
Netherlands) and hybridized to human whole-genome GeneChip arrays encoding 
17,699 genes, designed by the European Nutrigenomics Organization (NuGO) and 
manufactured by Affymetrix (Santa Clara, CA). Sample labeling, hybridization to 
chips, and image scanning were performed according to the manufacturers’ 
instructions.  
 
Microarray data analysis 
Results of quality control showed that 98 microarrays fulfilled our criteria. Microarrays 
were analyzed by using the reorganized oligonucleotide probes as described by Dai et 
al (29). All individual probes for a gene were combined, which allowed the possibility 
of detecting overall transcription activity on the basis of the latest genome and 
transcriptome information instead of on the basis of the Affymetrix probe set 
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annotation. Expression values were calculated with the Robust Multichip Average 
(RMA) method and normalized by using quantile normalization (30, 31). Only probe 
sets with normalized signals >20 on >5 arrays were defined as expressed and selected 
for analysis. Genes were defined as differently changed between the diets when the 
average normalized signal intensities showed a P value <0.05 in one-way ANOVA. 
Data were analyzed with the use of Ingenuity Pathway Analysis version 8.5 (Ingenuity 
Systems, Redwood City, CA) to identify canonical pathways that were most significant 
to the data set. Array data have been submitted to the Gene Expression Omnibus 
(GSE30509). 
 
Serum lipids 
Concentrations of triglycerides, total and HDL cholesterol were determined by a 
Dimension Clinical Chemistry System (Dade Behring Inc, Newark, NJ). LDL 
cholesterol was calculated by using the formula of Friedewald et al [88]. 
 
Plasma proteins 
Concentrations of a set of 124 proteins were measured in fasting plasma before and 
after the intervention by multiplex immunoassay (Rules Based Medicine Inc, Austin, 
Texas, USA). The set of proteins present on this assay consists of proteins that are 
implicated in chronic diseases, inflammation, endothelial function and metabolism. In 
online supplemental table 1 all measured proteins are listed 
(http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0014422#s)
Before analysis, 16 out of 124 proteins were removed from the dataset as the 
concentrations of these proteins were below the detection limit in more than half of the 
samples. For the remaining 108 proteins, values below the detection limit were 
replaced by 0.1*Least Detectable Dose. As IL-6 was one of the removed proteins and 
IL-6 was reported to be lowered after consumption of Mediterranean type of diets [49, 
120], this protein was separately measured by high-sensitive enzyme immunoassay 
(Human IL-6 Quantikine HS ELISA Kit, R&D Systems, Abingdon, United Kingdom). 
Apo lipoprotein B (ApoB) was not included in the Human Multi-Analyte Profiles, and 
ApoB levels were additionally measured on a Hitachi 912 autoanalyser (Roche, 
Lelystad, The Netherlands) using a commercially available kit (Roche cat. 
nr.1551779). In total, 110 proteins were included in the analysis.  
 
Statistical analysis 
The statistical package PASW (version 17.0; SPSS Inc, Chicago, IL) was used for 
analysis of the data. Differential changes between the diet groups were examined using 
one-way ANOVA followed by a Least Significance Difference (LSD) post hoc test. 
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Changes within diet groups were determined by paired t-tests. For not normally 
distributed data changes between groups were examined using the Kruskal-Wallis test 
and changes within subject groups were examined using the Wilcoxon signed-rank test. 
LSD post hoc tests for non-normally distributed variables were performed on rank 
scores for these variables.  
 
RESULTS 
 
From the 60 subjects entering the study, 57 subjects completed the study. For 49 of 
these 57 subjects protein concentrations were measured and high-quality microarray 
analyses were performed on PBMCs collected before and after the intervention 
(supplemental figure 1). Baseline characteristics of these 49 subjects are shown in table 
2. Adherence to the intervention diets caused small changes in body weight, but these 
changes were not significantly different between diet groups. Serum LDL cholesterol 
was reduced both by the MUFA diet (-0.40 mmol/L, 95%CI: -0.69,-0.12) and the MED 
diet (-0.54 mmol/L, 95%CI:-0.83, -0.25) compared with the SFA diet. The MED diet 
additionally increased HDL cholesterol (0.12 mmol/L, 95%CI 0.02, 0.21) compared 
with the MUFA diet. Triglyceride levels were reduced by the MED diet compared with 
the SFA diet (-0.32 mmol/L, 95% CI:-0.48; -0.15) and the MUFA diet (-0.24 mmol/L, 
95%CI: -0.41; -0.07). An extensive analysis of triglcyerides, cholesterol and other 
metabolic parameters measured in all 57 subjects has been published previously [117]. 
 
Table 2 Baseline subject characteristics 
 SFA diet 
(N=17) 
MUFA diet 
(N=17) 
MED diet 
(N=15) 
Sex (m/f) 8 / 9 8 / 9 6 / 9 
Age (years)  52.2 ± 6.9 58.4 ± 5.3 55.6 ± 6.5 
BMI (kg/m2) 26.3 ± 2.8 27.8 ± 5.6 29.5 ± 6.4 
Total cholesterol (mmol/L) 5.66 ±1.14 5.86 ± 0.67 5.75 ± 1.07 
LDL cholesterol (mmol/L) 4.00 ± 0.99 4.01 ± 0.65 3.99 ± 0.96 
HDL cholesterol (mmol/L) 1.27 ± 0.27 1.37 ± 0.35 1.21 ± 0.39 
Triglycerides (mmol/L) 1.08 ± 0.51 1.27 ± 0.49 1.52 ± 0.78 
Data is displayed as mean ± standard deviation 
Abbreviations: Saturated Fatty Acid (SFA), Monounsaturated Fatty Acid (MUFA), Mediterranean (MED) 
 
PBMC microarray analyzes 
A total of 656 genes was differently expressed between the three diets (ANOVA p-
value<0.05). Post-hoc tests revealed that 372 genes were differently regulated between 
the MUFA and SFA diet and 216 genes were differentially regulated between the MED 
and the SFA diet. 
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Ingenuity pathway analysis identified canonical pathways that were significant to our 
dataset and figure 1 shows the ten most significant pathways. The three most 
differentially regulated pathways between the diets were oxidative phosphorylation 
(OXPHOS), mitochondrial dysfunction and ubiquinone biosynthesis. To visualize the 
effects of each diet, average expression changes per diet of the genes presented in these 
pathways are shown in figure 2. This figure illustrates that the MUFA diet mainly 
caused a down regulation of genes involved in mitochondrial OXPHOS and most of 
these genes were also down regulated with the MED diet, although to a lower extent. 
Most of the other differentially regulated pathways were signaling pathways. Diet 
effects on these pathways were less univocal.  
 
Figure 1 Ten most significantly changed pathways between the SFA, MUFA and MED diets as analyzed by Ingenuity 
Pathway analysis. Horizontal bars indicate the –log (p value), squares indicate the number of differently regulated genes 
within a pathway. 
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Figure 2 Average expression changes of genes in the most significant differently regulated pathways (oxidative 
phosphorylation, mitochondrial dysfunction, ubiquinone biosynthesis). Average changes in expression (signal log ratios) 
for each diet group are displayed on a color scale, ranging from ≤ -0.25 (green) ≥ 0.25 (red). 
 
Plasma proteins 
Of the 110 plasma proteins analyzed, seven proteins were differently changed by the 
diets (table 3) and included Alpha-2-Macroglobulin (A2M), Apolipoprotein B (ApoB), 
Connective Tissue Growth Factor (CTGF), Interleukin 12p70, Myoglobin, Sex 
Hormone Binding Globulin (SHBG) and Thyroxine Binding Globulin (TBG). Posthoc 
analyzes showed that compared with the SFA diet both the MUFA and MED diet 
reduced concentrations of ApoB, CTGF and myoglobin. Additional effects of the 
MUFA diet were observed for TBG and SHBG concentrations that increased and for 
IL12p70 concentration that decreased. An additional effect of the MED diet was found 
for A2M which concentration decreased compared with the SFA diet. TBG 
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concentrations in the MUFA diet were not only increased compared to the SFA but 
also to the MED diet. Concentrations of all proteins before and after intervention are 
displayed in supplemental table 2. Concentrations of several pro-atherogenic and pro-
inflammatory proteins such as IL1β, Factor VII, macrophage inflammatory protein 
(MIP1α), Serum Amyloid P (SAP), Thrombopoietin (TPO) and Vascular Endothelial 
Growth Factor (VEGF) were significantly lowered in subjects within the MED diet 
group, but these changes were not significantly different from the smaller changes 
observed in the other groups. 
 
Table 3 protein concentrations of differentially changed proteins before and after diet intervention  
 SFA diet MUFA diet MED diet Between 
diets 
Protein Baseline After 
intervention 
Baseline After 
intervention 
Baseline After 
intervention 
P value # 
A2M 
(mg/mL) 
0.83±0.17 0.85±0.16 0.81±0.18 0.78±0.15 0.85±0.21 0.75±0.14* <0.05b 
Apo B 
(mg/mL) 
1.09±0.27 1.12±0.29 1.10±0.17 1.03±0.20* 1.15±0.24 1.02±0.24* <0.005a,b 
CTGF 
(ng/mL) 
2.02±0.72 2.11±0.94 2.6±1.01 2.23±0.88* 2.09±1.24 1.75±1.11* <0.05a,b 
IL12p70 
(pg/mL) 
70.7±38.9 77.8±37.0 70.3±20.2 66.1±21.1 65.8±15.6 65.5±13.1 <0.05a 
Myoglobin 
(ng/mL) 
10.0 
(8.4,14.5) 
12.4 
(9.4,15.0) 
11.8 
(8.9,16.2) 
10.8 
(7.9,15.4)† 
12.3 
(9.4,16.0) 
11.6 
(9.0,13.2) 
<0.05a,b 
SHBG 
(nmol/L) 
51.7±28.5 48.0±23.9* 39.8±15.9 41.4±18.9 36.5±15.0 36.5±14.9 <0.05a 
TBG 
(µg/mL) 
52.8±14.9 51.7±12.3 54.6±9 57.8±10.5* 57.5±16.6 54.8±15.0* <0.05a,c 
Data is displayed as mean ± standard deviation 
* significantly different from baseline ( p<0.05 in paired t-test) 
†
 significantly different from baseline (p <0.05 in Wilcoxon signed rank test), data displayed as median (interquartile 
range) 
#
 From one-way anova for normally distributed variables, from Kruskal-Wallis test for non-normally distributed variables 
a
 significantly different between MUFA and SFA diet (p<0.05 with LSD post-hoc test) 
b
 significantly different between MED and  SFA diet (p<0.05 with LSD post-hoc test) 
c
 significantly different between MED and MUFA diet (p<0.05 with LSD post-hoc test) 
Abbreviations: Alpha-2-Macroglobulin (A2M), Apolipoprotein B (Apo B), Connective Tissue Growth Factor (CTGF), 
Interleukin-12p70 (IL12p70), Sex Hormone Binding Globulin (SHBG), Thyroxine Binding Globulin (TBG) 
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DISCUSSION 
 
We investigated the effects of replacement of SFA by MUFA in a western type diet 
and the effects of a full Mediterranean (MED) diet high in MUFA on PBMC gene 
expression and plasma protein levels. Both MUFA-rich diets decreased expression of 
genes involved in OXPHOS. OXPHOS is an important process to generate energy but 
also reactive oxygen species (ROS) are produced, which can cause oxidative damage 
[126, 127]. Decreases in OXPHOS gene expression in various tissues have been linked 
to positive as well as negative health effects in previous studies.  
Studies [128] [129] showed that caloric restriction, which is considered protective 
against age-related decline and CVD [130], decreased expression of OXPHOS genes 
and oxidative stress related genes in PBMC and muscle. As a MED diet is also 
considered to protect against CVD and promote longevity [7, 111] and has been shown 
to reduce oxidative stress markers [131, 132], decreased OXPHOS might be an 
underlying mechanism behind these health effects. However, other studies measured 
decreased OXPHOS gene expression in skeletal muscle and PBMCs of type 2 diabetic 
subjects [133-135]. The findings in muscle led to the hypothesis that lowering of 
OXPHOS could cause intramuscular lipid accumulation which could lead to insulin 
resistance, but the association between OXPHOS and insulin resistance is still 
controversial. Pospisilik et al. [136] showed that a decrease of OXPHOS in muscle or 
liver of mice was associated with beneficial metabolic effects since it protected against 
diabetes. They suggested that decreased OXPHOS may be a consequence rather than a 
cause of insulin resistance. Expression of OXPHOS gene expression in our study was 
decreased after MUFA-rich diets, with concurrent improvement of serum lipid levels, 
but without a clear improvement in insulin sensitivity, as previously described [117]. 
Decreased OXPHOS gene expression in human muscle has been associated with short-
term high fat feeding [137]. Our diets were relatively high in fat but since all diets 
contained a similar fat percentage it seems more plausible that the fat composition (i.e. 
high MUFA content) and not the total fat content in the diets caused the differential 
changes in OXPHOS gene expression.  
Both MUFA-rich diets had distinct effects on expression of genes in signaling 
pathways. Compared to the MUFA diet, the MED diet contained additional bioactive 
components such as alcohol and polyphenols from red wine and extra virgin olive oil 
that could have affected PBMC gene expression. However, we observed that most 
genes were differently regulated by the MUFA diet and not by the MED diet. Other 
studies reported an effect of MED diet components on expression of genes related to 
inflammation and oxidative stress [120, 132, 138] but this was not seen in our study. 
When we looked more carefully at expression of inflammatory genes we observed an 
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unexpected high expression of some inflammatory genes such as IL1α, ILβ and TNFα 
in some PBMC samples. These samples were randomly distributed over the diet groups 
and testing days and as no correlating changes in plasma cytokine levels were observed 
we assumed that this effect might have been induced after blood collection. We also do 
not expect that this effect has influenced the outcome of our study as gene expression 
changes between diet groups were compared. Nevertheless, this randomly distributed 
high expression of inflammatory genes might have overruled possible subtle effects of 
the intervention diets on expression of these genes. 
In plasma, both MUFA-rich diets decreased concentrations of plasma CTGF, 
myoglobin and ApoB. CTGF stimulates vascular smooth muscle cell proliferation and 
extracellular matrix production [139] and hypothetically a decrease in CTGF might 
lower the risk to form atherosclerotic plaques. Moreover, a decrease in myoglobin 
concentration might be an indication of lower oxidative stress [140]. The decrease in 
ApoB concentration was in accordance with the measured decrease in LDL cholesterol 
concentrations. The reduction in LDL, TAG and concentration of pro-atherogenic 
proteins with MUFA-rich diets supports previous findings of an anti-atherogenic effect 
of MUFA [141]. Moreover it could indicate that MUFA reduced metabolic stress, 
which can have consequences for systemic health and might have reduced the need for 
OXPHOS activity. Furthermore, within subjects in the MED diet group lower 
concentrations of pro-inflammatory and pro-atherogenic proteins (i.e. IL1β, Factor VII, 
MIP1α, SAP, TPO and VEGF) [142] [143, 144] were measured which might suggest 
an additional anti-atherogenic of the MED diet. The decreases in these proteins were 
only significant within the MED diet group but we speculate that these changes might 
become more pronounced after longer MED diet consumption. In previous studies also 
decreases in plasma Factor VII and VEGF were observed after consumption of MED 
diet components [121, 145, 146]. In some other studies adherence to a MED style diet 
was associated with decreases in vascular inflammatory markers such as IL-6, IL-7, IL-
8, Inter-Cellular Adhesion Molecule 1, C Reactive Protein and Plasminogen activator 
inhibitor-1 [49, 120-122], while other studies [121, 147], including our study, did not 
observe changes in these markers. We speculate that it may be easier to lower 
concentrations of vascular markers in high risk subjects as included in some studies 
[49, 120]  than in the relatively healthy subjects included in our study. 
A strength of our study was the controlled food intake and high dietary compliance of 
the subjects. The number of subjects in our study was not very large but their food 
intake was accurately assessed as all meals were provided by us, in contrast to many 
larger studies in which dietary advice is given with a much lower control on dietary 
intake. Furthermore, the nutrigenomics approach applied provided us with extensive 
information about dietary effects on immune cells and circulating proteins. We have 
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used PBMCs as a model to study the systemic effects induced by consumption of diets 
varying in fat type. Although PBMCs are not a major cell type involved in the 
regulation of energy metabolism, PBMCs travel through the whole body and are 
exposed to all factors present in the circulation, therefore changes in OXPHOS in 
PBMCs may reflect systemic changes. In previous studies intake of various types of 
fatty acids or diets had differential effects on PBMC gene expression [24, 59, 124, 125, 
148]. Based on findings in this study and in previous studies, we postulate that PBMCs 
can be considered as ‘reporter’ cells for plasma fatty acid levels and reflect the 
nutritional state of an individual. PBMCs are a mixture of cell populations and changes 
in gene expression could also be due to a shift in cell populations. Changes in cell 
populations were not determined and instead we had a look at changes in expression of 
specific monocyte or lymphocyte genes within PBMCs. Some B-cell marker genes (i.e. 
CD19, CD79A, CD79B) were differently expressed between the diets but it is still 
questionable whether these changes in gene expression are proportional to changes in 
subpopulations. Moreover, it is not expected that a change in B-cell population is 
responsible for the changes in expression of OXPHOS-related genes, as B-cells are 
only a minor fraction of PBMCs with a low content of mitochondria. Although it is not 
confirmed that the subpopulations were unchanged, the total effect on PBMC gene 
expression changes was caused by the diets. Because one type of fat was replaced for 
another in the diets it is difficult to distinguish whether the effects of the MUFA-rich 
diets are due to higher contents of MUFA, lower contents of SFA or a combination of 
both. The additional effects of the MED diet may be attributed to bioactive components 
in this diet but we speculate that also the larger dietary variety of the MED diet may 
play a role since we hypothesize that high dietary variety may improve the metabolic 
flexibility of subjects. 
The diets induced modest changes in gene expression and plasma proteins, which was 
expected as MUFA and the MED food components were supplied in normal doses. 
Moreover the interindividual variability in response to the diets was high. Nevertheless, 
we think that these modest PBMC gene expression and protein changes can give 
information about potential mechanisms underlying the health effects of MUFA and a 
MED diet. Furthermore, as more information about effects of food patterns on PBMCs 
is emerging, the PBMC transcriptional profiles may serve as markers for dietary intake 
and to monitor compliance in intervention studies.  
In summary, we conclude that MUFA intake as replacement of SFA in a western-type 
diet had similar effects by downregulating OXPHOS genes and lowering serum lipids 
and plasma ApoB, CTGF and myoglobin as MUFA in a MED diet. We hypothesize 
that replacement of SFA by MUFA increased metabolic health as reflected by these 
plasma changes, thereby reducing metabolic stress and OXPHOS activity in PBMCs. 
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Downregulation of OXPHOS may have subsequent positive health effects by lowering 
oxidative stress. Consumption of a full MED diet might have additional anti-
atherogenic effects by lowering concentrations of pro-inflammatory plasma proteins. 
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Supplemental figure 1 Flowchart of subjects included for microarray analysis 
Abbreviations: Saturated Fatty Acid (SFA), Monounsaturated Fatty Acid (MUFA), Mediterranean (MED), Peripheral 
Blood Mononuclear Cell (PBMC) 
  
 
Supplemental Table 2, plasma protein concentrations in each diet group (mean +/- standard deviation)  
Protein SFA diet MUFA diet MED diet Comparison between 
diet groups 
 Baseline After 
intervention 
Baseline After 
intervention 
Baseline After 
intervention 
P value # 
Alpha-1 Antitrypsin (mg/mL) 1.99±0.22 2.00±0.26 1.96±0.32 2.13±0.48 2.09±0.42 2.07±0.36 0.231 
Angiotensin Converting Enzyme (ACE) (ng/mL) 118±33 116±27 121±41 121±37 115±31 114±25 0.875 
Adrenocorticotropic Hormone (ACTH) (ng/mL) 0.14±0.04 0.17±0.05* 0.19±0.2 0.20±0.15 0.24±0.19 0.22±0.16 0.095 
Adiponectin (µg/mL) 3.45±2.12 3.27±1.85 4.25±2.11 4.32±2.06 4.64±3.79 4.46±3.58 0.392 
Alpha-2-Macroglobulin (A2M) (mg/mL) 0.83±0.17 0.85±0.16 0.81±0.18 0.78±0.15 0.85±0.21 0.75±0.14* <0.05 
Alpha Fetoprotein (ng/mL) 3.71±1.17 3.77±1.23 3.95±1.36 3.93±1.41 3.68±1.44 3.59±1.40 0.715 
Angiotensinogen (ng/mL)  2.49 
(1.33,8.10) 
1.65 
(0.90,8.29)† 
1.59 
(1.32,6.73) 
1.32 
(0.91,3.78) 
1.83 
(1.12,6.12) 
1.51 
(1.05,8.47) 0.825 
Apolipoprotein A1 (Apo A1) (mg/mL) 0.30±0.07 0.29±0.07 0.31±0.07 0.31±0.11 0.27±0.10 0.29±0.10 0.593 
Apolipoprotein B (Apo B) (mg/mL) 1.09±0.27 1.12±0.29 1.1±0.17 1.03±0.20* 1.15±0.24 1.02±0.24* <0.005 
Apolipoprotein CIII (Apo CIII) (µg/mL) 86.4±18.1 85.6±30.2 98.1±27.8 87.6±30.0 100.4±29.7 84.3±29.4* 0.257 
Apolipoprotein H (Apo H) (µg/mL) 213±43 217±45 226±44 230±54 224±41 223±43 0.840 
Acylation Stimulating Protein (ASP) (ng/mL) 1704±365 1549±428 1889±380 1740±429 2014±366 1787±520* 0.793 
Beta-2 Microglobulin (B2M) (µg/mL) 1.58±0.41 1.51±0.29 1.8±0.32 1.84±0.41 1.69±0.27 1.62±0.25 0.469 
Betacellulin (pg/mL) 119±85 112±83 112±87 98±80 151±101 73±83 0.167 
Brain-Derived Neurotropic Factor (BDNF) (ng/mL) 1.64±1.69 0.23±0.25* 1.52±1.17 0.17±0.20* 3.45±5.09 0.38±0.56* 0.241 
Complement 3 (C3) (mg/mL) 0.91±0.13 0.89±0.11 1.01±0.15 1.04±0.18 0.97±0.16 0.95±0.17 0.358 
Cancer Antigen 125 (CA-125) (U/mL) 9.50±5.56 7.91±6.99 8.82±8.11 9.12±8.05 10.65±9.07 8.16±5.18 0.472 
Cancer Antigen 19-9 (CA-19-9) (U /mL) 6.73±6.01 6.37±5.45 7.22±8.18 7.25±7.69 6.78±5.08 7.32±5.88 0.114 
Calcitonin (pg/mL) 7.97±3.4 9.59±3.90 8.85±3.95 9.51±4.05 8.41±3.83 9.01±3.01 0.579 
CD40 (ng/mL) 0.62±0.08 0.56±0.08* 0.71±0.15 0.67±0.18 0.66±0.16 0.62±0.18 0.815 
CD40 Ligand (CD40L) (ng/mL) 0.24±0.22 0.06±0.04* 0.22±0.17 0.05±0.03* 0.29±0.29 0.09±0.10* 0.968 
Carcinoembryonic Antigen (CEA) (ng/mL) 1.48±0.88 1.53±0.80 1.32±1.58 1.47±1.97 1.59±0.66 1.51±0.57 0.140 
Creatine Kinase-MB (CK-MB) (ng/mL) 0.37±0.23 0.39±0.21 0.37±0.22 0.35±0.23 0.37±0.19 0.39±0.17 0.499 
Cortisol (ng/mL) 116±38 130±45 127±49 121±36 123±49 116±43 0.378 
C Reactive Protein (CRP) (µg/mL)  1.25 
(0.73,2.01) 
1.40 
(0.78,1.93) 
2.80 
(1.34,6.67) 
3.42 
(1.78,5.81) 
1.32 
(0.86,3.62) 
1.32 
(0.45,1.86) 0.128 
Connective Tissue Growth Factor (CTGF) (ng/mL) 2.02±0.72 2.11±0.94 2.6±1.01 2.23±0.88* 2.09±1.24 1.75±1.11* <0.05 
Epidermal Growth Factor (EGF) (pg/mL) 213±117 91±42* 214±105 109±74* 225±147 95±51* 0.847 
Epidermal Growth Factor Receptor (EGFR) (ng/mL) 142±35 136±37 135±39 128±36* 143±31 139±30 0.791 
  
 
Epithelial cell-derived neutrophil-activating peptide 78 
(ENA-78) (ng/mL) 0.88±0.75 0.12±0.14* 1.29±1.12 0.14±0.21* 1.37±1.45 0.10±0.14* 0.394 
Endothelin-1 (ET-1) (pg/mL) 22.4±11.5 18.2±7.1* 25.5±13.4 21.5±11.1 24.4±11.1 23.9±10.9 0.397 
Extracellular rage binding protein (EN-RAGE) (ng/mL) 5.55±3.14 5.93±4.49 9.39±8.39 6.37±4.16 9.76±6.49 7.51±7.41 0.329 
Eotaxin (CCL 11) (pg/mL) 139±75 121±78 141±53 116±74* 111±108 83±79 0.858 
Epiregulin (pg/mL) 26.0±24.5 28.3±31.5 17±12.5 18.5±12.4 36.1±42.4 33.7±38.7 0.610 
Erythropoietin (pg/mL) 75.1±93.7 90.9±157 101±89 107±101 73.2±66.6 70.3±65.5 0.545 
Fatty Acid Binding Protein (FABP) (ng/mL) 1.49±0.62 1.45±0.64 2.05±2.18 1.34±0.58 1.64±0.68 1.44±0.55* 0.258 
Factor VII (ng/mL) 520±90 522±87 563±108 534±82 527±79 494±68* 0.131 
Ferritin (ng/mL) 141±109 126±104* 169±102 140±94* 163±151 137±132* 0.458 
Fibroblast Growth Factor Basic (bFGF) (pg/mL) 163±152 129±116* 191±208 212±223 127±56 136±79 0.105 
Fibrinogen (mg/mL) 4.23±0.9 4.18±0.65 4.68±0.92 5.04±1.05 4.85±0.82 4.77±0.73 0.281 
Follicle Stimulating Hormone (FSH) (ng/mL) 15.5±10.2 14.0±9.4* 16±8.9 16.6±9.2 14.2±6.5 13.7±6.7 0.075 
Growth Hormone (GH) (ng/mL) 1.19±1.55 1.40±1.57 0.7±0.74 1.13±2.26 0.97±0.90 0.70±0.84 0.400 
Glucagon-like peptide-1 active (GLP1 active) (pg/mL) 18.4±4.9 17.7±7.8 18.2±5 17.9±5.5 17.7±4.6 16.8±6.0 0.955 
Glucagon-like peptide-1 Total (GLP1 total) (pg/mL) 83.9±37.5 84.9±39.6 73.2±34.5 77.8±39.3 73.8±33.6 72.1±27.7 0.347 
Glucagon (pg/mL) 718±230 713±276 593±248 610±233 695±211 666±209 0.452 
Glutathione S-Transferase (GST) (ng/mL) 1.02±0.31 1.03±0.23 1.01±0.29 0.99±0.15 0.96±0.42 0.99±0.20 0.910 
Haptoglobin (mg/mL) 1.22±0.73 1.33±0.52 1.55±0.64 1.87±0.84 1.67±0.97 1.40±0.97 0.109 
Heparin-Binding Epidermal Growth Factor (HB-EGF) 
(pg/mL) 94.9±42.8 91.9±41.8 79.8±13.5 78.3±18.4 114±66.0 105±57.2 0.464 
Inter-Cellular Adhesion Molecule 1 (ICAM 1) (ng/mL) 136±27 132±18 146±64 150±63 150±47 148±46 0.480 
Immunoglobulin A (IgA) (mg/mL) 1.31±0.63 1.25±0.64 1.57±0.49 1.63±0.69 1.36±0.53 1.41±0.57 0.287 
Immunoglobulin E (IgE) (ng/mL)  40.5 
(17.1,132) 
38.3 
(18.8,120) 
37.4 
(16.8,154) 
41.9 
(15.9,98.5) 
63.3 
(13.6,89.5) 
55.8 
(11.8,92.8) 0.934 
Immunoglobulin M (IgM) (mg/mL) 1.06±0.65 1.03±0.69 1.17±0.59 1.15±0.55 1.13±0.60 1.11±0.55 0.980 
Interleukin-10 (IL10) (pg/mL) 9.99±4.18 9.86±1.69 9.49±1.91 9.91±2.72 9.44±1.84 10.05±2.63 0.801 
Interleukin-11 (IL11) (pg/mL) 41.4±30.7 43.1±31.3 80.3±153 79.9±145 67.3±79.1 54.3±46.1 0.379 
Interleukin-12p70 (IL12p70) (pg/mL) 70.7±38.9 77.8±37.0 70.3±20.2 66.1±21.1 65.8±15.6 65.5±13.1 <0.05 
Interleukin-13 (IL13) (pg/mL) 59.6±16.7 58.9±14.4 58.5±14.8 60.0±15.1 50.7±9.9 51.6±8.0 0.845 
Interleukin-15 (IL15) (ng/mL) 0.32±0.12 0.31±0.12 0.3±0.09 0.28±0.09 0.31±0.08 0.31±0.08 0.693 
Interleukin-16 (IL16) (pg/mL) 415±108 376±58 486±270 391±141 463±198 352±75* 0.525 
Interleukin-17 (IL17) (pg/mL) 25.7±5.7 26.0±6.9 23.4±4.1 22.9±5.2 23.3±4.4 23.3±3.8 0.647 
Interleukin-18 (IL18) (pg/mL) 248±68 234±73 258±72 307±188 246±89 225±83 0.130 
  
Interleukin-1 beta (IL1b) (ng/mL) 1.86±1.51 1.20±0.60 1.56±0.67 1.23±0.52 2.85±2.87 1.21±0.55* 0.162 
Interleukin-1 receptor antagonist (IL1RA) (pg/mL) 100±60.9 97.0±47.1 104±57.8 118±71.2 130±60.7 119±46.8 0.234 
Interleukin-23 (IL23) (ng/mL) 0.87±0.68 0.96±1.04 0.88±1.09 0.87±1.29 0.89±0.80 0.83±0.91 0.751 
Interleukin-3 (IL3) (ng/mL) 0.08±0.06 0.08±0.06 0.07±0.06 0.08±0.05 0.05±0.03 0.06±0.04 0.990 
Interleukin-4 (IL4) (pg/mL) 32.5±10.9 31.8±10.7 34.5±9.2 31.5±6.1 32.7±10.9 30.5±10.6 0.560 
Interleukin-5 (IL5) (pg/mL) 9.6 
(6.3,13.8) 
10.6 
(8.1,13.8) 
7.3 
(6.1,12.4) 
10.3 
(4.6,11.9) 
10.0 
(4.4,13.8) 
8.10 
(4.4,13.8) 0.234 
Interleukin-6 (IL6) (pg/mL) 0.74±0.23 0.97±0.51 2.00±2.89 1.46±0.50 1.47±0.81 1.22±0.64 0.438 
Interleukin-7 (IL7) (pg/mL) 66.6±18.5 63.1±18.1 61.1±19.2 62.3±19.7 59.8±14.7 58.5±11.7 0.676 
Interleukin-8 (IL8) (pg/mL) 15.5±4.5 13.2±4.2 19.3±7.4 16.4±6.8 19.8±9.8 15.3±6.0 0.334 
Insulin (uIU/ml) 2.32±0.92 2.54±1.30 2.19±0.81 2.39±0.88 2.70±2.17 2.60±1.19 0.752 
Leptin (ng/mL) 11.9±12.8 9.5±8.3 17.1±19.1 17.0±17.2 16.7±18.9 14.9±19.0* 0.530 
Luteinizing Hormone (LH) (ng/mL) 1.8±0.7 1.79±0.78 1.79±1.43 1.91±1.68 1.41±0.55 1.50±0.66 0.499 
Lipoprotein a (LPA) (µg/mL)  67 
(14,116) 
47 
(13,128) 
122 
(31,431) 
126 
(38,481) 
215 
(86,500) 
307 
(88,500) 0.162 
Monocyte Chemotactic Protein-1 (MCP1) (pg/mL) 87.3±39.2 86.0±31.1 102±35 83.0±25.1* 126±118 81.3±25.8 0.206 
Macrophage colony-stimulating factor (MCSF) (ng/mL) 6.2±2.45 5.93±2.48 8.95±5.31 8.09±4.11 7.88±6.01 7.64±6.85 0.741 
Macrophage Derived Chemokine (MDC) (pg/mL) 361±91 358±77 386±99 393±100 409±73 382±67 0.155 
Macrophage Inflammatory Protein 1 alpha (MIP1a) 
(pg/mL) 57.5±11 57.6±10.3 60.8±8.1 60.1±8.8 58.1±10.2 55.5±8.3* 0.254 
Macrophage Inflammatory Protein 1 beta (MIP1b) (pg/mL) 137±43 138±47 222±177 202±164* 173±50 155±51 0.121 
Matrix Metalloproteinase-2 (MMP2) (ng/mL) 2049±297 2245±435 2117±416 2169±479 1994±471 2190±524* 0.364 
Matrix Metalloproteinase-3 (MMP3) (ng/mL) 0.06±0.06 0.06±0.06 0.11±0.15 0.08±0.07 0.06±0.05 0.07±0.04 0.131 
Matrix Metalloproteinase-9 (MMP9) (ng/mL) 104±97 92±59 94±70 60±33 161±188 151±200 0.708 
Myeloperoxidase (MPO) (ng/mL) 131±55 113±30 148±52 129±45* 161±60 134±48* 0.730 
Myoglobin (ng/mL)  10.0 
(8.4,14.5) 
12.4 
(9.4,15.0) 
11.8 
(8.9,16.2) 
10.8 
(7.9,15.4)† 
12.3 
(9.4,16.0) 
11.6 
(9.0,13.2) <0.05 
Plasminogen activator inhibitor-1 (PAI-1) (pg/mL) 38.0±22.7 28.9±15.4* 48.7±20.4 37.6±18.2 61.4±35.3 32.1±18.7* 0.051 
Pancreatic polypeptide (PP) (pg/mL) 185±79 162±50 244±179 213±96 161±90 150±48 0.842 
Prostatic Acid Phosphatase (PAP) (ng/mL)  0.22 
(0.20,0.34) 
0.25 
(0.20,0.39) 
0.25 
(0.20,0.30) 
0.25 
(0.21,0.29) 
0.28 
(0.23,0.39) 
0.26 
(0.25,0.34) 0.272 
Pregnancy-associated plasma protein A (PAPPA) 
(mIU/mL) 0.04±0.01 0.04±0.01 0.04±0.01 0.03±0.01 0.04±0.02 0.04±0.02 0.563 
Platelet-derived growth factor (PDGF) (pg/mL) 2134±1096 2344±1048 1869±1158 2205±862 2593±2216 2213±908 0.527 
Progesterone (ng/mL)  5.05 
(2.79,6.12) 
4.58 
(3.06,6.22) 
4.27 
(2.97,4.78) 
3.61 
(2.94,4.02)† 
4.61 
(3.02,4.88) 
4.49 
(3.28,6.91) 0.154 
  
 
Prolactin (ng/mL) 14.3±4.8 14.9±5.4 17.2±3.7 15.4±3.8 14.3±5.7 13.7±4.7 0.217 
Prostate Specific Antigen (PSA) (ng/mL) 0.11 
(0.03,0.67) 
0.10 
(0.04,0.58) 
0.07 
(0.04,1.04) 
0.07 
(0.04,1.04) 
0.07 
(0.03,0.57) 
0.05 
(0.04,0.43) 0.186 
Peptide YY (PYY) (pg/mL) 63.6±26.4 72.4±39.8 60.1±39.4 67.0±36.4 60.0±47.9 58.5±37.4 0.456 
Regulated on Activation Normal T Cell Expressed and 
Secreted (RANTES) (ng/mL) 6.50±5.70 1.11±1.20* 7.11±4.83 0.90±0.79* 
13.07±14.7
6 1.87±2.58* 0.205 
Resistin (ng/mL) 3.34±1.1 3.25±1.16 3.35±0.85 3.35±1.00 3.48±0.77 3.36±0.61 0.753 
Serum Amyloid P (SAP) (µg/mL) 18.4±4.7 17.9±4.2 19.8±4.8 20.2±5.3 20.8±4.7 18.8±5.6* 0.080 
Stem Cell Factor (SCF) (pg/mL) 219±69 208±62 231±67 196±77* 223±90 171±65* 0.078 
Serum glutamic oxaloacetic transaminase (SGOT) (µg/mL) 15.7±2.5 15.6±2.3 15.3±2.7 16.6±3.1 16.6±3.1 16.0±2.3 0.179 
Sex Hormone Binding Globulin (SHBG) (nmol/L) 51.7±28.5 48.0±23.9* 39.8±15.9 41.4±18.9 36.5±15.0 36.5±14.9 <0.05 
Thyroxine Binding Globulin (TBG) (µg/mL) 52.8±14.9 51.7±12.3 54.6±9 57.8±10.5* 57.5±16.6 54.8±15.0* <0.05 
Tenascin C (ng/mL) 1228±513 1248±508 1434±809 1415±674 1264±1003 1180±778 0.595 
Testosterone (ng/mL) 1.74±1.30 1.54±1.10* 1.57±1.12 1.49±1.10 1.50±1.19 1.45±1.24 0.383 
Tissue Factor (TF) (ng/mL) 0.71±0.37 0.69±0.35 0.66±0.28 0.71±0.30 0.60±0.30 0.58±0.29 0.204 
Tissue inhibitor of metalloproteinase 1 (TIMP1) (ng/mL) 80.5±13.5 73.3±9.5* 83.7±11.2 75.5±12.9* 90.2±24.9 71.1±8.7* 0.086 
Tumour necrosis factor alpha  receptor type II (TNFaRII) 
(ng/mL) 3.12±0.68 3.09±0.37 3.85±0.94 3.95±0.95 3.63±1.04 3.55±0.79 0.603 
Tumour necrosis factor alpha (TNFa) (pg/mL) 7.27±1.33 7.12±1.28 8.12±1.86 8.01±2.40 8.08±3.10 7.20±2.66 0.477 
Thrombopoietin (TPO) (ng/mL) 1.28±0.93 1.07±0.73 1.5±1.36 1.14±0.79 1.31±0.83 0.81±0.78* 0.571 
Thyroid Stimulating Hormone (TSH) (µIU/mL) 1.97±0.83 2.10±0.84 5.07±9.55 5.49±10.87 2.12±1.04 2.10±1.17 0.441 
Thrombospondin-1 (THBS1) (ng/mL) 7182 
±5934 
1104 
±1428* 
7066 
±5430 
733 
±825* 
12327 
±13609 
1981 
±3338* 0.382 
Vascular cell adhesion molecule-1 (VCAM1) (ng/mL) 542±113 534±84 553±104 590±120* 577±115 593±123 0.131 
Vascular endothelial growth factor (VEGF) (pg/mL) 594±155 556±119 635±118 612±98 632±166 573±119* 0.459 
von Willebrand Factor (vWF) (µg/mL) 27±10.7 26.2±8.3 36.1±11.8 38.7±14.1 28.8±210.7 25.2±8.1 0.201 
*significantly different from baseline ( p<0.05 in paired t-test), data displayed as mean ± standard deviation (all such values) 
†
 significantly different from baseline (p <0.05 in Wilcoxon signed rank test), data displayed as median (interquartile range) (all such values) 
#
 From one-way anova for normally distributed variables, from Kruskal-Wallis test for non-normally distributed variables 
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ABSTRACT  
 
Background: Biomarkers that allow detection of the onset of disease are of high 
interest since early detection would allow intervening with lifestyle and nutritional 
changes before the disease is manifested and pharmacological therapy is required.  
Objective: Our study aimed to improve the phenotypic characterization of overweight 
but apparently healthy subjects and to identify new candidate profiles for early 
biomarkers of obesity-related diseases such as cardiovascular disease and type 2 
diabetes.  
Design: In a population of 56 healthy, middle-aged overweight subjects Body Mass 
Index (BMI), fasting concentration of 124 plasma proteins and insulin were 
determined. The plasma proteins are implicated in chronic diseases, inflammation, 
endothelial function and metabolic signaling. Random Forest was applied to select 
proteins associated with BMI and plasma insulin. Subsequently, the selected proteins 
were analyzed by clustering methods to identify protein clusters associated with BMI 
and plasma insulin. Similar analyses were performed for a second population of 20 
healthy, overweight older subjects to verify associations found in population I. 
Results: In both populations similar clusters of proteins associated with BMI or insulin 
were identified. Leptin and a number of pro-inflammatory proteins, previously 
identified as possible biomarkers for obesity-related disease, e.g. Complement 3, C 
Reactive Protein, Serum Amyloid P, Vascular Endothelial Growth Factor clustered 
together and were positively associated with BMI and insulin. IL-3 and IL-13 clustered 
together with Apolipoprotein A1 and were inversely associated with BMI and might be 
potential new biomarkers.  
Conclusion: We identified clusters of plasma proteins associated with BMI and insulin 
in healthy populations. These clusters included previously reported biomarkers for 
obesity-related disease and potential new biomarkers such as IL-3 and IL-13. These 
plasma protein clusters could have potential applications for improved phenotypic 
characterization of volunteers in nutritional intervention studies or as biomarkers in the 
early detection of obesity-linked disease development and progression. 
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INTRODUCTION 
 
Cardiovascular disease (CVD) and type 2 diabetes (T2DM) are common disorders 
affecting millions of people worldwide. Evidence is accumulating that chronic low-
grade inflammation plays a role in the development of both diseases [149, 150]. 
Increased plasma levels of several pro-inflammatory proteins and decreased levels of 
anti-inflammatory proteins have been observed in subjects with obesity and obesity-
related diseases such as CVD and T2DM [151-154].  
Certain pro-inflammatory plasma proteins are used as diagnostic biomarkers for 
disease state but specific plasma proteins may also be used as biomarkers for early 
state in the development of a disease. Such an improved pre-disease diagnostic would 
allow intervening with relatively mild strategies such as lifestyle interventions with 
specific dietary regimes and increased physical activity in contrast to pharmacological 
therapy required once the disease is manifested. Identification of biomarkers that allow 
detection of the onset of disease will help in prevention of the disease. Plasma proteins 
might be good candidates as they circulate throughout the whole body, thereby 
reflecting total body metabolic and inflammatory status. Moreover, blood can be easily 
obtained from human subjects and therefore plasma proteins can be easily measured 
for screening purposes. 
So far, in most studies that investigated the use of plasma proteins as biomarkers only a 
few plasma proteins were measured. However, the etiology of diseases such as CVD 
and T2DM is complex and the measurement of multiple biomarkers will provide 
additional information about the individual phenotype and health status as compared 
with measurement of a single biomarker [155, 156]. Recent technological advances 
such as multiplex immunoassays allow for the measurement of over hundred proteins 
at a time in one small plasma sample. Identification of biomarker profiles in such large 
protein datasets requires advanced statistical analyses. Random Forest (RF) has shown 
to be suitable for analysis of complex data sets as derived from proteomics analysis 
[157, 158]. RF is a technique that can prioritize and select from a large number of 
variables a set of variables that is likely to be related to the outcome of interest. 
Furthermore, in the prioritization and selection process, it provides a way to take 
interactions between proteins into account [159, 160]. The proteins that are selected by 
RF can subsequently be analyzed by clustering methods, offering the opportunity to 
identify clusters of proteins that are associated with different health outcomes.  
Our study aimed to improve the phenotypic characterization of overweight but 
apparently healthy subjects and to identify new candidate profiles for early biomarkers 
of obesity-related diseases such as CVD and T2DM.  
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SUBJECTS AND METHODS 
 
Subjects 
Two populations were included in this study; population I was the primary study 
population of interest and population II was a smaller population used for verification 
of the results found in population I.  
Population I consisted of 56 healthy men and women who participated in a controlled 
feeding trial [117]. Subjects included were aged 40-65 years with a BMI ≥ 25 kg/m2 or 
a waist circumference ≥ 94 cm for men and ≥ 80 cm for women. Excluded were 
hypercholesterolemic subjects (fasting total cholesterol ≥ 8 mmol/L) and subjects with 
non-treated diabetes mellitus (according to WHO criteria) as measured by an oral 
glucose tolerance test during screening. Other exclusion criteria were the use of serum 
lipid or blood pressure lowering medication.  
Population II consisted of 20 healthy, independently living elderly men and women. 
This population is a subgroup of the population participating in the study of Van de 
Rest et al. [161]. Subjects included were aged >65 years without depression, dementia 
or serious liver disease. This population was chosen because subjects were healthy and 
had average BMI and insulin values comparable to those from population I.  
Both studies were approved by the Medical Ethics Committee of Wageningen 
University and all subjects gave written informed consent.  
 
Plasma proteins 
In population I, concentrations of 124 proteins, including insulin, were measured in 
fasting plasma by quantitative multiplex immunoassay based on Luminex xMAP 
technology (Rules Based Medicine Inc, Austin, Texas, USA) according to the 
procedure described by Domenici et al. [162] [163].  For each multiplex, both 
calibrators and controls were included on each microtiter plate. 8-point calibrators were 
run in the first and last column of each plate and 3-level controls were included in 
duplicate. Testing results were determined first for the high, medium and low controls 
for each multiplex to ensure proper assay performance. Unknown values for each of 
the analytes localized in a specific multiplex were determined using 4 and 5 parameter, 
weighted and non-weighted curve fitting algorithms included in the data analysis 
package. The plasma samples were run in duplicate and data reported as concentrations 
(average of two independent measures), together with data for the least detectable dose 
(LDD). Any value above the LDD will possess coefficients of variation (CV) less than 
20%. Rules-Based Medicine’s Multi-Analyte Profiles have been validated to Clinical 
Laboratory Standards Institute guidelines. 
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The set of proteins present on the assay consists of factors that are implicated in 
chronic diseases, inflammation, endothelial function and metabolism. In table S1 
(http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0014422#s5
) all proteins measured are listed. 
Before analysis 16 out of 124 proteins (table S1) were removed from the dataset as the 
concentrations of these proteins were below the detection limit in more than half of the 
samples. For the remaining 108 proteins, values below the detection limit were 
replaced by 0.1*Least Detectable Dose. As IL-6 was one of the removed proteins and 
IL-6 is an important factor for obesity and diabetes [154], this protein was separately 
measured by high-sensitive enzyme immunoassay (Human IL-6 Quantikine HS ELISA 
Kit, R&D Systems, Abingdon, United Kingdom). Apo lipoprotein B (ApoB) was not 
included in the Human Multi-Analyte Profiles, and ApoB levels were additionally 
measured on a Hitachi 912 autoanalyser (Roche, Lelystad, The Netherlands) using a 
commercially available kit (Roche cat. nr.1551779). In population II, the plasma 
concentrations of 107 out of the 124 proteins measured in population I, were 
determined using multiplex immunoassay (Rules Based Medicine Inc, Austin, Texas, 
USA) (table S1). In total, 110 proteins were included in the analysis for population I 
and 90 proteins were included in the analysis for population II (online figure S1, 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0014422#s5) 
 
Statistical analyses 
 
Univariate analyses 
The association between individual protein concentrations, BMI and plasma insulin 
concentration was calculated by univariate analysis. The statistical package PASW 
(version 17.0; SPSS, Chicago, IL) was used for the univariate analysis. Since the 
distribution of several variables was slightly skewed in the population, Spearman 
correlation coefficients were calculated for the association between protein 
concentrations, BMI and insulin concentrations.  
 
Random Forest 
Random Forest (RF) was used to provide a ranking in the importance of proteins in 
their relationship with BMI as well as with plasma insulin concentrations, taking 
possible interactions between proteins into account. The R package randomForest (R-
package randomForest, http://cran.r-project.org/), which is based on the original 
FORTRAN code from Breiman et al. [159] was used for the analysis 
(www.stat.berkeley.edu/~breiman/RandomForests/).  
CHAPTER 4 Human plasma protein profiling 
 
60 
 
In RF a group of tree-based models (the forest) is used to rank the proteins with an 
important contribution to BMI or insulin values [160, 164]. Each tree starts with the 
total data set, which is split into smaller and more homogeneous groups to fit models 
for predicting the outcome from the measured proteins. Within the forest, different 
trees are obtained by bootstrap sampling and random subset selection.  
Importance of proteins in association with the outcome of interest is defined by a 
measure referred to as the importance index, Im. For each protein, this Im is obtained by 
comparing the predictive performance of the forest for all proteins with the predictive 
performance of the forest in which the values of the protein are randomly permuted in 
the trees for the left-out observations. Larger differences in the predictive performance 
give a larger Im, indicating that the protein is more important. By permuting the values 
for one protein, not only the effect of this protein is taken into account, but also all 
possible interactions of this protein with other proteins. Interactions between proteins 
increase the Im for each of the proteins that are part of the interaction. Thus, in the 
ranking of proteins by their importance RF takes interactions between proteins into 
account.   
To perform the RF analyses we used the scaled mean decrease in prediction accuracy. 
To obtain stable estimates of the Im and to capture as many important interactions as 
possible, the analyses were performed with a large number of trees (40,000). Im was 
used as measure to rank the proteins. We chose not to apply a FDR estimation of the Im 
scores, because FDR estimation of importance scores derived by tree-based approaches 
usually overestimates the real FDR it can lead to an unreliable selection of a subset of 
variables [165]. 
For RF analysis a threshold value of significance does not exist. In this study a 
threshold was set at an Im of 5 and only proteins with an Im >5 were considered for 
subsequent cluster analyses. We chose for this liberal threshold to avoid the possibility 
of leaving out proteins that might be of importance in relation to BMI and insulin. 
 
Clustering of the proteins 
The program MultiExperimentViewer, version 4.3 was used for hierarchical clustering 
and visualization of the data [166]. Hierarchical clustering organizes the data into a 
binary tree that groups similar elements together. Proteins, BMI and insulin were 
clustered based on their Spearman correlation coefficients to select groups of proteins 
with high correlation with BMI or insulin and with each other. Besides clustering of the 
proteins with BMI and proteins with insulin based on their correlation coefficients also 
individual protein profiles were clustered based on similarities in protein 
concentrations. To compare the individual protein concentrations, z-scores were 
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calculated for each individual protein 




 −
σ
µx
. To compare the association of the 
identified clusters of proteins and BMI to the association of single traditional 
biomarkers and BMI regression analysis was performed using the statistical package 
PASW (version 17.0; SPSS, Chicago, IL). 
 
Pathway analysis 
Ingenuity Pathways Analysis, version 8.7 (Ingenuity® Systems, www.ingenuity.com) 
was used to identify connections between proteins and canonical pathways and 
diseases that were most significant to the data. Proteins were entered in Ingenuity 
based on their Swiss Prot ID and only connections, both direct and indirect, between 
proteins for humans and human primary cells were considered in the analysis. 
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RESULTS 
 
Baseline characteristics 
Characteristics of the two study populations used in the analysis are displayed in table 
1. BMI, waist circumference, insulin levels and percentage smokers were comparable 
in the two populations and age was significantly higher (13.7 ± 1.1) in population II.  
Plasma protein concentrations for both populations are displayed in online table S2 
(http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0014422#s) 
 
Table 1 Characteristics of the study populations 
 Population I (n=56) Population II (n=20) 
Sex (m/f) 23 / 33 10 / 10 
Age (years)* 56.4 ± 6.7 70.1 ± 3.1 
BMI (kg/m2) 27.4 ± 5.0 28.3 ± 5.4 
Smokers (%) 11 % 10 % 
Waist circumference (cm) 96.9 ± 13.2 99.0 ± 13.8 
Insulin (pmol/L) 16.11 ± 8.84 14.24 ± 8.05 
Data is displayed as mean ± standard deviation 
* Significantly different between the populations, p<0.05 
 
Associations of proteins with BMI 
In population I the RF Im of 20 proteins was above 5 and these proteins were 
considered to be associated with BMI (table 2). Using univariate analysis, 14 out of 
these 20 selected proteins correlated significantly with BMI (table 2). For these 20 
proteins and BMI mutual correlation coefficients were calculated. Based on these 
correlation coefficients a correlation matrix was constructed in which the proteins and 
BMI were clustered by similarity in their correlations (figure 1A). Using this approach, 
three clusters of proteins associated with BMI could be identified; cluster 1 and 3 were 
positively associated with BMI while cluster 2 was negatively associated with BMI. 
Cluster 1 showed robust associations with BMI and contains proteins highly positively 
associated with BMI and with each other and included insulin, leptin, Complement 3 
(C3), Interleukin 6 (IL-6), C Reactive Protein (CRP), Plasminogen Activator Inhibitor 
(PAI-1), Serum Amyloid P (SAP) and Vascular Endothelial Growth Factor (VEGF). 
Cluster 2 also showed robust associations with BMI and the included proteins were 
inversely associated with BMI and positively with each other (figure 1A) and 
contained the proteins Apolipoprotein A1 (ApoA1), Cancer Antigen 19-9 (CA 19-9), 
Eotaxin, IL-3 and IL-13. The third cluster includes proteins that were positively 
associated with BMI and each other but most of these associations were less 
pronounced than in clusters 1 and 2.  
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Table 2 Association of proteins with BMI in the two populations.  
 
 
Population I (n=56) 
 
Population II (n=20) 
Protein Im RF Spearman 
correlation  
Im RF Spearman 
correlation 
1. Leptin 71.8 0.47 ** 39.4 0.76 ** 
2. MCSF 49.1 0.18 n.d. n.d. 
3. IL-3 42.8 -0.43 ** 11.7 -0.67 ** 
4. Insulin 35.4 0.48 ** 51.4 0.74 ** 
5. Apo A1 33.0 -0.48 ** 24.4 -0.66 ** 
6. IL-13 25.7 -0.46 ** 26.1 -0.57 ** 
7. PAI-1 19.7 0.48 ** 22.7 0.63 ** 
8. Eotaxin 17.2 -0.40 ** <5  -0.29 
9. CA19-9 16.2 -0.06 <5  0.30 
10. CRP 15.0 0.46 ** 10.4 0.60 ** 
11. MDC 14.4 0.20 <5  0.01 
12. Resistin 14.1 0.27 * <5 0.37 
13. IL-6 11.4 0.42 ** n.d. n.d. 
14. Apo B 11.1 0.20 n.d. n.d. 
15. SAP 8.6 0.38 ** 34.6 0.70 ** 
16. C3 8.5 0.42 ** 36.5 0.48 * 
17. MIP1b 7.5 0.25 <5 0.31 
18. VEGF 6.1 0.38 ** 22.8 0.59 ** 
19. FABP 5.4 0.20 <5 0.11 
20. LPA 5.2 0.26 * <5 -0.11 
* p <0.05, ** p<0.005 
Abbreviations: not determined (n.d.), Importance Index Random Forest (Im RF), Macrophage colony-stimulating factor 
(MCSF), Apolipoprotein A1 (ApoA1), Plasminogen Activator Inhibitor-1 (PAI-1), Cancer Antigen 19-9 (CA 19-9), C 
Reactive Protein (CRP), Macrophage Derived Chemokine (MDC), Apolipoprotein B (ApoB), Serum Amyloid P (SAP), 
Complement 3 (C3), Macrophage Inflammatory Protein-1 beta (MIP1b), Vascular endothelial growth factor (VEGF), 
Fatty Acid Binding Protein (FABP), Lipoprotein A (LPA). 
 
In population II 22 proteins were associated with BMI, based on RF Im above 5, of 
which ten proteins were also associated with BMI in population I (table 2 and figure 
S1). A correlation matrix of these ten proteins and BMI was made for population II. 
Clustering of the proteins in population II was similar to the clustering in population I 
(figure 1A and 1B). The protein clusters 1 and 2, which showed robust associations in 
population I, were also associated with BMI in population II. The weaker associations 
of protein cluster 3 could not be confirmed. Associations in population II were more 
robust compared to associations in population I. 
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Regression analysis to compare the association of the identified clusters of proteins and 
BMI to the association of single traditional biomarkers such as CRP and IL-6 showed 
that the explained variance was higher when all proteins of cluster 1 were included in 
the model compared to when only IL6 or CRP or a combination of both were included. 
For BMI, the proportion of variance explained was 16.3% for IL-6 alone, 19.4% for 
CRP alone,  22.0% for CRP and IL-6 combined, and 32.3% when all proteins from 
cluster 1 were included in the model.  For insulin, cluster 1 explained 25.6% of the 
variance, compared to 8.3% by CRP alone, 11.8% by IL-6 alone, and 12.0% by CRP 
and IL-6 combined. 
 
Out of the cluster analysis we selected the highly BMI-associated proteins from cluster 
1 to plot individual plasma profiles (figure 2). Subjects with similar plasma protein 
concentrations were clustered and their BMI values were subsequently displayed. 
Figure 2 shows that, as expected, in general persons with higher BMI have higher 
concentrations of the selected proteins. However, a few persons with BMI values <25 
kg/m2 had high plasma levels of these proteins and a few persons with BMI values >30 
kg/m2 had low plasma protein levels  
 
Association of proteins with insulin concentration 
The association between protein profiles and fasting insulin concentration was 
investigated using the same approach as for BMI. In population I, RF analysis 
identified 20 proteins that were considered to be associated with insulin concentration 
(table 3). Using univariate analysis, ten of these proteins significantly correlated with 
insulin concentration. Hierarchical clustering of the 20 selected proteins and insulin 
based on correlation coefficients resulted in the formation of four separate protein 
clusters (figure 3A). The proteins forming cluster 1, 2 and 3 were all positively 
associated with insulin concentration and the proteins in the fourth cluster were 
negatively associated with insulin.  
In population II, 9 out of the 20 selected proteins in population I were associated with 
plasma insulin concentrations (table 3, figure 3B and figure S1). As for BMI 
associations with insulin in population II were more robust compared to associations 
with insulin in population I. 
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Table 3 Association of proteins with fasting plasma insulin in both populations 
 
 Population I (N=56) Population II (N=20) 
Protein Im RF  
 
Spearman 
correlation 
Im RF  Spearman 
correlation 
1. SAP 42.9 0.518** 25.8 0.579* 
2. Leptin 32.2 0.333* 23.3 0.695** 
3. PAP 29.2 0.411** < 5 -0.165 
4. MIP1b 28.8 0.376** < 5  0.104 
5. C3 18.5 0.379** 29.0 0.621** 
6. IL-7 16.9 0.077 < 5  -0.492* 
7. FABP 16.8 0.416** < 5 0.099 
8. ASP 16.0 0.383** < 5 0.220 
9. VEGF 11.1 0.296* 21.3 0.590* 
10. CK_MB 10.0 0.040 41.8 -0.614* 
11. TNFα 9.9 0.250 < 5  0.340 
12. MPO 9.0 0.257 30.4 0.450* 
13. IL-6 8.0 0.363** n.d. n.d. 
14. PP 7.8 -0.171 < 5 -0.219 
15. Apo CIII 7.5 -0.240 < 5 -0.072 
16. ENA-78 7.2 0.082 5.5 0.520* 
17. Factor VII 6.8 0.243 10.9 0.460* 
18. IL-8 6.1 0.149 < 5 0.155 
19. IL-18 5.8 0.230 < 5 -0.169 
20. CRP 5.1 0.317* 36.6 0.723** 
* p<0.05, ** p<0.005 
Abbreviations: Importance factor Random Forest analysis (Im RF), not determined (n.d), Serum Amyloid P (SAP), 
Prostatic Acid Phosphatase (PAP), Macrophage Inflammatory Protein-1 beta (MIP1b), Complement 3 (C3), Fatty Acid 
Binding Protein (FABP), Acylation Stimulating Protein (ASP), Vascular endothelial growth factor (VEGF), Creatine 
Kinase-MB (CK-MB), Tumor Necrosis Factor alpha (TNFα), Myeloperoxidase (MPO), Pancreatic Polypeptide (PP), 
Apolipoprotein CIII (Apo CIII), Epithelial neutrophil-activating peptide 78 (ENA-78), C Reactive Protein (CRP) 
 
Pathway analysis 
An overview of all clusters of proteins and interactions between the single proteins 
selected by RF is displayed in figure 4 (page 71). This figure also shows the top 5 most 
significant pathways and diseases for the BMI- and insulin-associated proteins.  Acute 
phase response signaling was the most significant pathway for BMI-associated proteins 
and was also significant for insulin-associated proteins. 
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Figure 1. Correlation matrix of selected proteins associated with BMI in population I (A) and II (B).  
Correlation coefficients are displayed on a color scale, ranging from -0.6 (green) to 0.6 (red). For population I (A) 20 
proteins selected by RF to be associated with BMI are included. This group of proteins was divided in three clusters based 
on similarity in the association with BMI and with each other. For population II (B) 10 proteins selected by RF and also 
associated with BMI in population I are included. This group of proteins was divided in two clusters based on similarity in 
the association with BMI and with each other.  
 
Figure 2. Clustering of personal profiles of robustly positively BMI-associated proteins in population I (A) and II (B). 
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Protein values are displayed on a color scale; red indicates higher values than group average, green indicated lower values 
than group average. The personal BMI values are displayed on a separate color scale; green for BMI<25, black for BMI 
25-30 and red for BMI>30. Only robustly positively BMI-associated proteins from cluster 1, as identified by RF and 
cluster analysis, were included in this figure. 
 
 
 
Figure 3. Correlation matrix of selected proteins associated with insulin in population I (A) and II (B).  
Correlation coefficients are displayed on a color scale, ranging from -0.6 (green) to 0.6 (red). For population I (A) 20 
proteins selected by RF to be associated with fasting plasma insulin are included. This group of proteins was divided in 
four clusters based on similarity in the association with insulin and with each other. For population II (B) 9 proteins 
selected by RF and also associated with BMI in population I are included. This group of proteins was divided in three 
clusters based on similarity in the association with insulin and with each other. 
Abbreviations: Creatine Kinase-MB (CK-MB), Pancreatic Polypeptide (PP), Prostatic Acid Phosphatase (PAP), Fatty 
Acid Binding Protein (FABP), Vascular endothelial growth factor (VEGF), Macrophage Inflammatory Protein-1 beta 
(MIP1b), Tumor Necrosis Factor alpha (TNFα), Epithelial neutrophil-activating peptide 78 (ENA-78), Apolipoprotein 
CIII (Apo CIII), Complement 3 (C3), Acylation Stimulating Protein (ASP), Myeloperoxidase (MPO), Serum Amyloid P 
(SAP), C Reactive Protein (CRP) 
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DISCUSSION 
 
Elevated plasma levels of several pro-inflammatory proteins are related to the 
development of obesity-linked diseases, in particular to T2DM and CVD [152, 167-
169]. In the current study we observed associations of clusters of pro- and anti-
inflammatory proteins with BMI and insulin in a presumably healthy population. These 
BMI- and insulin-associated protein clusters may serve as biomarkers for a pre-disease 
state of people at risk to develop CVD and T2DM. The protein clusters could possibly 
be used to improve individual disease risk prediction and help in the design of 
personalized strategies to prevent disease as early as possible. 
The protein cluster showing the most robust positive association with BMI contained a 
number of pro-inflammatory proteins of which several are involved in the acute phase 
response, such as CRP, IL-6, C3 and SAP. These and other proteins (i.e. ASP, MPO, 
PAI-1 and VEGF) included in this cluster and in cluster 1 that was associated with 
insulin were previously found to be increased in subjects with insulin resistance, CVD, 
or both [143, 151, 168, 170-178]. From prospective studies evidence has accumulated 
that increased levels of C3 and CRP can predict T2DM and coronary events and could 
be candidate biomarkers for a pathological state preceding the ultimate disease [151, 
156, 172, 173]. We hypothesize that the proteins clustering together with CRP and C3 
could be similar type of biomarkers. Moreover, Macrophage Colony-Stimulating 
Factor (MCSF) which was highly positively associated with BMI was discovered to be 
a prognostic marker of cardiovascular events in patients with chronic coronary artery 
disease [179]. We speculate that MCSF may also be an early biomarker for cardiac 
disease in healthy subjects.  
The positive correlations of BMI with leptin and other adipose-tissue derived proteins, 
as seen in our study, supports the view of adipose tissue as an important source of 
immune-related proteins [180]. However, besides adipose tissue-derived proteins also 
proteins produced by the liver, endothelial cells, immune cells and lipoproteins were 
associated with BMI and insulin in our healthy subjects. This indicates that low-grade 
inflammation in the early disease state is not only an adipose tissue-specific effect but 
that also organ cells increase their secretion of inflammatory proteins with increasing 
BMI or plasma insulin levels.  
A small cluster of proteins (ApoA1, CA19-9, Eotaxin, IL-3 and IL-13) was negatively 
associated with BMI. Plasma levels of tumor marker CA19-9 and ApoA1, the major 
protein component of plasma HDL, were reported to be lower in obesity [181, 182]. 
Less is known about the negative association of BMI with Th2 cytokines IL-3 and IL-
13 and Eotaxin, which are correlated with each other and closely clustered [183-185]. 
Concentrations of IL-3 and IL-13 were on average very low in the populations so we 
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should be careful with the interpretation of this data. Nevertheless we observed 
associations of IL-3 and IL-13 with BMI in both study populations, therefore these 
proteins might be considered as potential new early biomarkers for obesity-related 
diseases.  
Associations between strongly associated protein clusters 1 and 2 with BMI and insulin 
in the primary study population were confirmed in the second population. Weaker 
associations were not all confirmed which could be attributable to the lower number of 
subjects in population II and the fact that less proteins were measured reducing the 
chance of finding protein interactions with RF. However, the strong associations found 
in population I were even more pronounced in population II. The latter population was 
significantly older but concentrations of individual plasma pro-inflammatory proteins 
were not higher. Maybe an elevated BMI or insulin concentration in elderly subjects is 
directly linked to an increase in pro-inflammatory protein secretion while this is not 
always the case in younger subjects who may display a more flexible metabolic 
phenotype in handling changes in BMI or insulin concentration. 
Levels of individual proteins were not extremely elevated in our study subjects, but 
based on protein profiles subjects may be differentially classified with lower or higher 
risk to develop a more pathological phenotype. Despite the fact that the risk profile was 
BMI-related in the whole study population, there were a few subjects with low BMI 
also having this risk profile and a few subjects with high BMI not having the profile. 
Besides BMI, waist-to-height ratio can be used as a determinant for obesity-related 
health risk. When the same analyses were performed for the association of proteins 
with waist-to-height ratio similar results as for BMI were found. Our findings support 
the recent ideas of using a ‘multimarker’ approach, i.e. measuring multiple plasma 
proteins in instead of single biomarkers or only BMI to increase the prognostic value 
for individual disease risk [156, 186, 187].  
Still, the measurement of multiple proteins makes data analysis complex and calls for 
more advanced methods of data analysis. Using RF we were able to identify 
associations of proteins with BMI or insulin that were not observed when associations 
of each protein were analyzed separately, but combined with other proteins may be of 
relevance. For RF we chose a liberal threshold for selection of proteins associated with 
BMI or insulin, which increases the risk of selecting proteins that are not related to the 
outcome of interest. However, using this threshold, we observed a high overlap 
between the results from RF and univariate analysis.  Furthermore, we applied this 
analysis to two independent populations to replicate and verify the associations of 
protein clusters with BMI and insulin. In our view, this approach has increased the 
reliability of our results.  
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The results of our study are based on a single measurement of plasma proteins that 
provides a “snapshot” of the actual health status. Whether it can be used in predicting 
long-term health and inflammatory status requires more long-term studies. 
Furthermore, our primary study population consisted of a relatively low number of 
subjects. However, we have observed associations of proteins with BMI or insulin that 
are physiologically relevant and were found in epidemiological and clinical studies 
[143, 151, 153, 154, 156, 168, 170, 177, 178]. Moreover, we were able to confirm the 
most robust associations in a second, even smaller population consisting of subjects 
from a different age group. 
With our study it is not possible to draw conclusions about the causal relationship 
between elevated concentrations of the selected proteins and occurrence of disease. 
Further prospective studies with clinical end points are needed to determine whether 
the protein clusters found in this study could be used as reliable biomarkers for early 
identification of persons at risk for T2DM and CVD.   
Our study aimed at identifying new leads for clusters of early biomarkers of disease by 
using plasma protein profiling in healthy subjects. In healthy subjects we identified 
clusters of proteins associated with BMI and insulin that included previously identified 
biomarkers for obesity-related disease risk and potential new biomarkers for which an 
association with disease is not well-established. We showed that plasma protein 
profiling allows a more subtle phenotypic characterization and differentiation of people 
with otherwise similar phenotypical features such as BMI or insulin levels. This could 
be of great value for dietary and pharmacological intervention studies where subgroups 
of volunteers with matching phenotypes could be included in order to improve the 
power of such interventions. Improved individual risk assessment and classification of 
subjects may ultimately lead to a more tailored and adequate intervention either by 
pharmacology or changes in lifestyle. 
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Figure 4 (next page). BMI- and insulin-associated proteins, their interactions and pathways and diseases in which they are 
involved. 
All defined clusters of BMI and insulin-associated proteins are displayed, in red the positively associated clusters and in 
green the negatively associated clusters. In dark red or green BMI and insulin-associated proteins in both populations are 
shown, in light red and light green only the BMI and insulin-associated proteins in population I. Connections between 
proteins and the top 5 canonical pathways and diseases relevant to the data are shown.  
Abbreviations: Triggering Receptor Expressed on Myeloid cells 1 (TREM1) 
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ABSTRACT 
 
Background: The ability of subjects to respond to nutritional challenges can reflect the 
robustness and flexibility of their biological system. Nutritional challenge tests could 
be used as an indicator of health status but more knowledge on metabolic and immune 
responses of different subjects to nutritional challenges is needed.  
Objective: To compare the responses to high-fat challenges varying in fat type in 
subjects with different metabolic risk phenotypes. 
Design: In a cross-over design 42 men consumed three high-fat shakes containing 
saturated fat (SFA), monounsaturated fat (MUFA) or n-3 polyunsaturated (PUFA). 
Men were selected on BMI and health status (lean healthy, obese healthy or obese 
diabetic) and phenotyped with MRI for adipose tissue distribution.  Before and 2 and 4 
hrs after shake consumption blood was drawn for measurement of plasma triglycerides 
(TAG), glucose, insulin, cytokines and expression of metabolic and inflammation-
related genes in peripheral blood mononuclear cells (PBMCs) and ex vivo PBMC 
immune response capacity.  
Results: Obese healthy and obese diabetic subjects had different metabolic and PBMC 
gene expression responses to high-fat challenges compared to lean healthy subjects. 
The MUFA challenge induced the most pronounced TAG response, mainly in obese 
healthy and obese diabetic subjects. The MUFA and n-3 PUFA challenge, compared to 
the SFA challenge, induced higher changes in expression of inflammation genes MCP1 
and IL1β in PBMCs. 
Conclusion: The metabolic response and PBMC gene expression response to high-fat 
challenges were affected by metabolic risk phenotype and fat type. Based on our 
results we suggest using a MUFA challenge to reveal differences in response capacity 
of subjects. 
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INTRODUCTION 
 
In the western world food is generally continuously available and most of the day is 
spent in the postprandial state. Food intake can elicit a transient metabolic and low 
inflammatory response, especially when high fat is consumed [188-190]. The 
magnitude of this response reflects the ability of the biological system to adequately 
respond to nutrient intake. The presence of metabolic risk phenotypes such as obesity 
and type 2 diabetes might affect this ability as shown by elevated postprandial 
triglyceride levels in these subjects, in addition to metabolic abnormalities and chronic 
inflammation in the fasting state [191-195]. Not only the presence of overall obesity, 
but also body fat distribution, i.e. increased intra-abdominal (visceral) adipose tissue, 
might affect the metabolic condition and the postprandial triglyceride response [196].  
Elevated postprandial triglyceride levels are considered as risk factors for CVD and 
were shown to be higher associated with cardiovascular events compared to fasting 
triglyceride levels [197, 198]. The response to nutrition might thus be considered as a 
better biomarker of health status than fasting measures, since this will reflect the 
metabolic robustness and metabolic flexibility of a person [199]. A widely applied 
example of a nutritional challenge test is the oral glucose tolerance test for measuring 
glucose clearance capacity.  Nutritional challenge tests might be useful to detect small 
changes in health status, which could be of major importance in early detection and 
prevention of disease, but could also be used to test the effectiveness of (nutritional) 
interventions [199, 200]. However, at the moment relatively little is known about 
responses of different types of subjects to nutritional challenges such as a high-fat load 
which makes it difficult to use the response to challenges tests as biomarkers for the 
characterization of health status.  
Postprandial meal studies showed that the type of fat consumed could affect the 
metabolic and inflammatory response [24, 189, 201-204] and gene expression 
responses in circulating peripheral blood mononuclear cells (PBMCs) [24]. PBMCs are 
immune cells that have been shown to be metabolically active [55], moreover, gene 
expression profiles of PBMCs were shown to reflect metabolic disease state and 
changes in nutrient intake which makes these cells an interesting target to investigate 
responses to nutritional challenges in different subjects [87, 205, 206].  
The objective of this study is to characterize the metabolic, immune and PBMC 
response to high-fat challenges in subjects with different metabolic risk phenotypes. 
Responses to different types of fat (SFA, MUFA and n-3 PUFA) will be compared in 
order to reveal which type of fat may be best used in future high-fat challenges to test 
response capacity of subjects. 
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SUBJECTS AND METHODS 
 
Subjects 
In total 42 male Caucasian volunteers aged 50-70 years participated in the study. The 
study population consisted of three groups; 1) lean healthy (LH) subjects, 2) obese 
healthy (OH) subjects and 3) obese type 2 diabetic (OD) subjects. Subjects were 
excluded if they were vegetarian, regular tobacco smoker, allergic to dairy products or 
fish oil, current or recent user of fish oil supplements, ate more than four times 
fish/week, had an unstable body weight, used antibiotics or anti-inflammatory 
medication or had a long-term medical condition that could interfere with the study 
outcome. LH and OH subjects were excluded when using cholesterol-lowering 
medication; and lean subjects were excluded when using blood pressure lowering 
medication. OD subjects were all diagnosed with diabetes mellitus in the past, and did 
not use insulin and/or thiazolidinediones. During a screening visit an oral glucose 
tolerance test was performed and urinary glucose concentration was measured in 
healthy subjects to exclude the presence of (unknown) diabetes mellitus. Subjects were 
informed about the design and purpose of the study and all subjects provided written 
informed consent. The Medical Ethical Committee of Wageningen University (the 
Netherlands) approved the study.  
 
Study design 
All subjects randomly consumed three high-fat shakes enriched with either SFA, 
MUFA or n-3 PUFA in a crossover design, on three different days with at least one 
week between each study day.  
The evening before the study day, subjects had to consume an identical low-fat meal 
and they were not allowed to eat or drink anything after 8 pm except water. The next 
morning, subjects came to the university and a fasting blood sample was collected. 
Blood was drawn into EDTA-containing tubes for plasma isolation and into BD 
Vacutainer Cell Preparation Tubes containing sodium citrate (Becton Dickinson, 
Breda, Netherlands) for PBMC isolation. After the first blood sample subjects was 
given a high-fat milkshake, which they had to consume within 15 min. Blood samples 
were collected 2 hours and 4 hours after consumption of the high-fat shake. During a 
study day, subjects were physically inactive and were asked not to eat or drink 
anything except water.  
 
Shake composition 
All high-fat shakes were isocaloric and differed only in fat composition. The shakes 
contained low-fat yoghurt, low-fat milk, strawberry flavour, 7.5 gr of sugar and 95 gr 
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of the test fat. The SFA shake contained 95 gr palm oil (Research Diet Services BV, 
Wijk bij Duurstede, The Netherlands) and the MUFA shake contained 95 gr high-oleic 
acid sunflower oil (Aldoc BV, Schiedam, The Netherlands). The n-3 PUFA shake 
contained a combination of 40 gr palm oil and 55 gr Marinol D-40 (Lipid Nutrition, 
Wormerveer, The Netherlands) of which 40% was docosahexanoic acid (DHA). 
Vitamin E (165 mg Tocoblend L50, Vitablend, Wolvega, The Netherlands) was added 
to Marinol D-40 by the manufacturer to prevent oxidation. The same amount of 
vitamin E was added to the SFA and MUFA shakes. The macronutrient composition of 
the shakes was calculated based on the database of the Dutch Nutrient Databank and 
shown in table 1. 
 
Table 1. Macronutrient composition of the shakes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: Saturated fatty acids (SFA), Monounsaturated fatty acid (MUFA), Polyunsaturated fatty acid (PUFA), 
Eicosapentaenoic acid (EPA, C20:5), Docosahexaenoic acid (DHA, C22:6) 
 
Body weight, body composition and abdominal fat distribution 
Body weight was measured at screening and monitored during the study period. Body 
composition was determined on one study day by air-displacement plethysmography 
(BodPod; Life Measurement, Concord, CA) [85]. Abdominal fat distribution, i.e. 
abdominal visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue 
(SAT), was measured once during the study period in 17 LH, 18 OH and 4 OD 
subjects, using magnetic resonance imaging (MRI). Axial T1-weighted spin echo 
images were acquired with a Philips Gyroscan NT Intera 1.0T scanner using the body 
coil, with the subjects in supine position. A total of 14 10-mm-thick slices with no 
intersection gap were acquired, with the first slice at the superior border of the 
vertebral body of L5, and the remaining slices superiorly. Images were acquired during 
 
 
 
SFA 
shake 
MUFA 
shake 
n-3 PUFA  
shake 
Energy (kJ) 4074 4074 4074 
Energy (kcal) 987 987 987 
Protein (g) 10 10 10 
Carbohydrates (g) 22 22 22 
Fat (g) 95 95 95 
SFA (g) 51 8 32 
MUFA (g) 37 79 25 
PUFA (g) 6 8 38 
 EPA (g) - - 3 
 DHA (g) - - 23 
Vitamin E (mg) 165 165 165 
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breath-hold to avoid motion artefacts induced by breathing. Images were retrieved 
from the scanner using DICOM, and analysed using HIPPO (version 1.3), an IDL 
Virtual Machine 6.0-based freeware designed to quantify adipose tissue areas from MR 
images [207]. Automatically generated contour lines for SAT and VAT and the shape 
of Gaussian curve were manually adjusted by eye, as necessary, using the edit function. 
Retroperitoneal adipose tissue was excluded from VAT. VAT, SAT and VAT/SAT 
ratios derived from a single slice at the superior border of the vertebral body of L5 
were used in the analysis. 
 
Plasma glucose, insulin, triglycerides, free fatty acids  
Immediately after blood was drawn in EDTA-containing tubes it was centrifuged (750 
x g, 4°C, 10 min), and the plasma was stored at -80°C until analysis. Plasma FFA 
concentrations were analysed by the ACS-ACOD Method (NEFA HR kit, Wako 
Chemicals CmbH, Neuss, Germany). Plasma triglyceride and glucose concentrations 
were measured using the Dimension Clinical Chemistry System (Dade Behring Inc, 
USA). Glucose was measured by the Synchron LX20 System using hexokinase and 
glucose-6-phosphate dehydrogenase (Glucose reagent, Beckman Coulter, Fullerton, 
USA). Insulin concentrations were measured by enzyme-linked immunosorbent assay 
(Mercodia, Uppsala, Sweden). 
Serum fatty acid composition in the triglyceride fraction was determined in pooled 
samples per group and per high-fat challenge at 0 hrs and 4 hrs and measured by gas-
liquid chromatography as previously described [87].  
 
Plasma cytokines  
Plasma samples were analyzed on preformatted arrays (pro-inflammatory panel II, 
Meso Scale Diagnostics, LLC) on a SECTOR Imager 2400 reader (Meso Scale 
Diagnostics, LLC) for the measurement of IL1β and TNFα. 
 
PBMC RNA isolation, cDNA synthesis and q-PCR 
PBMCs were isolated from whole blood by using BD Vacutainer Cell Preparation 
Tubes according to the manufacturer’s instructions. PBMC RNA was isolated by using 
the Qiagen RNeasy Micro kit (Qiagen, Venlo, Netherlands) and reverse transcribed 
using a cDNA synthesis kit (Promega, Leiden, Netherlands). Standard Q-PCR was 
performed using SensiMix real-time PCR reagents (Bioline, London, United Kingdom) 
and a Bio-Rad CFX384 machine (Bio-Rad Laboratories BV, Veenendaal, the 
Netherlands). Primer sequences used were chosen based on the sequences available in 
PRIMERBANK (http://pga.mgh.harvard.edu/ primerbank/index.html). Q-PCR data 
were normalized by measuring cycle threshold ratios between candidate genes and a 
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housekeeping gene, human ribosomal protein LP0, which was shown to be consistent 
within PBMCs [208].  
Baseline and postprandial gene expression changes of immune-related genes (IL1b, 
IL8, MCP1, NFκB1, TNFα) and lipid metabolism related genes (ABCA1, PDK4, 
SREBP1, LDLr, LXRα, CYP27A1) were determined. These genes were selected 
because we previously showed that their expression was affected by high-fat 
consumption [24]. 
 
Ex-vivo PBMC immune stimulation 
PBMC immune response capacity in the fasted (0 hrs) condition and 4 hrs after the 
high-fat challenge was tested ex vivo and used as a measure of PBMC functionality. 
The ex vivo immune stimulation experiments were performed in a random subgroup of 
13 LH and 15 OH subjects. Immediately after isolation PBMCs were re-suspended in 
RPMI 1640 culture medium with 10% heat-inactivated fetal calf serum and 1% 
penicillin and streptomycin. Cells in a concentration of 2.5 x 104 per ml were 
stimulated for 2 hours at 37 °C with 1 ng/ml lipopolysaccharide (LPS). Subsequently, 
cells were centrifuged and supernatants collected and stored at -80°C until analysis. 
TNFα produced by the PBMCs was measured in the supernatants by enzyme-linked 
immunosorbent assay according to the manufacturer’s instructions (R&D Systems 
Europe Ltd, Abingdon, United Kingdom). LPS-stimulated TNFα production was 
corrected for TNFα production in non-stimulated cells. 
 
Statistical analysis 
The statistical package PASW (version 17.0; SPSS Inc. Chicago IL) and SAS (version 
9.1, SAS Institute Inc. 2004, Cary, NC, USA) were used for analysis. Differences in 
baseline characteristics between the groups were analysed by analysis of variance 
(ANOVA) for single measures (i.e. age, body weight, body composition) or by linear 
mixed model for repeated measures (all other factors that were measured on all three 
consecutive study days). The analyses were followed by post-hoc LSD tests. 
Differences in responses for the different high-fat shakes and subject groups were 
analysed by linear mixed model. Delta values (changes from baseline) were used as 
dependent variables in the analysis and baseline values were included as covariables. 
Time, shake and group were used as fixed factors and time and shake as repeated 
factors in the model. When statistical significance was found, post-hoc LSD tests were 
performed to identify differences between shakes or groups. 
The effect of VAT, SAT and VAT/SAT ratio on baseline and postprandial measures 
was only investigated within subject groups because of expected large differences in 
VAT and SAT between subject groups due to the predefined BMI categories. OD 
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subjects were excluded for this analysis due to the low number of subjects that was 
measured in the MRI scanner. For the analysis of the effect of body fat distribution 
VAT, SAT and VAT/SAT ratio were included as continuous covariables in the linear 
mixed model. 
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RESULTS 
 
Subject baseline characteristics 
Baseline subject characteristics are displayed in table 2. BMI, bodyfat percentage, 
abdominal VAT, abdominal SAT, plasma fasting TAG and insulin concentrations were 
significantly higher in the OH and OD subjects compared with the LH subjects. Fasting 
plasma glucose concentration was higher in the OD subjects compared with the LH and 
OH subjects. 
 
Table 2 Baseline characteristics of the subjects in the three groups 
 Lean Healthy 
(n=18) 
Obese Healthy 
(n=18) 
Obese Diabetic  
(n=6) 
Age (yrs) 61.8 ± 5.9 62.6 ± 3.2 64.2 ± 4.6 
BMI (kg/m2) 23.8 ± 0.8 32.4 ± 3.0 * 33.5 ± 3.3 * 
Body fat (%) 21.9 ± 5.7 38.2 ± 5.2 * 39.9 ± 5.1 * 
VAT (cm2) † 102 ± 40 231 ± 75 * 215 ± 31 * 
SAT (cm2) † 163 ± 52 350 ± 99 * 383 ± 42 * 
VAT/SAT ratio† 0.64 ± 0.20 0.68 ± 0.24 0.57 ± 0.12 
TAG (mmol/L) 1.5 ± 0.5 2.1 ± 0.9 * 2.0 ± 1.0 * 
FFA (mmol/L) 0.51 ± 0.21 0.51 ± 0.13 0.58 ± 0.11 
Insulin (mmol/L) 6.1 ± 2.8 13.4 ± 6.6 * 13.3 ± 7.8 * 
Glucose (mmol/L) 5.2 ± 0.4 5.5 ± 0.4 7.2 ± 1.0 * 
Data are presented as mean ± standard deviation. Abbreviations: Visceral adipose tissue (VAT), Subcutaneous Adipose 
Tissue (SAT), Free fatty acids (FFA), Triglycerides (TAG),  
* Significantly different (p<0.05) from healthy lean subjects  
†
 For VAT, SAT en VAT/SAT ratio n= 17 for lean healthy subjects, n=18 for obese healthy subjects and n=4 for obese 
diabetic subjects. 
 
Plasma FFA, TAG, insulin and glucose responses  
Changes in FFA, TAG, insulin and glucose concentration after the different high-fat 
challenges in the subject groups are depicted in table 3 and figure 1. Concentrations of 
FFA, TAG, insulin and glucose were changed after the high-fat challenges and the 
changes in all these metabolites were different between LH, OH and OD subjects.  The 
changes in TAG, FFA, insulin and glucose concentrations were also depending on the 
type of fat consumed. A high MUFA challenge caused a higher total TAG response 
(p<0.001) and a reduced drop in FFA concentrations at 2 hours (p<0.05) compared 
with a SFA and n-3 PUFA challenge. The n-3 PUFA challenge caused a less 
pronounced increase in insulin concentrations (p<0.01) at 2 hrs compared with SFA 
and MUFA.  
For TAG response an interaction effect between group and shake (p=0.048) was 
observed meaning that the postprandial TAG response was different for LH, OH and 
OD subjects depending on the type of high-fat shake consumed. No interaction 
between group and shake was found for FFA, insulin and glucose. 
  
 
Table 3 Changes (mean ± sd) in metabolic parameters in plasma at 2 hrs and 4 hrs after high fat shake consumption 
  SFA shake MUFA shake n-3 PUFA shake Main effects Interaction effects 
   
0 hrs 
∆  
2 hrs 
∆  
4 hrs 
 
0 hrs 
∆  
2 hrs 
∆ 
 4 hrs 
 
0 hrs 
∆  
2 hrs 
∆  
4 hrs 
group time shake group* 
time 
group* 
shake 
shake* 
time 
TAG 
(mmol/L) 
LH 1.53 
±0.49 
0.64 
±0.40 
0.48 
±0.48 
1.37 
±0.41 
0.91 
±0.47 
1.41 
±1.00 
1.50 
±0.50 
0.33 
±0.30 
0.78 
±0.58 
0.889 <0.001 <0.001 0.002 0.048 <0.001 
 OH 2.07 
±0.99 
0.58 
±0.40 
0.78 
±0.61 
2.13 
±1.06 
1.14 
±0.68 
2.28 
±1.18 
1.98 
±0.78 
0.30 
±0.26 
0.77 
±0.45 
      
 OD 2.17 
±1.16 
0.30 
±0.14 
0.80 
±1.21 
1.92 
±0.93 
1.08 
±0.49 
2.47 
±1.21 
2.05 
±1.21 
0.38 
±0.13 
1.05 
±0.49 
      
FFA 
(mmol/L) 
LH 0.51 
±0.21 
-0.21 
±0.19 
-0.04 
±0.22 
0.49 
±0.20 
-0.10 
±0.18 
0.03 
±0.23 
0.55 
±0.23 
-0.25 
±0.21 
-0.03 
±0.17 
0.004 <0.001 0.002 0.016 0.390 0.002 
 OH 0.48 
±0.10 
-0.18 
±0.12 
0.11 
±0.11 
0.50 
±0.15 
-0.09 
±0.16 
0.08 
±0.16 
0.54 
±0.15 
-0.21 
±0.11 
0.06 
±0.16 
      
 OD 0.53 
±0.13 
-0.20 
±0.12 
0.07 
±0.20 
0.58 
±0.13 
-0.08 
±0.18 
0.12 
±0.28 
0.62 
±0.05 
-0.12 
±0.25 
0.09 
±0.21 
      
Insulin 
(mmol/L) 
LH 6.52 
±2.55 
3.08 
±3.77 
-1.82 
±2.08 
5.80 
±3.38 
2.73 
±3.88 
1.00 
±3.98 
6.02 
±2.55 
-0.02 
±3.77 
-1.64 
±2.56 
0.017 <0.001 <0.001 0.028 0.808 <0.001 
 OH 13.52 
±7.40 
6.59 
±9.60 
-1.67 
±3.33 
12.81 
±5.24 
4.39 
±6.62 
1.79 
±6.07 
13.91 
±7.25 
2.33 
±5.87 
-2.04 
±3.09 
      
 OD 12.66 
±7.50 
8.85 
±4.64 
0.03 
±1.40 
13.57 
±8.78 
7.43 
±3.71 
2.66 
±5.30 
13.79 
±8.49 
1.27 
±4.26 
-0.75 
±4.20 
      
Glucose 
(mmol/L) 
LH 5.19 
±0.39 
-0.30 
±0.35 
-0.40 
±0.21 
5.17 
±0.35 
-0.29 
±0.31 
-0.08 
±0.28 
5.29 
±0.53 
-0.42 
±0.39 
-0.33 
±0.25 
0.872 <0.001 0.002 <0.001 0.660 <0.001 
 OH 5.50 
±0.41 
-0.16 
±0.48 
-0.43 
±0.39 
5.53 
±0.43 
-0.18 
±0.32 
-0.31 
±0.28 
5.54 
±0.28 
-0.43 
±0.38 
-0.52 
±0.33 
      
 OD 7.22 
±0.94 
0.47 
±0.67 
-1.52 
±0.48 
7.17 
±1.04 
-0.03 
±1.14 
-0.68 
±0.85 
7.23 
±1.25 
-0.48 
±1.43 
-1.00 
±0.68 
      
Abbreviations: Saturated fatty acids (SFA), Monounsaturated fatty acid (MUFA), Polyunsaturated fatty acid (PUFA), Triglycerides (TAG), Free fatty acids (FFA), Lean 
healthy (LH), Obese healthy (OH), Obese Diabetic (OD) 
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Figure 1 Mean (± SEM) effects of consumption of 3 shakes enriched in saturated fatty acids (SFA), monounsaturated fatty 
acids (MUFA) and n-3 polyunsaturated fatty acids (n-3 PUFA) on plasma TAG (A), FFA (B), Insulin (C) and Glucose 
(D). Different letters indicate significant differences (p<0.05) between shakes at a given time. 
 
Serum fatty acid composition 
Baseline values and changes in fatty acid composition of the TAG fraction in pooled 
serum samples 4 hours after the high-fat challenge are shown in table 4. The 
percentage palmitic acid was 1.1-fold higher after the SFA challenge, the percentage 
oleic acid was 1.6-fold higher after the MUFA challenge and the percentage DHA was 
9.5-fold higher after the n-3 PUFA challenge, reflecting composition of the shakes.  
CHAPTER 5 Responses to high-fat challenges varying in fat type 
 
84 
 
Table 4 Serum fatty acid composition in the TAG fraction (% of total) of pooled samples for group and time point. Only 
values for palmitic acid, oleic acid and DHA are displayed 
 SFA shake MUFA shake n-3 PUFA shake 
 0 hrs ∆ 4 hrs 0 hrs ∆ 4 hrs 0 hrs ∆ 4 hrs 
Palmitic acid       
Lean healthy 27.45 2.87 25.76 -11.54 27.06 -0.56 
Obese healthy 28.14 2.54 27.89 -11.22 29.13 0.30 
Obese diabetic 27.77 3.74 26.99 -11.09 28.74 0.32 
Oleic acid       
Lean healthy 35.78 2.52 38.14 22.79 37.41 -2.48 
Obese healthy 36.14 1.12 36.02 20.68 35.71 -0.55 
Obese diabetic 36.79 0.72 39.02 20.21 36.73 -1.48 
DHA       
Lean healthy 0.68 -0.09 0.44 -0.12 0.32 4.56 
Obese healthy 0.66 -0.09 0.63 -0.16 0.55 2.86 
Obese diabetic 0.96 0.27 0.90 -0.39 0.54 3.31 
 
 
PBMC gene expression 
Gene expression level at baseline (fasting) was not different between the subject 
groups. The high-fat challenge altered expression of several metabolic genes and 
inflammation-related genes (table 5). Changes in expression of the metabolic genes 
ABCA1 and LDLr and the inflammation-related genes IL1b and MCP1 were also 
depending on whether the subjects were LH, OH or OD. Changes in expression of 
ABCA1 and LDLr were less pronounced for OH and OD subjects (p<0.05) compared 
with LH subjects. Differences in expression changes of IL1b and MCP1 were most 
likely due to higher increases of expression of these genes in OD subjects compared 
with LH and OH subjects, since the effects were not significant when OD subjects 
were excluded from analysis.  
Changes in expression of PDK4, LDLr, IL8 and MCP1 expression were depending on 
the type of fat in the challenge. When OD subjects were excluded from analysis also 
IL1b expression was different between the fat challenges. The MUFA challenge 
induced a lower decrease in PDK4 expression at 2 hours (p<0.001) compared with the 
other challenges. The MUFA and n-3 PUFA challenge induced a higher change in 
MCP1 and IL8 expression at 4 hrs (p<0.05) compared with the SFA challenge. There 
were no interaction effects between subject groups and shakes for the measured genes. 
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PBMC immune response capacity 
Fasting levels and changes in PBMC immune response capacity after the high-fat 
challenges, measured as ex vivo LPS-stimulated TNFα production of PBMCs, were 
neither depending on the metabolic risk profile of the subjects, nor depending on the 
type of fat in the challenge (table 6). However, TNFα production was significantly 
lower (P<0.001) 4hrs after the high-fat challenge compared with the fasting state.   
 
Plasma cytokines 
Fasting plasma IL1β concentration was higher in the OD subjects compared to LH and 
OH subjects (table 6). Plasma concentrations of TNFα after the challenge were also 
different between the groups, with lower TNFα concentrations in LH compared with 
OH and OD subjects (p<0.05), however TNFα responses were not different between 
the groups. Changes in plasma concentrations of IL1β varied according to the type of 
fat in the challenge and whether the subjects were LH, OH or OD. These group and 
shake effects were probably mainly due to the different IL1β responses to the different 
types of fat in OD subjects, since the shake and shake* group effects were not 
significant when the OD subjects were excluded from the analysis.  
 
Abdominal fat distribution  
Within the group of LH subjects and within the group of OH subjects there was no 
significant influence of abdominal fat distribution (i.e. VAT, SAT or VAT/SAT) and 
changes in plasma FFA, TAG, insulin or glucose concentrations, changes in PBMC 
gene expression, or changes in cytokine levels in response to the high-fat challenges. 
 
  
 
Table 5 Changes (mean ± sd) in PBMC gene expression at 2 hrs and 4 hrs after high-fat shake  
  SFA shake MUFA shake n-3 PUFA shake Main effects Interaction effects 
  ∆ 2 hrs ∆ 4 hrs ∆ 2 hrs ∆ 4 hrs ∆ 2 hrs ∆ 4 hrs group time shake group* 
time 
group* 
shake 
shake* 
time 
Metabolism             
ABCA1 LH 0.49± 1.03 1.05± 0.78 0.36± 0.62 0.59± 0.70 0.42± 0.89 0.39± 0.70 0.007 <0.001 0.235 0.038 0.877 0.261 
 OH 0.42± 0.84 0.28± 0.93 0.42± 0.84 0.36± 1.11 0.03± 0.55 0.03± 0.62       
  OD -0.11±0.75 0.34± 0.77 0.31± 0.70 0.10± 0.75 0.36± 0.97 0.41± 1.04       
CYP27A1 LH 0.41± 0.60 0.53± 0.55 0.41± 0.63 0.66± 0.49 0.39± 0.43 0.65± 0.65 0.576 <0.001 0.682 0.325 0.704 0.921 
 OH 0.40± 0.53 0.34± 0.64 0.47± 0.72 0.60± 1.07 0.25± 0.63 0.32± 0.58       
 OD 0.10± 0.53 0.44± 0.75 0.14± 0.50 0.21± 0.55 0.53± 0.44 0.50± 0.46       
LDLr LH -0.45±0.49 -0.40±0.58 -0.67±0.59 -0.19±0.57 -0.51±0.46 -0.42±0.41 0.034* <0.001 0.040* <0.001 0.642 0.025 
 OH -0.28±0.46 -0.16±0.52 -0.28±0.58 0.03± 0.80 -0.31±0.48 -0.24±0.59       
 OD -0.16±0.33 0.01± 0.56 -0.11±0.45 0.33± 0.40 0.17± 0.46 0.33±0.49       
LXRα LH 0.06± 0.61  0.21± 0.73 0.04± 0.73 0.05± 0.66 -0.02±0.48 -0.16±0.59 0.225 0.789 0.904 0.620 0.937 0.108 
 OH -0.05±0.74 0.12± 0.72 -0.23±0.81 -0.25±0.81 0.05± 0.39 -0.02±0.40       
 OD -0.25±0.38 0.20± 0.74 0.26± 0.33 0.10± 0.55 0.48± 0.86 0.13± 0.87       
PDK4 LH -0.28±0.64 0.39± 0.69 0.00± 0.53 0.53± 0.60 -0.55±0.43 0.46± 0.60 0.563 <0.001 <0.001 0.292 0.770 <0.001 
 OH -0.28±0.61 0.25± 0.65 0.06± 0.37 0.55± 0.46 -0.47±0.31 0.29± 0.64       
 OD -0.22±0.50 0.42± 0.64 0.58± 1.55 0.88± 1.63 -0.38±0.50 0.28± 0.39       
SREBP1 LH -0.05±0.54 0.13±0.38 0.16±0.53 0.32±0.51 0.17±0.48 0.05±0.69 0.006* 0.343 0.879 0.338 0.638 0.379 
 OH -0.08±0.62 -0.06±0.62 0.16±0.81 0.12±0.76 0.06±0.31 -0.03±0.43       
 OD -0.11±0.37 0.02±0.63 -0.30±0.58 0.04±0.84 -0.06±0.59 0.12±0.53       
 
  
  
 
  SFA shake MUFA shake n-3 PUFA shake Main effects Interaction effects 
  ∆ 2 hrs ∆ 4 hrs ∆ 2 hrs ∆ 4 hrs ∆ 2 hrs ∆ 4 hrs group time shake group* 
time 
group* 
shake 
shake* 
time 
Inflammation             
IL1b LH 0.13± 0.64 0.02± 0.62 0.07± 0.78 0.41± 0.87 -0.08±0.37 0.07± 0.85 0.351 <0.001* 0.293† 0.014* 0.638 0.167 
 OH -0.13±1.16 -0.11±0.65 0.08± 0.71 0.18± 1.10 -0.11±0.60 0.23± 0.56       
 OD 0.35± 0.49 0.54± 0.85 0.61± 1.73 1.17± 1.99 0.18± 0.72 0.79± 1.04       
IL8 LH 0.20± 1.46 0.98± 1.28 0.10± 1.16 1.89± 1.35 -0.35±1.15 1.68± 1.83 0.359 <0.001 0.032 0.239 0.932 0.003 
 OH -0.86±2.09 0.68± 1.38 0.18± 1.44 1.59± 1.67 -0.66±1.18 2.01± 1.36       
 OD 0.02± 1.00 1.74± 0.70 0.27± 1.42 2.04± 1.29 0.13± 2.68 2.48± 1.84       
MCP1 LH 0.48± 1.11 0.31± 0.91 0.37± 1.49 1.37± 1.51 0.39± 0.92 0.94± 1.36 0.500 <0.001 0.006 0.037* 0.730 0.015 
 OH -0.02±1.05 0.22± 1.40 0.36± 1.51 0.97± 1.89 0.29± 0.88 0.77± 0.69       
 OD 0.65± 1.22 1.11± 1.08 1.22± 0.69 1.96± 0.93 0.75± 1.55 1.77± 1.67       
NFκB1 LH 0.09±0.78 0.21± 0.51 -0.13±0.46 -0.16±0.85 0.07±0.47 -0.07±0.56 0.113 0.927 0.870 0.808 0.278 0.877 
 OH -0.04±0.61 -0.28±0.59 0.02±0.72 -0.16±0.87 -0.03±0.37 0.10±0.69       
 OD 0.03±0.39 0.08±0.47 0.14±0.50 0.10± 0.58 -0.05±0.99 0.08±0.64       
TNFa LH 0.40± 0.55 0.33± 0.44 0.45± 0.65 0.27± 0.77 0.26± 0.42 0.13± 0.47 0.761 <0.001 0.085 0.280 0.750 0.529 
 OH 0.19± 0.57 0.06± 0.40 0.38± 0.69 0.25± 0.84 0.33± 0.50 0.37± 0.55       
 OD 0.51± 0.52 0.61± 0.45 0.48± 0.49 0.57± 0.50 -0.09±0.55 0.09± 0.51       
 
*no significant effect when OD subjects are excluded from analysis, †significant effect (p 0.034) when OD subjects are excluded from analysis 
Abbreviations: Saturated fatty acids (SFA), Monounsaturated fatty acid (MUFA), Polyunsaturated fatty acid (PUFA), Lean healthy (LH), Obese healthy (OH), Obese Diabetic 
(OD), ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1), cytochrome P450, family 27, subfamily A, polypeptide 1 (CYP27A1), low density lipoprotein 
receptor (LDLr), liver X receptor (LXR), pyruvate dehydrogenase kinase, isozyme 4 (PDK4), sterol regulatory element binding transcription factor 1 (SREBP1), Monocyte 
chemotactic protein 1 (MCP1), nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFκB1), tumor necrosis factor alpha (TNFα)  
  
  
 
Table 6 Changes (mean ± sd) in plasma cytokines and ex vivo LPS-stimulated TNFα production of PBMCs after high fat shake consumption 
  SFA shake MUFA shake n-3 PUFA shake Main effects Interaction effects 
   
0 hrs 
∆  
2 hrs 
∆  
4 hrs 
 
0 hrs 
∆ 
2 hrs 
∆  
4 hrs 
 
0 hrs  
∆  
2 hrs 
∆  
4 hrs 
group time shake group* 
time 
group* 
shake 
shake* 
time 
Plasma                 
IL1β 
(pg/mL)  
LH 0.75 
±0.42 
0.02 
±0.19 
0.00 
±0.16 
0.68 
±0.30 
0.05 
±0.10 
0.00 
±0.16 
0.69 
±0.27 
0.02 
±0.15 
0.02 
±0.16 
0.512 0.740 0.036* 0.676 0.041* 0.784 
 OH 0.70 
±0.51 
0.09 
±0.14 
0.07 
±0.12 
0.75 
±0.49 
0.00 
±0.10 
0.04 
±0.16 
0.76 
±0.55 
0.05 
±0.25 
-0.01 
±0.10 
      
 OD† 1.44 
±1.03 
0.01 
±0.12 
-0.06 
±0.32 
1.29 
±0.97 
0.12 
±0.48 
0.17 
±0.34 
1.60 
±0.93 
-0.24 
±0.45 
-0.07 
±0.58 
      
TNFα 
(pg/mL) 
LH 6.54 
±1.55 
0.04 
±0.54 
-0.14 
±0.64 
6.43 
±1.48 
-0.19 
±0.64 
-0.20 
±0.54 
6.73 
±1.76 
-0.26 
±0.60 
-0.11 
±1.00 
0.004 0.280 0.993 0.369 0.536 0.295 
 OH 7.27 
±2.04 
0.22 
±0.53 
-0.02 
±0.60 
7.31 
±1.68 
0.14 
±0.55 
0.07 
±0.67 
7.58 
±1.81 
-0.10 
±0.65 
-0.09 
±0.86 
      
 OD 7.93 
±1.35 
0.14 
±0.33 
-0.28 
±0.52 
8.15 
±1.50 
0.19 
±0.78 
-0.17 
±0.41 
7.57 
±1.54 
0.21 
±0.66 
0.29 
±1.11 
      
Ex vivo LPS-stimulated#              
TNFα 
(pg/mL) 
LH  164 
±92 
 -26 
±72 
138 
±95 
 -5 
±85 
210 
±262 
 -20 
±64 
0.063 <0.001 0.900 0.084 0.962 0.639 
 OH 141 
±86 
 -50 
±86 
162 
±130 
 -50 
±137 
170 
±113 
 -67 
±84 
      
* no significant effect when OD subjects are excluded from analysis,  † baseline values significantly different from those of LH and OH subjects, # This measurement was done 
in a subsample of 13 LH and 15 OH subjects. 
Abbreviations: Lean healthy (LH), Obese healthy (OH), Obese Diabetic (OD) 
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DISCUSSION 
 
Within this comprehensive study we showed that responses to high fat challenges in 
subjects with different metabolic risk phenotypes were characterized by differences in 
the plasma metabolic parameters TAG, FFA, glucose and insulin and in expression of 
the metabolic genes ABCA1, LDLr and inflammatory genes IL1β and MCP1 in 
PBMCs. Moreover, comparison of responses to high-fat challenges high in SFA, 
MUFA or n-3 PUFA showed that a high MUFA challenge induced the most 
pronounced response, especially for TAG. 
The high-fat challenge-induced differential changes in TAG and insulin concentrations 
in LH, OH and OD subjects are in line with results from other postprandial studies 
showing higher TAG and insulin responses in obese and diabetic subjects after high-fat 
meal consumption [191, 194, 195, 209, 210]. We consider the differential changes in 
TAG and insulin as a reflection of reduced cellular adaptation capacity to respond to a 
high-fat challenge in the presence of obesity and/or diabetes.  
The change in expression of the cholesterol metabolism genes ABCA1 and LDLr in 
lean subjects in response to the challenge was comparable with observations in lean 
subjects in earlier studies performed by us and others [24, 211]. The new finding of 
less pronounced changes in expression of these genes in OH and OD subjects may 
reflect a less optimal metabolic adaptation response of their PBMCs to a high-fat 
challenge. This might be caused by a lower lipid uptake by the cells and/or a lower 
activation of gene expression in response to high-fat intake, possibly due to lowered 
sensitivity of the cells to lipids. Changes in expression of ABCA1 and LDLr in response 
to a high-fat challenge might thus be considered as potential markers of health status.  
Expression changes of the inflammatory genes IL1β and MCP1 in response to high-fat 
challenges were also different between subjects groups, but since these effects were 
mainly due to different changes in OD subjects, and not in OH subjects, we might 
consider changes in expression of these genes as indicators of a more severe metabolic 
phenotype. Higher changes in IL1β expression were not accompanied by higher 
changes in plasma IL1β concentrations. One of the reasons for this difference could be 
the fact that IL1β is also produced by other cells than PBMCs. A potential other 
explanation for the absence of differences in plasma cytokines is the low power to 
detect significant effects in the small OD subject group with high variation in cytokine 
response. 
The amount of VAT, SAT or VAT/SAT did not influence the response to a high-fat 
challenge within subject groups. Although the number of subjects in each subgroup 
might have been too small to detect a significant effect of fat distribution, it is also 
arguable whether high VAT is strongly affecting metabolic health; some studies found 
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effects of VAT, mainly on TAG response [196, 212, 213], but others [214, 215] 
suggested that liver fat might be a more sensitive determinant of metabolic health.  
The plasma metabolic and PBMC gene expression response to the challenge was also 
depending on the main type of fat present. The MUFA challenge had a stronger TAG-
raising effect compared with the SFA and n-3 PUFA challenges. This effect was more 
pronounced in OH and OD subjects, suggesting that high MUFA intake might be a 
stronger metabolic challenge for subjects with a metabolic risk phenotype. In our study 
the MUFA challenge revealed differences in TAG response between lean and obese 
subjects that were both defined as healthy. It should be further investigated in other 
subject groups whether the plasma TAG response to a MUFA challenge could be used 
as a biomarker to detect small differences in health status in subjects with more 
comparable phenotypes. 
The MUFA challenge may have been the most challenging for the biological system 
because it contained almost exclusively oleic acid (83% of total fat) while the other 
shakes contained a mixture of fatty acids. The body might have difficulties 
metabolizing this high dose of a single fatty acid as mixtures of fatty acids are more 
commonly consumed. Habitual intake of fish n-3 PUFA is low and therefore we 
prepared a n-3 PUFA shake consisting of a mixture of palm oil and 55 gr fish oil, a 
well-tolerated dose in a former study at our group [24]. In the latter study, consumption 
of a n-3 PUFA shake containing this high dose of 55 gr n-3 PUFA and no palm oil, 
decreased the expression of LXR signalling genes in PBMCs of young, lean men when 
compared to consumption of a SFA shake with 55 gr butter. Although we gave a higher 
total fat load in our study, we observed no expression differences for these genes. This 
may be due to differences in fat types (palm oil vs. butter), shake composition, 
sampling time (4 hrs vs 6 hrs) or age of the subjects.  
Remarkably, the n-3 PUFA shake in our study induced a lower increase in insulin 
concentration compared with the other shakes. Only few other studies have reported 
acute insulin-lowering effects of n-3 PUFA intake [201, 216]. Peak insulin 
concentrations are reached normally between 0-2 hours after a meal [191, 204, 217], 
but we lack data for these early time points. n-3 PUFA intake might have caused an 
earlier insulin peak resulting in lower insulin concentrations at later time points.  
The n-3 PUFA and the MUFA challenge induced higher changes in MCP1 and IL8 
expression compared to the SFA challenge, which is in line with findings from a 
previous study showing that acute high n-3 PUFA intake induced a pro-inflammatory 
PBMCs gene expression profile [24]. A possible explanation for this induction is that 
unsaturated fatty acids are more prone to oxidation than SFA and might induce more 
oxidative stress and in turn affect inflammatory status. Another explanation may be 
that palmitic acid, because it is in general more regularly consumed, poses less stress to 
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PBMCs resulting in lower expression changes of inflammation genes than high doses 
of oleic acid or DHA. A high-fat shake consisting of palm oil may thus be less suitable 
to challenge the system compared to shakes containing unsaturated fats. 
All high-fat challenges reduced PBMC immune response capacity but whether this 
reduction is an indication of lower inflammatory status or diminished immune 
functioning of the cells cannot be distinguished. As only effects after a challenge were 
observed an effect of circadian rhythm on PBMCs cannot be excluded. Since 
differences in PBMC immune response capacity between subject groups did not reach 
significance, this ex vivo challenge might not be a sensitive indicator for differences in 
health status.  
In our study we monitored different aspects of the response to high-fat challenges i.e. 
plasma metabolites, inflammatory proteins, PBMC gene expression and immune 
functioning. We selected these determinants based on literature and previous 
transcriptome profiling [24]. We were able to detect differential changes in expression 
of metabolic parameters and certain genes between the selected subject groups 
differing in BMI and health status. However, for the identification of small differences 
between responses of subjects that are phenotypically more similar, more sensitive 
monitoring of the challenge response is needed. Whole genome transcriptome, 
proteome or metabolome profiling tools could be used for a more extensive 
characterization of the challenge response. As shown in previous studies, extensive 
profiling could identify subtle changes of genes, proteins or metabolites in pathways 
and clusters [200, 218]. The combination of challenge tests and extensive profiling 
may result in detection of changes in health status at a very early stage [62].  
In conclusion, of the three fat types studied most pronounced changes were seen for the 
high oleic sunflower oil (MUFA), this fat type seems to be the most promising to be 
applied in challenge studies to test metabolic response capacity. Moreover, we 
identified a combination of plasma metabolic measures and genes expressed in PBMCs 
that were differently responding to a high-fat challenge in subjects with distinct 
metabolic risk phenotypes. These potential markers are likely candidates to be further 
tested and used in high-fat challenge tests to define metabolic response capacity of 
subjects.  
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ABSTRACT 
 
Background: Extreme caloric restriction (CR) is applied for rapid weight loss and 
other health reasons but presents a challenge to the human body. Subjects with 
metabolic syndrome (MetS) show several abnormalities in their metabolic system and 
this might affect their ability to deal with a period of extreme CR . 
Objective: To identify whether basal PBMC gene expression profiles are different 
between MetS subjects and healthy subjects and whether these subjects will respond 
differently to a challenge of extreme CR. 
Design: Nine women with MetS (≥3 MetS characteristics) and ten healthy women (≤ 1 
MetS characteristics) received a run-in low-caloric diet for 2 days followed by an 
extreme CR period of 7 days (250 kcal/day). Blood was drawn after run-in (day 0) and 
at after 3 and 7 days of CR. PBMCs were isolated and samples from day 0 and 7 were 
used for whole genome expression analysis. 
Results:  Before CR 809 genes were differently expressed between MetS subjects and 
healthy controls, while after CR this increased to 1394 differently expressed genes. 
Major differences between MetS subjects and controls were seen for genes involved in 
mitochondrial energy metabolism and these differences became more pronounced after 
CR. The subject groups showed differences in response to CR. Healthy subjects 
showed a downregulation of immune-related genes, while this was not clearly seen in 
MetS subjects.  
Conclusion: A metabolic challenge in the form of CR enlarged differences in PBMC 
gene expression between MetS subjects and healthy controls. The differences in PBMC 
gene expression response to fasting suggests that differences in metabolic status can 
play an important role in adaptive molecular responses to metabolic challenges. 
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INTRODUCTION 
 
The prevalence of obesity has become alarmingly high in the last decade which poses a 
serious threat to public health. Obesity has been associated with other metabolic risk 
factors including glucose intolerance, hypertension and dyslipidemia, which often 
cluster together, collectively referred to as the metabolic syndrome. The current 
increase in obesity and metabolic syndrome can be largely attributed to changes in diet. 
In the past our ancestors faced alternate periods of fasting and overfeeding, depending 
on the availability of food. In order to survive periods of food shortage the human body 
has evolved to regulate efficient energy storage during periods of overfeeding. 
However, nowadays there is continuous nutritional abundance and this in combination 
with a lower need for physical activity has led to the obesity epidemic.  
Periods of voluntary fasting are still practiced worldwide, mostly for religious reasons, 
but extreme caloric restriction (CR) is also common practice among overweight people 
desiring rapid weight loss [219]. Moreover, fasting has found its way in health retreats 
where it is considered as a way to ‘clean’ or detoxify the body and thereby improve 
health. Also in the field of integrative medicine fasting is used as a method to enhance 
lifestyle modification [220]. 
Long term mild CR has been demonstrated to increase longevity in several animal 
models and has beneficial health effects in humans as well [221, 222]. However, 
although mild long-term CR has been proven to be beneficial for human health, 
scientific evidence for health effects of short-term extreme CR regimes in which only 
water or juice is consumed is limited. This extreme type of CR will not only lead to 
rapid weight loss but will also stress the human body requiring adequate metabolic 
adaptations to maintain homeostasis. During CR the body needs to slow down 
metabolic rate and has to shift from the use of carbohydrate as an energy source to fat 
and protein in order to conserve glucose. It has been shown that subjects with 
characteristics of the metabolic syndrome, compared to healthy subjects, experience 
difficulties with handling of metabolic stressful challenges such as high lipid or 
glucose loads [223, 224]. Moreover, the presence of metabolic syndrome is associated 
with metabolic disturbances, such as elevated lipid and glucose levels, and low-grade 
inflammation in the fasting state [225]. Previous studies have demonstrated that 
differences between healthy subject and obese or diabetic subjects can be reflected in 
PBMC gene expression [134, 226]. Moreover, gene regulation of PBMCs can be 
affected by challenges such as fasting [87].  
In this study we will investigate whether one week of extreme CR has different effects 
on PBMC whole genome expression in metabolic syndrome subjects compared to 
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healthy subjects and whether the CR challenge affects the potential differences in 
PBMC gene expression of both groups of subjects. 
 
 
SUBJECTS AND METHODS 
 
Subjects  
In total, 19 female subjects who visited the Kliniken Essen-Mitte (Essen, Germany) 
were willing to participate in the study. The healthy control group (n=10) consisted of 
subjects with ≤ 1 out of the 5 NIH criteria for MetS (i.e. abdominal obesity waist 
circumference >88 cm, blood pressure > 130/85 mm Hg, fasting plasma glucose >5.9 
mmol/L, HDL <1.3 mmol/L, TAG>1.7 mmol/L). The MetS group (n=9) consisted of 
subjects with ≥3 criteria for MetS. 
Total serum cholesterol, low-density and high-density cholesterol, and triglycerides 
were measured in a Synchron LX 20 (Beckman, Brea, CA, USA). Non-HDL 
cholesterol was calculated as total cholesterol minus HDL cholesterol. Serum fasting 
insulin was determined by microparticle enzyme immunoassay (Insulin RIA DSL-
1600, Diagnostic Systems Laboratories, Sinsheim, Germany). Plasma free fatty acids 
concentrations were analysed by the ACS-ACOD Method (NEFA HR kit, Wako 
Chemicals CmbH, Neuss, Germany).  
 
Study design 
All subjects received a run-in low-caloric diet (800-1000 kcal/day) for 2 days before 
the start of the extreme CR period. This run-in diet contained fruit, vegetables and pure 
rice or potatoes. Subjects subsequently followed a 7-day CR regime which started the 
evening of run-in. During this CR period the daily energy intake was 250 kcal/day 
consisting of 250-300 ml of fruit juice (apple juice, mixed vegetable juice, carrot juice 
or orange juice, as per choice). 
 
PBMC and RNA isolation 
PBMCs were isolated from whole blood on day 0, 3 and 7 using Optiprep (Axis-shield, 
Oslo, Norway) according to the manufacturer’s manual. Subsequent RNA isolation 
was performed using the Qiagen RNAeasy kit (Qiagen, Venlo, the Netherlands).  
The RNA yield was quantified with a Nanodrop ND 1000 spectrophotometer 
(Nanodrop Technologies, Wilmington, DE), and RNA integrity was checked on an 
Agilent 2100 bioanalyzer with RNA 6000 Nano chips (Agilent Technologies, South 
Queensferry, United Kingdom). Only samples with a RIN value >8 were selected for 
microarray analysis. 
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Microarray processing 
Total RNA (500 ng/sample) from the PBMC samples at day 0 and day 7 was labeled 
by using an one-cycle cDNA labeling kit (MessageAmpTM II-Biotin Enhanced Kit; 
Ambion Inc, Nieuwekerk a/d IJssel, Netherlands) and hybridized to human whole-
genome GeneChip arrays encoding 17,699 genes, designed by the European 
Nutrigenomics Organization (NuGO) and manufactured by Affymetrix (Santa Clara, 
CA). Sample labeling, hybridization to chips, and image scanning were performed 
according to the manufacturers’ instructions.  
 
Microarray data analysis  
Quality control was performed and fulfilled the criteria for array hybridization 
suggested by the Tumor Analysis Best Practices Working Group [91]. Microarrays 
were analyzed using the reorganized oligonucleotide probes as described by Dai et al. 
[92]. They combined all individual probes for a gene, enabling the possibility to detect 
overall transcription activity, based on the latest genome and transcriptome 
information, instead of the Affymetrix probe set annotation. Expression values were 
calculated with the Robust Multichip Average (RMA) method and normalization  was 
done using quantile normalization [93, 94].  
Only probe sets with normalized signals above 20 on at least 5 arrays were defined as 
expressed and selected for analysis.  
Genes were defined as different between the subject groups when comparison of the 
average normalized signal intensities showed a p-value below 0.05 in a t-test with 
Bayesian correction (Limma) [95]. Genes were defined as changed by CR in each 
subject group when comparison of the average normalized signal intensities showed a 
p-value below 0.05 in a paired t-test with Bayesian correction (Limma). Genes were 
defined as differently changed between the subject groups when comparison of the 
average changes in normalized signal intensities showed a p-value below 0.05 in a t-
test with Bayesian correction (Limma).  
Data were further analyzed with the use of Ingenuity Pathway Analysis (Ingenuity
 
Systems). This analysis identified canonical pathways that were most significant to the 
data.  
 
Statistical analyses 
The statistical package PASW (version 18.0; SPSS Inc, Chicago,IL) was used for 
analysis of the data. Differences between subject groups were determined by unpaired 
t-tests. Changes within subjects groups were determined by paired t tests.  
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RESULTS 
 
Subject characteristics 
Baseline characteristics of the healthy control and MetS subjects are summarized in 
table 1.  
Body weight decreased after CR in the control subjects (-5.6 ± 1.2 kg) and in the MetS 
subjects (-5.8 ±2.1 kg), but weight changes were not significantly different between 
groups. 
 
Table 1 Subject baseline characteristics (mean ± st dev) 
 Healthy subjects 
(n=10) 
MetS subjects 
(n=9) 
Age (yrs) 44.0 ± 8.0 52.9 ± 7.1a 
BMI (kg/m2) 25.4 ± 3.5 36.3 ± 6.9a 
Weight (kg) 72.1 ± 10.1 103.5± 17.3a 
Total cholesterol (mmol/L) 5.23 ± 0.77 5.51 ± 1.37 
LDL cholesterol (mmol/L) 3.03 ± 0.68 3.76 ± 1.26 
HDL cholesterol (mmol/L) 1.77 ± 0.33 0.99 ± 0.27a 
TAG (mmol/L) 0.79 ± 0.34 1.71 ± 0.59a 
Insulin (mmol/L) 10.8 ± 12.3 16.9 ± 17.2 
Glucose (mmol/L) 4.8 ± 0.6 5.5 ± 0.7a 
FFA (mmol/L) 0.42 ± 0.18 0.45 ± 0.20 
MetS characteristics 0: n=5 
1: n=5 
3: n=3 
4: n=2 
5: n=4 
a 
significantly different (p<0.05) from healthy controls  
 
Microarray analyzes 
Differences between PBMC gene expression profiles of MetS and control subjects  
Before CR 809 genes were differently expressed between MetS and control subjects 
and this number increased to 1394 differently expressed genes after CR, 393 of these 
genes were differently expressed between MetS and control subjects both before and 
after CR (figure 1A). Most differentially expressed genes (63%) were lower expressed 
in MetS compared with controls and this became more pronounced after CR (figure 
1C).  
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Figure 1 Number of genes changed for each comparison analysis. A: number of genes differently expressed between 
healthy subjects and MetS subjects, both before and after caloric restriction (CR). B: number of genes changed by CR in 
healthy subjects and MetS subjects. C: number and percentage of differently higher and lower expressed genes in PBMCs 
between MetS subjects and healthy control subjects before and after CR.  
 
Ingenuity pathway analyzes revealed that several significantly lower expressed genes 
in MetS subjects both before and after CR were involved in pathways related to energy 
metabolism (i.e. oxidative phosphorylation (OXPHOS), mitochondrial dysfunction, 
ubiquinone biosynthesis), estrogen receptor signaling and pyrimidine metabolism 
(figure 2). The differences between MetS subjects and controls in most of these 
pathways became more pronounced after CR.  
 
 
Figure 2 Significantly different pathways between MetS and controls before (day 0, grey bar) and after (day 7, black bar) 
caloric restriction (CR). Only pathways with a p value <0.01 before and/or after CR were selected. A negative –log p 
value indicates that the pathway is lower expressed in MetS subjects compared with control subjects and a positive –log p 
value indicates that the pathway is higher expressed in MetS subjects compared with control subjects 
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Figure 3 shows that the expression levels of genes involved in these pathways 
decreased with the presence of a higher number of MetS characteristics. In addition, 
several genes encoding mitochondrial ribosomal proteins (MRPs) and ribosomal 
proteins were lower expressed in MetS subjects, and the number of differently 
expressed (mitochondrial) ribosomal proteins was increased after CR (figure 3 and 
supplemental table 1) and expression levels are decreased with the presence of a higher 
number of MetS characteristics. Gene expression of peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha (PGC1α), a regulator of mitochondrial energy 
production, and expression of dihydroorotate dehydrogenase (DHODH), involved in 
pyrimidine biosynthesis, was also lower in MetS subjects (supplemental table 1). 
Pathway analysis revealed that significantly higher expressed genes in MetS subjects 
were involved in several signaling pathways related to the immune response such as 
Toll-like receptor signaling and NFκB signaling. Differences between subject groups in 
most of these pathways became more pronounced after CR. 
Further analysis showed that several genes involved in cell adhesion and platelet 
activation e.g. vWF, GP1AB, GP1BB, GP6, GP9, ITGA2B, ITGB3, SELP were higher 
expressed in MetS subjects, mainly before CR (figure 3 and supplemental table 1). 
 
Differences in response to CR of MetS and healthy control subjects 
CR changed the expression of 1408 genes in healthy control subjects and of 1190 
genes in MetS subjects, of these genes the expression 408 genes was changed in both 
subject groups (figure 1B). Further analysis showed that the expression of 303 genes 
was differently changed by CR between MetS and control subjects. Ingenuity pathway 
analysis revealed that genes related to immune processes were significantly differently 
changed between the subjects groups (table 2). Of these genes several were involved in 
natural killer (NK)-cell response and were downregulated in controls and not in MetS 
subjects. Among these genes were NK-cell receptors of the C-type lectin family such 
as i.e. KLRB1, KLRD1, KLRF1, KLRG1 and also genes involved in the NK-cell 
mediated release of cytolytic granules i.e. perforin, granzymes, granulysin. In addition, 
expression of chemokines CCL4 and CCL5, involved in activation of immune cells, 
was reduced in healthy controls and not in MetS subjects. Also genes involved in 
platelet activation were downregulated in control subjects but not in MetS subjects, as 
shown in figure 4. A few other immune-related genes such as EREG, PTGS2 and 
EGR1 were specifically upregulated in the MetS subjects and not in the controls.  
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Figure 3. Average scaled expression levels (scale from -1 white to +1 black) per gene, involved in OXPHOS, ubiquinone 
and mitochondrial dysfunction, cell adhesion and platelet activation or encoding for (mitochonodrial) ribosomal proteins, 
for subjects with different numbers of MetS characteristics. Colour scale represents gene expression values relative to the 
mean of all subjects, with black representing a higher than average expression and white indicating a lower than average 
expression. 
 
Table 2 Differently changed pathways by CR in MetS subjects and controls  
Ingenuity Canonical Pathways p value Genes 
1. Tumoricidal Function of Hepatic Natural Killer Cells <0.005 PRF1, GZMB, AIFM1 
2. Pathogenesis of Multiple Sclerosis <0.01 CCL4, CCL5 
3. Crosstalk between Dendritic Cells and Natural Killer 
Cells 
<0.01 PRF1, KLRD1, TLR7, CD226, 
IL2RB 
4. Aminoacyl-tRNA Biosynthesis 0.021 RARS, AARSD1, FARSA 
5. RhoA Signaling 0.021 ROCK1, SEPT3, CIT, MYL6B, 
PIP4K2C 
6. Granzyme B Signaling 0.021 PRF1, GZMB 
7. Role of Pattern Recognition Receptors in Recognition of 
Bacteria and Viruses 
0.026 TLR7, C1QA, CCL5, C3AR1 
8. Aminosugars Metabolism 0.027 PDE6G, PGM3, NQO1, LTK 
9. Differential Regulation of Cytokine Production in 
Macrophages and T Helper Cells by IL-17A and IL-17F 
0.027 CCL4, CCL5 
10. Graft-versus-Host Disease Signaling 0.028 PRF1, HLA-DQA1, GZMB 
11. Gα12/13 Signaling 0.028 ROCK1, PXN, CDH1, F2R, MYL6B 
12. Autoimmune Thyroid Disease Signaling 0.030 PRF1, HLA-DQA1, GZMB 
13. Granzyme A Signaling 0.030 GZMA, PRF1 
14. Actin Cytoskeleton Signaling 0.034 ROCK1, PXN, F2R, PDGFD, 
MYL6B, PIP4K2C, MATK 
15. IL-8 Signaling 0.039 ROCK1, BRAF, CDH1, HBEGF, 
PTGS2, IRAK2 
16. Differential Regulation of Cytokine Production in 
Intestinal Epithelial Cells by IL-17A and IL-17F 
0.039 CCL4, CCL5 
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Figure 4 Selection of genes differentially changed by CR in healthy control and MetS subjects. Individual 
expression changes (signal log ratios) are shown on a color scale (-0.5 is green, 0.5 is red). 
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DISCUSSION 
 
This study demonstrated that PBMC gene expression profiles are different between 
female MetS and healthy control subjects and that the differences between these 
subject groups became more pronounced after an extreme CR challenge. Moreover, we 
showed that a CR challenge had distinct effects in MetS and healthy subjects. 
Several genes involved in pathways related to mitochondrial energy production (i.e. 
OXPHOS, ubiquinone biosynthesis, mitochondrial dysfunction) were lower expressed 
in MetS subjects compared to healthy subjects. One of the major regulators of 
mitochondrial energy production, PGC1α, was also lower expressed in MetS subjects. 
Moreover, a number of mitochondrial ribosomal proteins (MRPs) were lower 
expressed in MetS subjects. MRPs are needed for the translation of mRNAs encoding 
for components of the OXPHOS system. The combination of lower expression of 
PGC1α, several mitochondrial energy production genes and a lower expression of 
MRPs in MetS subjects can point to mitochondrial dysfunction resulting in 
impairments in mitochondrial energy production [227].These finding support the 
prevailing hypothesis that defective mitochondrial function is central to chronic 
diseases such as obesity and type 2 diabetes [228]. The presence of insulin resistance 
and diabetes have been associated with lower mitochondrial mass, reduced expression 
of genes related to mitochondrial energy production and reduced expression of 
ribosomal proteins in PBMCs and muscle [134, 135, 229, 230]. This has led to the 
hypothesis that mitochondrial deficiency would cause insulin resistance, however 
results from other studies invalidated this hypothesis [136, 231, 232]. Chronic over 
nutrition or high-fat consumption leading to obesity have been considered as potential 
causes of mitochondrial dysfunction [137]. On the other hand, it was shown that obese 
subjects who were not responding to a weight loss intervention had lower expression of 
OXPHOS genes in whole blood than obese subjects who were losing weight during the 
intervention [233]. Moreover, young, non-insulin resistant subjects that are susceptible 
to weight gain on a high-fat diet showed lower expression of OXPHOS genes in 
adipose tissue compared to lean subjects that were non-susceptible to weight gain 
[234]. These results might suggest that diminished mitochondrial functioning is a not a 
consequence but merely a cause of obesity.  
In PBMCs of MetS subjects we also measured a higher expression of genes involved in 
immune signaling processes, possibly pointing to a higher pro-inflammatory status of 
MetS subjects. Furthermore, genes involved in cell adhesion and platelet activation 
such as several glycoproteins, vWF and adhesion molecule P selectin were lowered 
expressed in MetS subjects compared to control healthy subjects. It has been reported 
that circulating plasma glycoproteins Ib and IX levels are positively associated with 
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metabolic syndrome [235]. Moreover, it is known that platelets of diabetic subjects 
show increased surface expression of glycoproteins GP1b and GPIIb/IIIa [236, 237] 
and increased expression of adhesion molecules [238]. The higher expression of these 
genes in our study was measured in PBMCs and not in platelets, but the gene 
expression changes in the PBMCs may reflect systemic changes and could be 
indicative of a pro-atherogenic state of MetS subjects.  
Since we collected PBMC samples from the same subjects both before and after CR we 
were able to see which differences between MetS and healthy subjects were consistent 
over time. More importantly we were able to determine the effects of the extreme CR 
challenge in MetS and healthy subjects. Since CR is often applied for its positive 
effects on health and rapid weight loss one might expect that gene expression profiles 
of MetS subjects after CR would become more similar to those of healthy subjects, as 
was previously seen for adipose tissue gene expression profiles after a longer CR 
intervention [74]. Interestingly, we observed that the total number of differently 
expressed genes between MetS and healthy subjects was increased after CR. In general 
the CR challenge magnified existing differences in gene expression profiles, as seen for 
expression of genes encoding for ribosomal proteins and genes involved in 
mitochondrial energy and pyrimidine metabolism. Pyrimidine metabolism is coupled to 
the mitochondrial respiratory chain via the mitochondrial enzyme dehydroorotic acid 
dehydrogenase (DHODH) which was also lower expressed in MetS subjects 
(borderline significant). It has been suggested that mitochondrial dysfunction could 
result in a decrease in pyrimidine synthesis. The lower expression of genes involved in 
mitochondrial dysfunction in MetS subjects might thus possibly be linked to the lower 
expression of genes involved in pyrimidine metabolism [239].  
Beneficial health effects of CR in other studies were mainly reported on the long term, 
when CR is relatively mild. It is arguable whether it is beneficial for MetS subjects to 
follow the extreme regime of CR applied in our study. We hypothesize that regular 
exposure to (nutritional) challenges may improve the metabolic condition which might 
on the long run result in an increased ability to handle stressful metabolic situations 
[240]. However, on the short term the CR challenge did not only magnify the 
differences between MetS and control subjects but did also induce different responses 
in MetS and healthy subjects, for instance for immune genes. We observed that CR 
downregulated genes involved in NK-cell immune response, but only in healthy 
subjects. NK-cell activity was earlier found to be affected by fasting and the number of 
perforin, granulysin, and/or granzymes A/B-expressing cells has been associated with 
eating a balanced diet [241, 242]. A change in expression of genes involved in NK-cell 
response after an alteration in nutritional status is therefore probably a normal response 
of a healthy body, but this response was not seen in MetS subjects. Whether this should 
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be interpreted as an impaired response of MetS subjects to nutritional challenges or as 
an indication of sustained immune functioning of MetS subjects after CR is 
questionable. In MetS subjects and not in healthy subjects, the genes EREG, EGR1 and 
PTGS2 were upregulated after CR which might point to a pro-inflammatory response 
in MetS subjects. 
Previous studies have shown that CR can reduce weight with concurrent 
downregulation of oxidative stress and inflammation genes in PBMCs of obese 
subjects and upregulation of genes involved in mitochondrial biogenesis in muscle 
[243] [128, 244]. These effects on gene expression were not seen in PBMC from the 
MetS subjects in our study, despite their weight loss. This might be due to the higher 
degree of CR applied in our study compared to the other studies. 
A limitation of our study was the heterogeneity within the MetS subject group. MetS is 
defined as a combination of 3 to 5 metabolic risk factors. Based on this definition 
subjects with different combinations of these characteristics could be included in the 
MetS group. The health status and response of subjects to a challenge might vary and 
depend on the specific characteristics present. Interestingly, we observed that an 
increasing number of characteristics, regardless which characteristics, resulted in lower 
expression of genes involved in mitochondrial energy metabolism. We should also take 
into consideration that PBMCs are a mixture of cell populations and therefore changes 
in PBMC gene expression, such as the changes in genes related to NK-cell response, 
could also be due to a shift in cell populations. It was previously shown that fasting can 
decrease the total number of lymphocytes and the percentage of CD4+ cells but other 
lymphocyte subsets (CD2, CD3, CD8 and CD19) were not changed [241]. We did not 
determine changes in cell populations and can therefore not exclude whether the 
observed gene expression changes were due to changes in cell populations.  
One of the strengths of this study is the second measurement in the same individuals 
after CR which reflects similar differences before CR and showed that differences 
become more pronounced after CR. This points to quite consistent, although small, 
differences between healthy control subjects and MetS subjects and shows the 
reproducibility of PBMC gene expression measurements. Our study highlighted the 
applicability of PBMCs as a model to reflect metabolic disease state and to study the 
systemic effects of MetS.  
In conclusion, we have shown that an extreme CR challenge enlarges differences in 
PBMC gene expression between MetS subjects and healthy subjects. The differences in 
PBMC gene expression response to CR in both groups suggests that metabolic status 
can play an important role in adaptive molecular responses to metabolic challenges. 
 
  
CHAPTER 6 PBMC gene expression in response to a caloric restriction challenge 
 
107 
 
SUPPLEMENTAL DATA 
 
Supplemental table 1 Selection of significantly different expressed genes between MetS and healthy control subjects 
 
Gene symbol Gene name Before CR FC 
MetS/controls 
After CR FC 
MetS/controls 
Cell adhesion and platelet activation   
GP1BA  glycoprotein Ib (platelet), alpha polypeptide 1.66 1.58 
GP1BB  glycoprotein Ib (platelet), beta polypeptide 1.56 n.c. 
GP6  glycoprotein VI (platelet) 1.28 n.c. 
GP9  glycoprotein IX (platelet) 1.48 n.c. 
ITGA2B  integrin, alpha 2b  1.71 n.c. 
ITGB3  integrin, beta 3  1.47 1.41 
CXCL5 chemokine (C-X-C motif) ligand 5 1.90 1.93 
SELP  selectin P  1.58 n.c. 
VWF  von Willebrand factor 1.26 n.c. 
Ribosomal proteins   
LOC126235  similar to 40S ribosomal protein S4, X isoform -1.09 n.c. 
LOC390860  similar to 60S acidic ribosomal protein P0 (L10E) -1.15 n.c. 
LOC390876 similar to 60S ribosomal protein L35 -1.14 n.c. 
LOC728453  similar to 40S ribosomal protein S28 -1.10 n.c. 
RPL19  ribosomal protein L19 -1.05 n.c. 
RPL4  ribosomal protein L4 -1.06 n.c. 
RPS19  ribosomal protein S19 -1.05 n.c. 
RPS19BP1  ribosomal protein S19 binding protein 1 -1.05 n.c. 
RPS5  ribosomal protein S5 -1.09 -1.06 
RPS6KB2  ribosomal protein S6 kinase, 70kDa, polypeptide 2 -1.07 n.c. 
RRP1  ribosomal RNA processing 1 homolog  -1.09 -1.06 
FAU  40S ribosomal protein S30 -1.04 -1.06 
LOC401974  similar to ribosomal protein S2 n.c. -1.08 
LOC440733  similar to 40S ribosomal protein S15  n.c. -1.15 
LOC440737  similar to 60S ribosomal protein L35 n.c. -1.10 
LOC728453  similar to 40S ribosomal protein S28 n.c. -1.11 
LOC729955  similar to ribosomal protein L18a n.c. -1.08 
RPL10L  ribosomal protein L10-like n.c. -1.11 
RPL18  ribosomal protein L18 n.c. -1.08 
RPL39L  ribosomal protein L39-like n.c. -1.17 
RPL8  ribosomal protein L8 n.c. -1.05 
RPLP1  ribosomal protein, large, P1 n.c. -1.04 
RPLP2  ribosomal protein, large, P2 n.c. -1.04 
MRP63  mitochondrial ribosomal protein 63 n.c. -1.07 
MRPL12  mitochondrial ribosomal protein L12 -1.11 n.c. 
MRPL23  mitochondrial ribosomal protein L23 n.c. -1.15 
MRPL24  mitochondrial ribosomal protein L24 -1.10 -1.06 
MRPL34  mitochondrial ribosomal protein L34 n.c. -1.13 
MRPL37  mitochondrial ribosomal protein L37 -1.11 -1.16 
MRPL38  mitochondrial ribosomal protein L38 n.c. -1.10 
MRPL41  mitochondrial ribosomal protein L41 n.c. -1.07 
MRPL42  mitochondrial ribosomal protein L42 1.18 1.15 
MRPL45  mitochondrial ribosomal protein L45 -1.06 n.c. 
MRPL48  mitochondrial ribosomal protein L48 -1.09 n.c. 
MRPL53  mitochondrial ribosomal protein L53 n.c. -1.14 
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MRPL54  mitochondrial ribosomal protein L54 n.c. -1.16 
MRPL55  mitochondrial ribosomal protein L55 -1.11 -1.12 
MRPS15  mitochondrial ribosomal protein S15 -1.11 -1.11 
MRPS2  mitochondrial ribosomal protein S2 -1.08 -1.11 
MRPS18A  mitochondrial ribosomal protein S18A n.c. -1.07 
MRPS24  mitochondrial ribosomal protein S24 -1.08 -1.11 
MRPS26  mitochondrial ribosomal protein S26 -1.07 n.c. 
MRPS30  mitochondrial ribosomal protein S30 -1.07 n.c. 
MRPS34  mitochondrial ribosomal protein S34 n.c. -1.06 
MRPS6  mitochondrial ribosomal protein S6 n.c. -1.06 
MRPS9  mitochondrial ribosomal protein S9 -1.15 -1.16 
Other    
DHODH dihydroorotate dehydrogenase n.c. -1.09* 
PGC1α peroxisome proliferator-activated receptor gamma, -1.22 -1.24 
Not significantly changed, p value<0.05 (n.c.). A positive fold change (FC) indicates that the gene is higher expressed in 
MetS subjects compared to control subjects, a negative FC indicates that the genes is lower expressed in MetS subjects 
compared to control subjects. *borderline significant (p=0.06) 
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In this thesis we investigated the acute and longer-term effects of intake of different 
types of dietary fat. In addition we identified plasma protein profiles that were 
associated with BMI and insulin concentrations of abdominally overweight subjects. 
Furthermore, we investigated how subjects with different metabolic risk phenotypes 
respond to dietary challenges, such as a high-fat load varying in fat type or a period of 
extreme caloric restriction.  
In this chapter both local and systemic effects of intake of different types of fat will be 
discussed, followed by a discussion of the use of protein profiling and challenge test 
for the determination of health status. In addition to the results of our studies, several 
relevant methodological issues will be outlined and our findings will be discussed in 
relation to current dietary recommendations. 
 
Local effects of fatty acids in adipose tissue 
We showed that consumption of a high SFA diet for 8-weeks resulted in increased 
expression of genes involved in inflammation processes in adipose tissue whereas 
consumption of a MUFA-rich diet led to a more anti-inflammatory gene expression 
profile. These findings are of specific interest since inflammation in adipose tissue has 
been associated with insulin resistance and plays a role in the onset of T2DM and 
metabolic syndrome [40, 64, 245]. Changes in inflammatory status have mainly been 
measured in parallel with changes in adipose tissue mass [50, 51] but according to our 
results eating a diet with 20 energy% SFA for 8 weeks, without weight gain, may also 
induce inflammation in adipose tissue.  
The effect of the SFA diet on inflammation genes may be mediated via different 
mechanisms. Genes involved in T-cell and B-cell related processes and chemokines 
were significantly upregulated after SFA consumption which may point to increased 
attraction and activation of immune cells in adipose tissue. Moreover,  we already 
suggested that increased activation of the Toll-like Receptor pathway or decreased 
activation of PPARγ activation may play a role in the SFA-mediated effects on 
inflammation. The reduced PPARγ expression after the SFA diet, accompanied by 
decreased expression of adiponectin and increased expression of CD11c and  
EMR1(F4/80) might also point to a polarisation from alternatively activated 
macrophages (M2) towards more classically activated pro-inflammatory macrophages 
(M1), a phenotypic switch which is also associated with obesity-induced adipose tissue 
inflammation  [245-248]. 
Recently, activation of caspase 1 by a protein complex called the inflammasome has 
been identified as a novel pathway that can play a role in obesity-induced adipose 
tissue inflammation and insulin sensitivity [249, 250]. Consumption of the SFA-rich 
diet did not change gene expression of caspase 1 itself, but upregulated expression of 
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some genes involved in its activation such as ASC (apoptosis-associated speck-like 
protein containing a caspase recruitment domain), NOD2 (nucleotide-binding 
oligomerization domain containing 2) and AIM2 (absent in melanoma 2). Activation of 
caspase 1 can lead to processing of IL1β and IL18, and although expression and plasma 
protein concentration of IL1β was unchanged, gene expression of IL18 was increased 
after the SFA-rich diet. Expression of these inflammasome-related genes were 
unchanged by the MUFA diet which is in line with recent findings of Wen et al. 
showing that the specifically SFA, but not MUFA, induces activation of the NLRP3-
ASC inflammasome in mouse macrophages [251]. Overall, our results suggest that 
inflammasome-mediated caspase 1 activation might be involved in SFA diet-induced 
inflammation, but these findings need to verified before clear conclusions could be 
drawn. 
Our study also showed that consumption of a MUFA-rich diet may have anti-
inflammatory effects in adipose tissue since it downregulated macrophage genes and 
genes of the complement system. The complement system plays an important role in 
initiation of inflammatory processes. Our results in adipose tissue and our findings of a 
positive correlation of plasma complement 3 concentration with BMI and insulin 
concentration also suggest a potential role of the complement system in adipose tissue 
inflammation and insulin resistance [171].  
 
The observed gene expression changes on inflammatory genes in adipose tissue after 
the SFA-rich and the MUFA-rich diet occurred in the absence of clear systemic effects 
on whole body insulin sensitivity, on circulating pro-inflammatory plasma proteins or 
on pro-inflammatory gene expression in circulating PBMCs. Therefore we hypothesize 
that the observed adipose tissue gene expression changes are early diet effects that are 
only locally manifested but may later lead to more systemic effects. 
Studies in mice revealed that T-cell and B-cell infiltration are the first steps in adipose 
tissue inflammation and development of obesity-mediated insulin resistance, followed 
by accumulation of macrophages in a later stage when also insulin resistance develops 
[34] [252, 253]. Our findings that an SFA-rich diet induced changes in expression of 
genes involved in T-cell and B-cell related processes in adipose tissue without changes 
in insulin sensitivity or macrophage infiltration are in line with these findings and 
support our hypothesis that the gene expression changes in adipose tissue are early diet 
effects. In humans little is known about the sequence of events in adipose tissue 
inflammation tha may lead to insulin resistance. One human overfeeding study 
reported that weight-gain induced insulin resistance was observed in the absence of 
changes in inflammation in adipose tissue, thereby suggesting that local inflammation 
occurs secondary to insulin resistance in humans [254]. This which would contradict 
CHAPTER 7 General discussion 
 
112 
 
our hypothesis, but weight gain-induced effects might be different from diet-induced 
effects without weight gain. Moreover, only expression changes of macrophage-related 
genes were measured in adipose tissue samples of the overfeeding study so changes in 
T-cell and B-cell related genes and pathways may not have been detected.   
In our study no effect of the SFA-rich or MUFA-rich diet was observed on insulin 
sensitivity, neither when determined by euglycemic hyperinsulinemic clamp in a 
subgroup of subjects from which adipose tissue samples were collected, nor when 
determined by HOMA-IR in the total study population [255]. Our initial hypothesis 
that replacement of SFA by MUFA would differently affect insulin sensitivity was 
based on epidemiological evidence and results from intervention studies at that time 
which suggested a positive effect of MUFA on insulin sensitivity [6, 16, 17, 256, 257]. 
The low number of subjects and the relatively short duration of our diet intervention 
might be possible explanations for not finding an effect on insulin sensitivity in our 
study. However, two recently performed multi-centre studies investigating the effect of 
fat modification on insulin sensitivity for longer periods in a higher number of subjects 
also showed no effect of replacement of SFA by MUFA on insulin sensitivity [18, 19]. 
Based on these results it is questionable whether there is indeed an effect of 
replacement of SFA by MUFA on insulin sensitivity.  
Obesity-induced adipose tissue inflammation has often been associated with increased 
concentrations of pro-inflammatory proteins (adipokines) [36] [258]. Although a small 
decrease of plasma adiponectin concentration was measured in the SFA diet group, in 
general our intervention diets did not induce clear differential changes in concentration 
of circulating pro-inflammatory proteins, except for changes in ApoB, CTGF, 
myoglobin, IL12p70, SHBG and TBG concentrations that decreased with MUFA 
compared to SFA, but these proteins are not well-known to be secreted from adipose 
tissue. Other tissues can also secrete proteins and therefore plasma levels may reflect 
more systemic changes and not necessarily the degree of inflammation within one 
specific tissue. The absence of changes in pro-inflammatory proteins might thus be 
because the inflammation in adipose tissue was still a local effect, not resulting in 
release of pro-inflammatory adipokines, or because changes in adipokine 
concentrations after 8 weeks were still too small to detect in plasma, possibly due to 
the contribution of other non-inflamed tissues.  
In our study no systemic effects of the diets on PBMC gene expression of 
inflammatory genes were measured. Previous studies have shown that intake of various 
types of fatty acids or diets had differential effects on PBMC gene expression related to 
inflammation [24, 59, 125, 259]. Also in our high-fat challenge study we observed 
distinct effects of different fatty acids on expression of inflammatory genes in PBMCs, 
but hardly any effects on inflammatory genes were seen in our longer-term intervention 
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study. PBMCs travel through the whole body and are exposed to all factors present in 
the circulation and therefore gene expression changes in these cells, in comparison with 
adipose tissue, may reflect more systemic effects induced by consumption of the 
different diets. The absence of a diet-induced effect on inflammation in PBMCs might 
thus support our hypothesis that consumption of the intervention diets for 8 weeks only 
had a local effect in the adipose tissue, before systemic effects could be detected. 
However, there might also be other reasons for the absence of a diet effect on 
inflammation in PBMCs. In the first place, the different sampling moment of the blood 
and adipose tissue samples may have affected the results. Due to practical limitations, 
most adipose tissue samples were collected before the run-in period of the study, when 
subjects were still consuming their regular diet, whereas PBMCs were collected after 2 
weeks run-in on a SFA-rich diet. For PBMCs, the effects of consumption of a SFA diet 
were thus measured when subjects were already adapted to this diet for 2 weeks, which 
might explain why fewer changes were found in PBMCs compared to adipose tissue.  
Moreover, the unexpected findings of an extremely high inflammatory gene expression 
in some PBMC samples, possibly due to contamination during the sample processing, 
might have overruled small diet-induced effects on inflammation.  
 
In summary, it was seen that a SFA rich diet induced a pro-inflammatory gene 
expression profile in adipose tissue, whereas a MUFA rich diet induced a more anti-
inflammatory profile. The fact that these effects were not accompanied by systemic 
effects on insulin sensitivity, circulating pro-inflammatory proteins or pro-
inflammatory gene expression in PBMCs might be due to various reasons as outlined 
above, but in our opinion the most plausible explanation for our findings is that the 
effects of the diets after 8 weeks are still local. Adipose tissue could be an early 
response organ for dietary fat-induced changes and the changes in pro-inflammatory 
gene expression might be one of the first hallmarks in the development of adipose 
tissue inflammation and insulin resistance. 
 
Systemic effects of fatty acids in blood 
In both the longer-term intervention study as well as the high-fat challenge study the 
effects of intake of different fatty acids on PBMCs gene expression were measured. In 
the longer-term intervention study it was shown that MUFA intake lowered expression 
of OXPHOS genes in PBMCs, in both a western type diet and a MED type of diet, 
which thus might be regarded as a specific MUFA effect. The effect of MUFA on 
lowering expression of OXPHOS genes might seem a little unexpected in light of the 
findings from our caloric restriction study showing that lowered expression of 
OXPHOS genes in PBMCs is associated with metabolic syndrome. We hypothesize 
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that MUFA intake increased metabolic health and thereby reduced metabolic stress and 
OXPHOS activity. The lowered OXPHOS gene expression after MUFA intake might 
thus be due to a reduced need for OXPHOS capacity while the lowered expression in 
metabolic syndrome subjects might reflect reduced OXPHOS capacity due to 
mitochondrial dysfunction. Whether this reduced OXPHOS in MetS subjects is a cause 
or a consequence of insulin resistance and/or obesity has been subject of debate in 
several studies [136, 260, 261], but based on our results we cannot draw clear 
conclusions about this cause-effect relationship. 
 
PBMCs were also used to investigate the response to high-fat challenges containing 
SFA, MUFA, or n-3 PUFA in subjects with different metabolic risk phenotypes. This 
challenge study identified a high MUFA load as the most challenging for the biological 
system, based on the metabolic response and the PBMC gene expression response. The 
high MUFA load had the highest TAG-raising effect compared with SFA and n-3 
PUFA. Since postprandial TAG levels are associated with CVD risk [198], one might 
conclude based on these results that MUFA intake is pro-atherogenic, which would be 
in contrast to our previous conclusions and results from earlier studies, showing a 
LDL-lowering effect of MUFA intake which would suggest an anti-atherogenic effect 
of MUFA [14, 255]. We hypothesize that consumption of an acute high dose of MUFA 
in the form of oleic acid (±70 en%) would pose a higher stress to the metabolic system 
compared to gradual adaptation to a diet containing 20 en% of MUFA in combination 
with a significant amount of other fatty acids and other macronutrients. Results from 
the studies of Bouwens et al. illustrate this hypothesis by showing that acute high n-3 
PUFA intake caused a stress response in gene expression while long term low n-3 
PUFA intake had anti-inflammatory gene expression effects in PBMCs [24] [59]. 
However, for SFA intake we observed opposite outcomes; longer-term consumption of 
SFA was found to be pro-inflammatory, whereas an acute high SFA load did elicit a 
lower metabolic and immune cell response compared to a high MUFA load. This may 
be because the SFA load, high in palm oil, contained a mixture of fatty acids which is 
more comparable with normal dietary fat composition. Therefore it could be a less 
strong challenge for the metabolic system than a high dose of one specific fatty acid, in 
the case of the MUFA load.  
In summary, our results clearly showed that acute effects of fatty acids can be very 
different from longer term effects of the same type of fatty acids. Acute consumption 
of an extremely high dose of one specific fatty acid, which is not regularly consumed, 
might be a challenge for the metabolic system, whereas longer term consumption of a 
lower dose of the same fatty acid can have positive health effects. 
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Defining metabolic health status  
For defining health status in nutrition research often traditional medical biomarkers 
were used but these are mainly markers for disease and do give limited information 
about health status. A multimarker approach to measure protein profiles and gene 
expression profiles instead of the traditional single marker approach might result in 
better phenotyping and improved detection of small deviations from a healthy 
phenotype. Results from our diet intervention study already showed that by measuring 
a whole genome expression profile subtle, early diet-induced changes could be 
detected and changes in processes could be identified because changed genes clustered 
together in pathways with similar function. The value of measuring protein profiles for 
health status was also illustrated in this thesis. Protein profiling was used to define 
clusters of plasma proteins that are associated with BMI and insulin in healthy 
populations. Concentrations of single proteins were not highly elevated in individual 
subjects, but by comparing protein profiles, subjects which might be more likely to 
have increased risk for obesity-related disease may be identified. We also revealed that 
proteins such as MCSF, SAP, IL13 and IL3 were higher correlated with BMI and 
insulin than well-known and often measured biomarkers for obesity-related disease risk 
such as IL6 and TNFα. The plasma concentration of some of the identified proteins 
such as IL3 is very low in non-diseased subjects, but despite that we were able to show 
a correlation with BMI in two small populations, however, the practical use of IL3 as a 
biomarker of health status would require sensitive measurements. Due to the 
explorative character of this study no clear conclusions could be drawn about the 
predictive value of the identified protein clusters for disease risk and therefore it would 
be interesting for future research to measure the identified protein clusters in 
prospective cohort studies. 
 
Another method we have used for more accurately defining health status was to impose 
subjects to nutritional challenges such as a high-fat load or a period of extreme caloric 
restriction (CR). Both the high-fat challenge study and the CR study showed the 
potential of using challenges tests to reveal differences between subjects with different 
metabolic phenotypes. The different responses to a challenge of obese, obese diabetic 
and metabolic syndrome subjects compared to lean healthy subjects indicates that the 
presence of a metabolic risk phenotype changes subjects’ ability to handle stressful 
metabolic situations.  
The results from the CR study clearly showed that differences in PBMC gene 
expression between metabolic syndrome and control subjects were enlarged by a CR 
challenge. This is a good example how differences in health status become more 
pronounced after a challenge and illustrates the relevance of a challenge test in defining 
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small differences in health status between subjects that could not be detected in the 
‘unchallenged’ condition. Although an one week CR challenge might not be the most 
practical to perform, high-fat challenges, glucose tolerance tests or other types of acute 
challenge tests might be incorporated in intervention studies to test changes in different 
aspects of health status [61, 62] [200]. 
In our studies we have compared responses to challenges between subject groups that 
were already pre-selected based on differences in BMI or health status. Future studies 
are needed to determine whether challenge tests could also reveal differences between 
subjects with more similar phenotypes. 
 
Methodological issues 
In addition to the results of our studies there are several methodological issues 
concerning the design of the studies, the high between-subject variation and small 
effect size and the intervention diets/shakes that need to be discussed.  
One difficulty in human studies is the high variation in responses in gene expression 
and protein concentrations between subjects. People are metabolically, physiologically, 
and genetically different which provides interesting possibilities for dietary advices 
according to person’s genetic profiles, but it makes it difficult to define robust effects 
of a nutritional intervention. Effects caused by other factors than the intended 
nutritional effects should therefore be minimized, which requires good study designs 
and careful selection of subjects. In the high-fat challenge study we therefore used a 
cross-over design that allowed within subject comparison. Although this is the most 
optimal design to correct for individual variation in response, using this design for the 
longer term completely controlled dietary intervention study was practically not 
feasible. A cross-over design would have tripled the study duration which would be 
very demanding for the participants, probably resulting in high drop-out rate and/or 
low adherence to the diets. Therefore a parallel design was used, but gene expression 
and protein concentrations were measured both before and after intervention to be able 
to compare within the same subject. 
In order to diminish variation between subjects as much as possible certain pre-
selection criteria for participation were set. For our longer-term dietary intervention 
study and the high-fat challenge study subjects were mainly selected based on their 
age, BMI, glucose tolerance and medication use. However, using these selection 
criteria might have led to selection of too healthy subjects, not representative for all 
other overweight or obese subjects of the same age class. There might have been 
additional selection bias in the dietary intervention study since subjects that were 
already consuming high olive oil or a Mediterranean type of diet might have been more 
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willing to participate. This might also be a reason why the SFA diet, compared to the 
MUFA diet, induced more changes in adipose tissue gene expression.  
For the caloric restriction study subjects were selected based on the presence of 
metabolic syndrome, however, because of the heterogeneity of this syndrome this also 
resulted in variety within the subject group. To lower this variety and to select a 
suitable, homogenous target group for a dietary intervention more sensitive and 
extensive phenotyping of subjects may be required, possibly by applying challenge 
tests and measuring protein profiles to determine health status, or by using imaging 
techniques such as MRI. 
 
In general the dietary interventions produced subtle changes in gene expression levels 
in human tissues, as indicated by relatively low fold changes. Dietary human 
intervention studies are known for their relatively small effect sizes [55, 262]. Our 
biological system is quite robust and short term dietary interventions will therefore not 
induce dramatic changes. As dietary products are freely available and, in contrast to 
medication, should be consumed without serious adverse side effects and without any 
instructions about dosage, dietary products are also not expected to induce major 
changes in gene expression within a short period of time. Although dietary 
interventions induce small changes in gene expression, expression of a high number of 
genes can be changed. All these subtle changes may have profound biological effects 
on the long term but it is a challenge to distinguish noise from data with relevant 
physiological meaning in large genomic datasets and subsequently to interpret these 
data and define biological effects.  
There is no uniform way of microarray data analysis and selection of the suitable 
approach depends on several factors [263]. Our method of microarray data analysis has 
been criticized [264] and in a letter [265] we have extensively addressed these issues 
but this also deserves some attention in this discussion. In our analysis differently 
expressed genes were selected based on p value and not on mean fold change since 
mean fold changes can be highly influenced by a few high responders, especially in 
small sample sizes when subject variation is high, as in our studies. Moreover, our gene 
expression data was not corrected for multiple testing which will increase the risk of 
finding more false positive genes and therefore care should be taken in the analysis of 
single genes. In our analyses changes in expression of genes were only considered 
meaningful if several genes were changed in one pathway or network and when genes 
were changed in the same direction within most subjects. The subtle gene expression 
changes were often consistent over subjects and pathways, and therefore reflect a clear 
response of the subjects to the diets. Analysis of data from the caloric restriction study 
showed that several differences in PBMC gene expression between subject groups 
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were also consistent over time, showing the reproducibility of PBMC gene expression 
measurements.  
 
Another important issue in human dietary intervention studies is the selection of the 
dietary components or diets that are tested, but also the selection of an appropriate 
control diet is of importance. The SFA diet in our longer-term intervention study was 
initially assumed to be a control diet which would reflect normal intake of middle-aged 
people in the Netherlands. However, based on the SFA diet effects in adipose tissue 
this was certainly not the case for most subjects. The use of the SFA diet as a run-in 
diet to adjust energy intake and eating habits before the actual intervention started may 
have affected the study results for parameters measured in blood samples that were 
collected after run-in. However, because of the highly variable eating habits of subjects 
the design of a control diet that does not have an effect is impossible. A control diet 
will always induce changes, not only reflecting effects of participation in a trial or 
seasonal effects, but also reflecting diet effects.  
For our high-fat challenge study we have chosen to compare effects of high-fat shakes 
with each other and not with controls such as low-fat shakes or water since these will 
have a different energy and/or macronutrient content, which also can affect the 
response. Changes after water intake can also reveal fasting or circadian rhythm 
effects, thereby affecting gene expression [266]. Therefore, comparison between high-
fat shakes was in our opinion the best way to test the effects of fat type in a challenge.  
In our studies we were interested in the effect of different fatty acids and therefore we 
used diets and shakes that were very similar in nutrient composition, except for the fat 
type which would make it easier to attribute the observed diet effects to a specific fat 
type. However, the fat types were exchanged for each other to keep the total fat content 
and the energy content similar, which makes it difficult to determine whether the 
effects we observed in the long-term study are for example the result of an increase in 
SFA or a reduction in MUFA, or a combination of changes.  
We have only tested the effects of 8-weeks consumption of a SFA diet consisting of 
50% palmitic acid, 20% stearic acid and 15% myristic acid. Other high SFA diets 
might have different effects, depending on the chain length of SFA, but also the food in 
which SFA is present [13] [267]. The same holds true for n-3 PUFA and also for 
MUFA. In Northern countries MUFA intake is not primarily from olive oil but largely 
derived from animal products which also contain a significant proportion of SFA and 
might influence the effect of MUFA. The effects of fatty acids might also depend on 
the diet in which it is incorporated since many components can interact with each other 
[108]. This was also a reason why we investigated the effects of MUFA from olive oil 
in a western type diet and in a Mediterranean (MED) type of diet. However, when 
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investigating effects of such complex diets it is difficult to establish which effects can 
be attributed to which components, it might also be the synergy between components. 
We also hypothesize that it might be the high dietary variety of the MED diet and the 
exposure to different mild stressing components such as polyphenols, PUFA and 
alcohol that could have affected gene expression; however, no major differences in 
stress-related pathways between the diets were found. This might be because we 
measured longer term MED diet effect in fasting blood samples instead of acute 
responses to the potential stressing diet components.  
A mild degree of daily stress in the form of polyphenols, PUFA or alcohol might 
stimulate cells to train their response mechanisms which may improve the ability to 
resist stress and to enhance flexibility [240]. This might also be a mechanism how 
regular stress to the metabolic system, for instance by metabolic challenges, might on 
the long run improve the metabolic condition.  
 
Dietary recommendations 
Current guidelines emphasize the need to lower SFA intake to reduce risk for coronary 
heart disease (CHD) which would be in line with consumption of a MED diet or a 
MUFA-rich diet. Although the effect of reducing SFA on lowering CHD risk are still 
being discussed [268-270], our results suggest that reducing SFA intake might be 
beneficial to prevent adipose tissue inflammation, which might in the long run lower 
the risk for CHD and diabetes.  
There is also an on-going discussion which nutrient should best replace SFA. Recent 
decades the focus of food producers was mainly on reducing the amount of fat by 
substituting it with carbohydrates. However, replacement of SFA by carbohydrates, 
especially refined carbohydrates and added sugars, has been associated with increased 
levels of TAG and reduced levels of HDL [271-273] and adverse effects on glycemic 
control in diabetic subjects [274, 275].  
In general, people prefer to eat fatty foods because these are very palatable and, even 
though food choice should be more focused on health, still palatability and pleasure are 
major determinants of food choice. In this regard replacement of SFA by MUFA might 
be a good alternative since it fulfils the need for palatability and pleasure and our study 
showed that it was also associated with positive health effects. However, we should be 
careful with translating effects found on risk markers into effects on disease outcome. 
On the long term there is still no strong evidence that replacement of SFA by MUFA 
would have a positive effect on CHD and diabetes risk [267, 269, 270, 276]. Mente et 
al. concluded in their systematic review that only a Mediterranean dietary pattern, and 
not MUFA intake, is strongly related to CHD in randomized trials [270]. Although this 
is one of many studies, including ours, suggesting that adoption of a MED diet pattern 
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would be beneficial for health [10, 255, 277], there is also criticism on this diet and its 
applicability. Since there is no universal definition of a MED diet the term can be used 
to describe different dietary habits in countries around the Mediterranean Sea. Positive 
health effects of a MED diet as reported in studies around the Mediterranean Sea might 
be confounded by effects of climate, lifestyle and stress level. However, in the 
controlled setting of our study also beneficial effects of a MED diet on several CVD 
risk factors were shown.  
Practical issues might withhold people from adopting a MED diet pattern; a MED diet 
contains many fresh products which need more preparation time and are more 
expensive compared to the currently consumed energy dense pre-packaged and (semi-) 
prepared foods. Replacement of SFA by MUFA would be easier to implement in daily 
diets and also food producers could have a role in this; supermarkets already sell a few 
products in which SFA is replaced by olive oil, but this could be more widely 
implemented. 
 
Conclusion 
In conclusion, this thesis showed that 8-weeks consumption of a SFA-rich diet resulted 
in a pro-inflammatory gene expression profile whereas consumption of a MUFA-rich 
diet caused a more anti-inflammatory profile, in addition to reductions in LDL 
cholesterol and some plasma proteins. Since the effects of the diets on inflammation 
were still local and not accompanied by systemic changes in inflammatory status or 
insulin sensitivity we hypothesize that adipose tissue could be an early response organ 
for dietary fat-induced changes. The changes in pro-inflammatory gene expression 
might be one of the first hallmarks in the development of adipose tissue inflammation 
and insulin resistance which on the longer term may lead to inflammation-related 
diseases such as metabolic syndrome. 
Moreover, our studies showed the potential of whole genome expression profiling, 
plasma profiling and the use of challenges tests to detect subtle diet effects and small 
differences in health status. Using these tools in future studies will result in more 
knowledge about health status and about mechanisms behind dietary effects. 
Eventually this might lead to earlier detection of small deviations from a healthy 
phenotype and to evidence-based dietary advice to improve health and to prevent 
disease. 
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Achtergrond 
Het aantal mensen met risicofactoren voor het ontwikkelen van type 2 diabetes en hart- 
en vaatziekten is de laatste jaren hard toegenomen. Het is daarom van belang dat er 
tijdig met preventie begonnen wordt. Veranderingen in voedingsgewoonten kunnen 
hierbij een belangrijke rol spelen. Een verandering in type vet, zoals het vervangen van 
verzadigd vet door onverzadigd vet uit olijfolie, zou een gezondheid bevorderend 
effect kunnen hebben door de risicofactoren voor ziekte te verlagen. Een Mediterraan 
voedingspatroon bevat veel olijfolie, maar wordt daarnaast ook gekarakteriseerd door 
een relatief hoge inname van plantaardige producten (groente, fruit, noten, 
peulvruchten, graanproducten) en matige inname van vis en rode wijn. Consumptie van 
dit voedingspatroon wordt geassocieerd met diverse positieve gezondheidseffecten. 
Over de onderliggende mechanismes van gezondheidseffecten van voeding is nog niet 
veel bekend. Om meer kennis te krijgen over deze mechanismes kunnen zogenaamde 
microarrays gebruikt worden. Dit zijn kleine glasplaatjes waarop fragmenten van 
duizenden genen van de mens gefixeerd zijn. Genen die actief zijn en tot expressie 
komen produceren boodschapper-RNA's (mRNA's), die een kopie van de gen-
informatie bevatten. Met een microarray wordt gemeten welke genen in een bepaald 
weefsel tot expressie komen en welke niet. Door microarrays te gebruiken in 
voedingsonderzoek is te bepalen van welke genen de activiteit verandert wanneer een 
bepaald type voeding gegeten wordt. Dit geeft aan welke processen er dan in het 
lichaam veranderd zijn.  
Voor het meten van genexpressie zijn lichaamscellen nodig, maar in gezonde mensen 
zijn niet van alle organen eenvoudig cellen te verkrijgen. Daarom wordt er 
tegenwoordig ook steeds vaker gekeken naar voedingseffecten in een relatief makkelijk 
verkrijgbare type witte bloedcellen, de perifere bloed mononucleaire cellen (PBMCs). 
Een belangrijk doel van voedingsonderzoek is het voorkomen van ziekte en behoud 
van gezondheid door middel van goede voeding. Hiervoor is het van belang dat er 
goede indicatoren van gezondheidstatus zijn zodat vast te stellen is welke mensen een 
verhoogd risico op ziekte hebben. De huidige indicatoren zijn met name gericht om 
ziekte op te sporen, maar minder geschikt om gezondheidsstatus nauwkeurig te 
bepalen. Het gebruik van uitgebreide screenings technieken en het meten van de 
respons capaciteit van het lichaam op metabool stressvolle situaties zouden mogelijke 
methodes zijn om een betere indicatie te krijgen van gezondheid.  
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Doel 
Het doel van dit promotieonderzoek was tweezijdig; ten eerste, het bestuderen van 
acute en langere termijn effecten van consumptie van verschillende types vet. Ten 
tweede, onderzoeken of een uitgebreide karakterisatie van gezondheidsstatus bereikt 
kan worden door het gebruik van moderne genomics technieken en door het bepalen 
van de respons op metabole stress testen. 
 
Methodes 
Allereerst is een gecontroleerde voedingsproef uitgevoerd waarbij de effecten van 8 
weken consumptie van een voeding rijk aan verzadigd vet en een voeding rijk aan 
enkelvoudig onverzadigd vet gemeten werden op insulinegevoeligheid, serum 
cholesterol concentraties en genexpressie in vetweefsel. 
Daarnaast zijn ook de effecten van vervanging van verzadigd vet door enkelvoudig 
verzadigd vet in zowel een ‘westers voedingspatroon’ als ook in een ‘Mediterraan 
voedingspatroon’ vergeleken op genexpressie in PBMCs en plasma eiwit concentraties. 
Gegevens over plasma eiwit concentraties van de deelnemers, gemeten voordat de 
voedingsproef begon, zijn gebruikt om eiwitten en eiwitclusters te identificeren die 
geassocieerd zijn met BMI en plasma insuline concentraties en mogelijk kunnen dienen 
als indicatoren van gezondheidsstatus. Dezelfde analyses werden gedaan in een 2e 
groep mensen met overgewicht om bevindingen te verifiëren.  
In twee andere studies is onderzocht hoe gezonde mensen met een normaal gewicht en 
mensen met verschillende metabole risico fenotypen (aanwezigheid van obesitas, en/of 
diabetes, en/of metabool syndroom) reageerden op metabool stressvolle situaties. In 
één studie is de metabole en PBMC genexpressie respons op inname van een hoog-vet 
shake met verschillende types vet vergeleken. In de andere studie is de respons op een 
periode van extreme restrictie van calorie inname bepaald. In diezelfde studie werden 
ook de PBMC genexpressie profielen van mensen met metabool syndroom vergeleken 
met PBMC genexpressie profielen van gezonde mensen. 
 
Resultaten 
Resultaten van de gecontroleerde voedingsproef lieten zien dat consumptie van een 
voeding rijk aan verzadigd vet de expressie van inflammatie- (ontstekings) genen in 
vetweefsel verhoogde terwijl een voeding rijk aan enkelvoudig onverzadigd vet leidde 
tot een minder inflammatoir genexpressie profiel. Deze veranderingen gingen niet 
gepaard met veranderingen in insuline gevoeligheid. Verder leidde een hoge inname 
van enkelvoudig onverzadigd vet uit olijfolie, als onderdeel van zowel een westerse 
type voeding als ook van een Mediterrane voeding, tot een verlaging van expressie van 
genen betrokken bij oxidatieve fosforylering in PBMCs. Daarnaast zorgde hoge 
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inname van enkelvoudig onverzadigd vet ook voor een verlaging van serum LDL 
cholesterol en plasma ApoB, connective tissue growth factor en myoglobine 
concentraties wat kan duiden op een verbeterde metabole gezondheid. 
In plasma van de gezonde deelnemers hebben we clusters van eiwitten geïdentificeerd 
die geassocieerd waren met BMI en insuline waardes. Deze clusters bevatten bekende 
indicatoren voor obesitas-gerelateerde ziekte en potentiele nieuwe indicatoren. 
De studie waarbij de respons op een hoge dosis vet werd gemeten liet zien dat de 
plasma metabole respons (triglyceriden, insuline, glucose en vrije vetzuren) en de 
PBMC genexpressie respons na een hoog vet inname beïnvloed werden door de 
aanwezigheid van obesitas en/of diabetes type 2. Vergelijking van de respons op een 
hoge dosis verzadigd, enkelvoudig onverzadigd en meervoudig onverzadigd vet liet 
zien dat een hoge dosis enkelvoudig verzadigd vet de meest uitgesproken respons 
induceerde, met name in mensen met obesitas en type 2 diabetes, en daarom het meest 
geschikt lijkt als metabole stress test. 
De studie waarbij extreme restrictie van de calorie inname werd toegepast liet zien dat 
PBMC genexpressie profielen verschillend waren tussen mensen met metabool 
syndroom en gezonde mensen, met name voor genen die betrokken zijn bij processen 
gerelateerd aan mitochondriaal energie metabolisme. Verder zagen we dat een periode 
van extreme calorische restrictie de verschillen in PBMC genexpressie tussen de 
groepen mensen vergrootte.  
 
Conclusie 
Dit promotieonderzoek heeft aangetoond dat 8 weken consumptie van een voeding rijk 
aan verzadigd vet leidde tot een pro-inflammatoir genexpressie profiel in vetweefsel, 
terwijl consumptie van een voeding rijk aan enkelvoudig onverzadigd vet leidde tot een 
meer anti-inflammatoir genexpressie profiel, naast een afname van LDL cholesterol, 
enkele plasma eiwitten en expressie van oxidatieve fosforyleringsgenen in PBMCs. 
Omdat de effecten van de voeding op inflammatie vooral lokaal gemeten werden en 
niet gepaard gingen met systemische veranderingen in inflammatoire status of 
insulinegevoeligheid komen we tot de hypothese dat vetweefsel mogelijk een vroeg 
responderend orgaan is voor vet-geïnduceerde veranderingen. De veranderingen in 
inflammatoire genexpressie zouden één van de eerste tekenen kunnen zijn in de 
ontwikkeling van systemische inflammatie en insuline resistentie, wat op de langere 
termijn zou kunnen leiden tot inflammatie-gerelateerde ziektes zoals metabool 
syndroom. 
Onze studies lieten verder zien dat het meten van genexpressie profielen, het meten van 
plasma eiwit profielen en het gebruik van metabole stress testen geschikte methodes 
kunnen zijn om subtiele voedingseffecten en kleine verschillen in gezondheidsstatus 
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aan te tonen. Het gebruik van deze methodes in toekomstige studies kan bijdragen aan 
meer kennis over gezondheidsstatus en mechanismes achter effecten van voeding. 
Uiteindelijk zou dit kunnen leiden tot een eerdere detectie van kleine afwijkingen van 
een gezond fenotype en ‘evidence-based’ voedingsadvies om gezondheid te verbeteren 
en ziekte te voorkomen. 
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